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ABSTRACT 
 
Background: Streptococcus pneumoniae (pneumococcus) is a major cause of morbidity and 
mortality in young children. Pneumococcal conjugate vaccines are restricted in their serotype 
coverage, and hence, focus has been directed towards common protein-based antigens. 
However, there have been problems associated with testing protein-based antigens in animal 
models. These include inhumane endpoints, use of large sample sizes, and the inability to 
detect subtle differences between antigens. This study describes a novel intranasal pneumonia 
co-inoculation model conducted in mouse and aims to address some of these limitations. 
 
 
Methods: Eighty female NMRI mice were equally distributed into the vaccinated and 
placebo groups. The mice were subcutaneously inoculated with recombinant PspC or PpmA 
or adjuvant (control). Both groups were co-inoculated with 50 µL of a bacterial suspension 
containing D39:: rpsL (serotype 2) or PJ351:: rpsL (serotype 1) wild-type strains and their 
isogenic knockout strains containing a trimethoprim resistance marker. Mice (n = 5 per 
group) were terminated at 0, 6, 12 and 24 hours post-inoculation. Bacterial samples were 
obtained from nasopharyngeal washings, bronchoalveolar lavage fluid (BAL fluid) and 
homogenised lung tissue. Bacterial counts were obtained from selective media containing 
either streptomycin or trimethoprim, and the ratios of wild-type and knockout were 
determined. Serum was collected by cardiac puncture and ELISA was used to monitor the 
levels of IgG antibodies. To further refine the model, a single time point (T = 24h) in which 
events were more pronounced was chosen for the rest of the experiments and the number of 
mice was scaled down to 20 mice per experimetal procedure. A group of 20 mice (10 in 
placebo and 10 in vaccinated mice) were subcutaneously vaccinated with either recombinant 
PspA, IgA protease and SlrA or adjuvant (control). Both vaccinated and adjuvant groups 
were co-inoculated with 50 µL of a bacterial suspension containing D39:: rpsL (serotype 2) 
or PJ351:: rpsL (serotype 1) wild-type strains and their isogenic knockout strains. Bacterial 
samples were collected from mice as described above. 
 
 
Results: Pneumococcal knockouts of D39 and PJ351 lacking the genes encoding PpmA and 
PspC were attenuated in their ability to colonise the nasopharynx, BAL fluid and lungs of 
mice. Knockouts deficient in PspA, IgA bacterial protease and SlrA in the PJ351 background 
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were attenuated in all sites sampled, whereas knockouts in the D39 background were 
attenuated only in the nasopharynx. PspC IgG antibodies were able to elicit clearance of 
PspC producing wild-type D39 and PJ351 strains more effectively compared to PspC deletion 
knockouts, which were able to persist in the nasopharynx, BAL fluid and lungs. Responses in 
PpmA vaccinated mice were dependent on the genetic background of the inoculation strains. 
Clearance of D39 wild-type strains was more noticeable in the nasopharynx than in the BAL 
fluid and lungs, whereas the wild-type PJ351 was cleared more efficiently than the knockout 
in the BAL fluid and lungs, compared to the nasopharynx. Responses in IgA bacterial 
protease vaccinated mice were also dependent on the genetic background of the inoculation 
strains, with a clearance of the D39 wild-type strain being more noticeable in the 
nasopharynx. PspA and SlrA IgG antibodies were not protective against infection with both 
strains of the pneumococcus in the mouse model. 
 
 
Conclusion: Using PspC, PpmA, PspA, IgA bacterial protease and SlrA as examples, we 
demonstrated that this mouse co-colonisation model could effectively detect subtle 
differences in the clearance of wild-type and knockout bacteria in the presence of antibodies 
against non-essential surface antigens. The model is humanely more acceptable, as it uses far 
fewer animals than conventional testing, with greater sensitivity. Further, it relies on 
measurements of bacterial density, rather than fatal disease as endpoints. The model also 
provides additional benefits in terms of monitoring the virulence characteristics of the target 
antigens. 
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CHAPTER 1 INTRODUCTION 
  
1.1 Preface 
 
Invasive pneumococcal disease (IPD) remains the leading cause of mortality among 
children <5 years of age and in the elderly >65 years. It was estimated that around 935,000 
children under 5 years of age died in 2013 from pneumococcal infections (WHO Pneumonia 
fact sheet 2014). This situation is exacerbated by the emergence of antibiotic-resistant strains 
of Streptococcus pneumoniae, particularly strains resistant to penicillin. This has encouraged 
the need for the development of other effective means of combating pneumococcal disease. 
 
 
1.2 Cell structure and virulence factors involved in the pathogenesis of S. pneumoniae 
 
The outer surface of the pneumococcus comprises of the cell wall, surface proteins and 
polysaccharide capsule (as shown in Figure 1.1). The pneumococcal cell wall consists of a 
peptidoglycan (PG), teichoic acid (TA) and lipoteichoic acids (LTA). Both teichoic acids 
have identical chain structures but differ in their positioning on the cell wall. Techoic acid is 
covalently linked to the peptidoglycan layer of the pneumococcal cell wall whereas LTA is 
attached to the cytoplasmic membrane by a lipid (Neuhaus & Baddiley 2003). TA and LTA 
contain phosphorylcholine, which promotes adherence and invasion of the pneumococcus by 
forming a complex with G-protein-coupled platelet activating factor receptor (PAF receptor) 
(Cundell et al. 1995). Both teichoic acids also serve as an anchor for surface-located choline 
binding proteins. The pneumococcus also has over 100 surface proteins. Pneumococcal 
proteins are responsible for the virulence of the pneumococcus by assisting in establishing 
colonisation and causing invasive disease. 
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Figure 1.1 Diagram showing pneumococcal cell wall and surface exposed proteins. 
Figure is adapted from (Bergmann & Hammerschmidt 2006). 
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Covering the external surface of the pneumococcus is an extracellular sugar coating 
layer mainly composed of high molecular weight polysaccharides (Buttery et al. 2002). The 
capsule was the first virulence factor to be identified in the pneumococcus (Griffith 1928; 
Avery & Goebel 1931). Early experiments showed that knockout strains lacking the capsule 
were avirulent in mice compared to the parental strain. At least 93 different capsular types 
(serotypes) have been identified (Bratcher et al. 2011; Park et al. 2007; Calix & Nahm 2010). 
They differ in their chemical structure and are distinguished antigenically by their capsular 
polysaccharide composition. 
 
 
The ability of the pneumococcus to regulate the amount of capsule production is 
important to its survival in the host environment. Depending on its location in the host, the 
pneumococcus can preferentially switch between a transparent phase and opaque phase. 
Colonies in the opaque phase have a thick capsule, and are more likely to cause systemic 
infection. The thick capsule assists the invasive strains to evade opsonophagocytosis. 
Organisms that express the transparent phenotype are predominantly found in the 
nasopharynx wherein a thin capsule is produced and the strains are less subjected to 
opsonophagocytosis than in the blood stream or lower respiratory tract. Transparent 
organisms have been shown to express higher amounts of techoic acids, PspC and LytA 
compared to opaque organisms (Kim & Weiser 1998). These structures are thought to 
enhance the ability of the pneumococcus to adhere to the epidermal surfaces of the 
nasopharynx. The role of surface proteins on pneumococcal pathogenesis is discussed in 
detail in section 1.5. 
 
 
The requirement of capsule during colonisation is less defined. By employing knockout 
strains with decreased ability to synthesise capsule, Yother and Magee were able to 
demonstrate the inefficiency of knockout strains to colonise the nasopharynx of adult mice 
(Yother & Magee 2001). This was corroborated by Cron et al, who also noticed a reduced 
ability from one strain that produced low levels of capsule to successfully colonise the 
nasopharynx of adult CD1 mice (Cron et al. 2011). The ability of the pneumococci to 
establish colonisation was also shown to be related to the number of carbon repeating units in 
the capsule. The fewer carbons per repeat unit, the heavier encapsulated the serotype and 
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more likely to persist in the nasopharynx of mice (Weinberger et al. 2009). Nelson et al, 
however, revealed that the capsule inhibited the agglutination of strains to the luminal 
mucosal layer, ensuring successful colonisation of the epithelial layer (Nelson et al. 2007). In 
fact, the heavy capsule could prevent adhesins such as PspC, SpxB and NanA from gaining 
access to the epithelial surface, where successful colonisation is established.  
 
 
What is clear from these studies is that the capsule, to some extent is involved in 
colonisation by the pneumococcus. The question of whether less or more production of the 
capsule is enough in order for colonisation to be established remains uncertain. The crucial 
factor is for the pneumococcus to control the production of the capsule to ensure successful 
colonisation, without triggering an inflammatory response.  
 
 
1.3 PROTEIN VIRULENCE FACTORS 
 
1.3.1 Choline binding proteins (CBPs) 
 
Choline binding proteins are anchored to the pneumococcal surface via non-covalent 
interactions with phosphorylcholine moieties on cell wall teichoic acid and membrane 
lipoteichoic acid (As shown in Figure 1.1). The examination of the S. pneumoniae genome 
sequences identified 6 and 15 CBPs in the R6 and TIGR4 strains, respectively (Pérez-Dorado 
et al. 2012). The most studied proteins in this family are PspC (Pneumococcal surface protein 
C) and PspA (Pneumococcal surface protein A) (Yother & White 1994). These ones are also 
the most highly developed as potential vaccine antigens (See Sections 1.6.2.1 and 1.6.2.2). 
Other proteins that associate with the cell surface by binding choline include CbpG, CbpD, 
PcpA and Hydrolases (Gosink et al. 2000).  
 
 
1.3.1.1 Pneumococcal surface protein C (PspC)/Choline binding protein (CbpA)/SpsA)  
 
This surface protein which exists in different allelic forms referred as SpsA, CbpA, 
PbcA and Hic, is the paralog of PspA because of their similar structural domains involved in 
cell wall adhesion. PspC proteins are heterogenous in nature, and they are not always 
recognised to belong to the same group. As such, they can be classified into 11 groups, with 
PspCs from groups 1-6 attached to the bacterial surface by a phosphocholine moiety. The 
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remaining groups termed PspC-like proteins are anchored to the bacterial surface via an 
LPXTG motif (Iannelli et al. 2002). PspC is an adhesin that plays a vital role in aiding the 
pneumococcus in the establishment of nasopharyngeal colonisation. PspC can bind human 
complement factor H, which then promotes entry of the pneumococcus into epithelial cells 
through an integrin-mediated pathway. Furthermore, it can bind IgA secretory fragment that 
assists it to cross the mucosal epithelium thus establishing colonisation (Hammerschmidt et 
al. 1997; Agarwal et al. 2010; Zhang et al. 2000). In a mouse model of colonisation, PspC 
was attenuated in its ability to colonise the nasopharynx of mice compared to its isogenic 
wild-type strain (Balachandran et al. 2002). 
 
 
On the other hand, there are conflicting results regarding the role of PspC in 
pneumonia. A serotype 19F strain that lacked a pspC gene  was attenuated in a CBA/N 
pneumonia mouse model (Balachandran et al. 2002). Using an MF1 fatal pneumonia mouse 
model, strain specificity in virulence of PspC was demonstrated. Serotypes 2, 3 and 19 
deficient in PspC behaved similar to their isogenic wild-type strains, whereas a pspC 
knockout in a serotype 4 strain was easily cleared from the system (Kerr et al. 2006). A pspC 
knockout in a D39 background was not attenuated in an intraperitoneal CBA/N fatal 
pneumonia mouse model (Ogunniyi et al. 2007).  
 
 
There are also some conflicting data on the role of PspC in bacteraemia. In vitro studies 
demonstrate that PspC avoids phagocytosis by recruiting functionally active factor H with the 
Hic surface protein, therefore ensuring its survival in invasive disease (Jarva et al. 2004). A 
pspC knockout in a D39 background using BALB/c intraperitoneal model of septicaemia was 
however not attenuated in its ability to survive in the bloodstream of mice (Rosenow et al. 
1997). In the BALB/c intravenous bacteraemia model, a pspC knockout in a serotype 19F 
strain background showed an increased ability to grow in the bloodstream of mice 
(Balachandran et al. 2002). These in vivo results suggested that PspC does not contribute to 
the development of septicaemia. Other studies were, however, able to demonstrate the role of 
PspC in sepsis. The survival time of CBA/Jico and MF1 mice intravenously infected with 
D39 pspC
-
 and A66 pspC
- 
knockout strains was significantly delayed (Iannelli et al. 2004). 
This indicated the contribution of PspC in the development of septicaemia. 
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These studies show that the choice of pneumococcal strain affected the outcome of 
results in pneumonia and bacteraemia models. The role of PspC in bacteraemia was only 
demonstrated in mouse models where the intravenous route was used, with the exception of 
BALB/c mice. This indicates that in addition to the choice of the mouse strain, the route of 
infection also affected the results in the bacteraemia model. Although the CBA/Jico and MF1 
intravenous septicaemia models gave successful results, several studies have shown that 
pneumococci introduced via the intravenous route are relatively avirulent. A theoretical 
disadvantage of the intravenous route could be that the smaller inoculum is unable to adapt 
with respect to phase variation/capsule expression, which enables it to persist in the blood 
and is thus easily cleared from the mouse system. The disparity in studies showing the role of 
PspC on bacteraemia makes it difficult to link its role in bacteraemia. 
 
 
1.3.1.2 Pneumococcal surface protein A (PspA) 
 
Pneumococcal surface protein A is the most extensively studied of the CBPs. PspA N-
terminal domain is a highly charged α-helical region, with a coiled-coil structure that extends 
from the cell wall and protrudes outside of the capsule (Jedrzejas 2006). Based on the 
sequence variability of the N-terminal region, PspA proteins have been classified into six 
classes that can be grouped into 3 families (family 1- clades 1+2, family 2- clades 3, 4+5 and 
family 3- clade 6) with 95% of isolates belonging to families 1 (clades 1 and 2) or 2 (clades 3, 
4 and 5) (Vela Coral et al. 2001). Its role is to protect the pneumococcus from host immune 
defences by interfering with complement fixation. PspA prevents activation of C3b by 
interfering with complement factor B (Tu et al. 1999). Recently a novel mechanism of 
complement inhibition by PspA which involves phosphocholine (PC) has been described 
(Gang et al. 2012). PspA binds to PC and inhibits the interaction of Complement Reactive 
Protein (CRP) with PC and, therefore, curbing the classical pathway that leads to the 
opsonophagocytosis of the pneumococcus. PspA may also promote colonisation of host 
mucosa by binding lactoferrin and preventing killing by apaloctoferrin (Shaper et al. 2004).  
 
 
In vivo studies also confirm the contribution of PspA on pathogenesis of the 
pneumococcus. A knockout deficient in pspA in a D39 background significantly delayed the 
median survival time of CBA/N (McDaniel et al. 1987). Similarly, a serotype 3 pspA 
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knockout was cleared from the bloodstream of CBA/N within 6 hours of infection (Tu et al. 
1999). A pspA
-
 knockout in the D39, WU2 and DBL5 strains extended the survival time of 
CBA/N mice compared to pspA
+
 wild-type strains (Briles et al. 1988). Contrary to other 
published data, virulence of D39 pspA knockout strains was similar to that of isogenic wild-
type strain in BALB/c mice (Berry & Paton 2000). There are conflicting reports on the in 
vivo role of PspA in colonisation. A strain deficient in pspA colonised the nasopharynx of 
BALB/c and CBA/N mice the same way as the isogenic D39 wild-type strain (Balachandran 
et al. 2002; Orihuela et al. 2004). In another study, however, a pspA knockout in a D39 
background was attenuated in its ability to colonise the nasopharynx of CD1 mice (Ogunniyi 
et al. 2007). 
 
 
In all these studies in which inbred BALB/c mice were used, the role of PspA on 
invasive disease and colonisation was not successfully demonstrated. CBA/N mice were 
appropriate in demonstrating the role of PspA on invasive disease but not colonisation. The 
strain of pneumococcus did not seem to affect the outcome of the results, as D39 was the 
most frequently used strain in these studies. Taken together, these results indicate that the 
choice of mouse strain has a great impact on the outcome of virulence studies. 
 
 
1.3.2 Lipoproteins 
 
A second family of surface proteins are lipoproteins that contain a lipobox motif 
LxxC near the N terminus that is cleaved and covalently attached to the palmitic acid in the 
outer surface of the plasma membrane. Lipoproteins serve a number of important roles such 
as substrate-binding components of ATP-binding cassette (ABC) transport systems 
(Khandavilli et al. 2008). ABC transporters contribute to many bacterial processes such as 
acquisition of vital nutrients, stress responses and intracellular signalling, which are vital for 
bacterial growth and survival in vivo and ex vivo Of the 50 lipoproteins, 15 are non-ABC 
transporters of which their function is not well known (Miyaji et al. 2013). Pneumococcal 
surface antigen A (PsaA) is the most studied protein under ABC transporters and it is one of 
the candidate protein based pneumococcal vaccine epitopes (Talkington et al. 1996). PsaA is 
a 37-KDa highly conserved protein produced by all pneumococcal strains. PsaA shares 
homology with the family of metal binding lipoproteins which are involved in manganese 
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and zinc transport. Initially the role of PsaA as an adhesin was deduced from its clonal 
relationship with members of this protein family designated, lipoprotein receptor-associated 
antigen I (LraI). These proteins promote adhesion of the streptococcus genus to oral cavities 
or mucosal surfaces of the respiratory tract. The class includes fimbrial adhesin (FimA) from 
Streptococcus parasanguis, streptococcal saliva-binding protein (SsaB) from Streptococcus 
sanguis, streptococcal coaggreation adhesin (ScaA) from Streptococcus gordonii, and of 
course, PsaA from S. pneumoniae (Burnette-Curley et al. 1995; Kolenbrander et al. 1998). 
Work done by Berry and Paton was the first of its kind to demonstrate PsaA as an adhesin. 
The authors demonstrated the inability of PsaA deficient knockout strains to adhere to 
pneumocytes (Berry & Paton 1996). Romero-Steiner et al expanded on the role of PsaA as an 
adhesin. In their studies, they demonstrated that PsaA knockout strains were attenuated in 
their ability to adhere to nasopharyngeal cells. (Romero-Steiner et al. 2003). Although there 
was some doubt as to whether PsaA was a direct adhesin or not (Russell et al. 1990), work 
done by Anderton et al showed that PsaA adhered to nasopharyngeal cells through interaction 
with the human cellular receptor, E-cadherin (Anderton et al. 2007). The in vivo role of PsaA 
on pneumococcal pathogenesis was demonstrated by the inability of psaA null knockout 
strains to establish colonisation, cause systemic infection or otitis media (Marra et al. 2002; 
Novak et al. 1998). This could be attributed to the hypersensitivity of PsaA knockouts to 
oxidative stress and impaired growth in Mn2
+  
(McAllister et al. 2004). Other proteins studied 
in this class are the iron uptake lipoproteins PiuA and PiaA. These proteins are highly 
conserved among the pneumococcal strains and are immunologically cross-reactive. 
Immunization with a combination of PiuA and PiaA provides a higher degree of protection 
against systemic disease than with PiuA alone (Brown et al. 2001).  
 
 
Under the latter class of lipoproteins, non-ABC transporters, there is Putative proteinase 
maturation protein A (PpmA) and Streptococcal lipoprotein rotamase A (SlrA). Although 
they are known to be immunogenic, their potential as vaccine candidates needs to be 
investigated (Bergmann & Hammerschmidt 2006). Peptidyl–prolyl cis/trans isomerases 
(PPIases) are universal enzymes that accelerate the process of protein folding by reducing the 
energy of cis-trans conformational changes of peptidyl proline bonds. PPIases can be 
classified into three groups: i) Cyclophilins, which have a high binding affinity to 
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immunosuppressant cyclosprin A ii) Parvulins, and iii) FK506-binding protein, which have a 
high affinity for the immunosuppressant drug FK506. S. pneumoniae expresses two 
conserved lipoproteins attached to the surface of the pneumococcus that share homology with 
two families of PPIases namely: the putative maturation proteinase A (PpmA) and 
streptococcal lipoprotein rotamase A (SlrA) (Hermans et al. 2006; Overweg et al. 2000). 
PpmA is a 35 Kda protein which shares identity with the parvulin class; however, PPIase 
activity could not be demonstrated. Studies by Overweg et al demonstrated the contribution 
of PpmA to pathogenicity of the pneumococcus in a serotype 2 mouse model of pneumonia 
(Overweg et al. 2000). The median survival time of mice infected with a PpmA null strain 
was significantly longer compared to the mice infected with the wild-type strain. A knockout 
deficient in PpmA was also shown to be mutated in its ability to colonise the nasopharynx of 
mice, elucidating the role of ppmA in colonisation (Cron et al. 2009). SlrA belongs to a class 
of cyclophilins that has been demonstrated to possess PPIase activity, and presumably is 
involved in the correct folding of proteins on the cell surface. D39 slrA null knockout strains 
were attenuated in their ability to colonise the nasopharynx and BAL fluid of mice. It does 
not, however, have a role in invasive disease as both the knockout and its isogenic wild-type 
strain were equal in their ability to infect lungs and bloodstream of mice (Hermans et al. 
2006). To date, the exact role in virulence of both these proteins is unclear; however, their 
contribution to colonisation in mouse models of disease has been well documented.  
 
 
1.3.3 Sortase dependent proteins (LPXTG-anchored proteins) 
 
Sortase dependent proteins are an unrelated family of proteins that are characterised by 
a recognition signal that consists of the motif LPXTG (Leu-Pro-any-Thr-Gly), followed by a 
highly hydrophobic transmembrane sequence, then a cluster of basic residues such as 
arginine. Cleavage occurs between the Thr and Gly, with transient attachment through the 
Thr residue to the active site Cys residue, followed by transpeptidation that attaches the 
protein covalently to the cell wall. Within this heterogeneous class of proteins, there are 
proteases; HtrA (high-temperature requirement A) and PrtA (serine protease). There are zinc 
metalloproteases; immunoglobulin A1 (IgA1), zinc metalloproteases (ZmpB, ZmpC and 
ZmpD). There is also adhesins, pneumococcal serine-rich protein (PsrP) and Rlr pilus 
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(consisting of three protein subunits RrgA, RrgB and RrgC) and three sialidases; 
neuraminidases (NanA, NanB) and beta-galactosidase (BagA) (Pérez-Dorado et al. 2012).  
 
 
1.3.3.1 IgA1 bacterial protease 
 
IgA1 bacterial protease is one of the most extensively studied proteins in this group. 
IgA1 bacterial protease specifically cleaves IgA1, but not IgA2, at its hinge region releasing 
the Fcα effector domain from the antigen-binding Fab fragments. These α effector domains 
are able to adhere to host epithelial cells in vitro and inhibit phagocytic killing of 
pneumococci in vitro and in vivo (Weiser et al. 2003). Moreover, surface-bound specific 
IgA1-Fab fragments might shield pneumococci from intact antibody molecules and 
complement proteins, thus maintaining the survival of S. pneumoniae within the host (Kilian 
et al. 1988). One of the challenges with working with IgA1 bacterial protease is that the 
specificity of IgA1 cleavage is limited to human host IgA1, and thus there are no suitable 
animal models which one can use (Reinholdt & Kilian 1991). Despite this, animal 
experiments have indicated that it is an important virulence factor as it contributes to some 
stages of pathogenesis. In mouse models of pneumonia and colonisation, strains deficient in 
IgA1 bacterial protease were attenuated in their ability to cause infection and establish 
colonisation (Chiavolini et al. 2003; Hava & Camilli 2002). Other studies report that strains 
deficient in igA are attenuated in a septicaemia mouse model (Polissi et al. 1998). However, 
these results are not consistent with its suggested role as an adhesin that promotes 
colonisation. There is data that suggests that IgA bacterial protease is not a virulence factor as 
it does not contribute to any stage of pathogenesis (Lau et al. 2001). As in other studies, the 
choice of mouse model appeared to be a critical factor determining the outcome.  
 
 
1.3.3.2 Neuraminidase A (NanA) 
 
NanA is a well characterised member of the sialidases and the only one with 
neuraminidase activity. Although its exact role in pathogenesis is not well known, increased 
NanA expression is associated with colonies in the transparent phase which are associated 
with nasopharyngeal colonisation (King et al. 2004). This is supported by the inability of 
nanA deficient strains to adhere to nasopharyngeal and epithelial cells (Brittan et al. 2012). 
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There are studies that also demonstrate the requirement of nanA on long term nasopharyngeal 
carriage and persistent growth in the middle ear. This was evident by the effective clearance 
of strains deficient in the nanA gene from the nasopharynx of chinchillas two weeks earlier 
compared to their D39 parent strain. Similarly, the isogenic D39 strain persisted in the middle 
ear of chinchillas for approximately 20 days, compared to the knockout strain which was 
cleared in 10 days (Tong et al. 2000). NanA thus contributes to the formation of otitis media 
by revealing receptors on the host cells such as lactoferrin and IgA2, which are important for 
adherence ( King et al. 2004). This protein was also essential in biofilm formation (Trappetti 
et al. 2009); with an indication that nanA knockout strains had a reduced capacity to form 
biofilms during in vitro biofilm experiments (Parker et al. 2009). The involvement of NanA 
in formation of biofilms thus contributes to prolonged colonisation by the pneumococcus.  
 
 
1.3.4 Other virulence factors 
 
There are proteins which are located in the cytoplasm, i.e. pneumolysin; and those that 
are surface exposed but lack classic leader signal peptides and membrane-anchoring motifs, 
i.e. Serine-threonine kinase P (StkP), pneumococcal cell surface protein A (PavA), 
pneumococcal cell surface protein B (PavB), Enolase, Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH), 6-phosphogluconate dehydrogenase (6PGD) and 
Phosphoglycerate kinase (PGK). These proteins contribute to the virulence of the 
pneumococcus by promoting systemic infection and colonisation by the pneumococcus. 
PavA and PavB mediate adherence and invasion of the pneumococcus into epithelial cells 
through their interaction with host proteins, fibronectin and plasminogen (Jensch et al. 2010; 
Kadioglu et al. 2010). Proteins of interest in this group are pneumolysin, which is one of the 
first proteins to be considered as a potential pneumococcal vaccine; and serine threonine 
kinase (StkP) which is one of the novel types of pneumococcal vaccine antigens discovered 
using genomic scale antigenic fingerprinting. Below is a brief description of these proteins.  
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1.3.4.1 Pneumolysin  
 
Pneumolysin is a thiol-activated haemolysin which is located in the cytoplasm and 
released when cells undergo autolysis. Pneumolysin uses cholesterol as a receptor for binding 
to the host’s cell membrane, followed by formation of oligomeric transmembrane pores 
causing lysis. In vitro results demonstrated the importance of Ply in colonisation by the 
pneumococcus by inhibiting the ciliary beat of the human respiratory epithelium (Steinfort et 
al. 1989), therefore allowing it to adhere to the epithelial cells where successful colonisation 
could be established. In addition, the toxin is also important for disrupting the tight junctions 
between epithelial cells and allowing a portal of entry for pneumococcal invasion (Thornton 
& McDaniel 2005). Data from the same study by Thornton & McDaniel showed that ply 
induces transcription of host ICAM-1, an epithelial cell adhesion molecule that plays a role in 
pneumococcal adherence. In a mouse model of systemic infection, ply
- 
knockout strains 
survived longer than mice infected with wild-type isogenic strains (Berry & Paton 2000), 
therefore demonstrating the requirement of Ply for survival in the bloodstream. Ply deficient 
knockout strains were also attenuated in their ability to multiply in lungs of mice compared to 
their isogenic wild-type strains (Kadioglu et al. 2000). Work done by Ogunniyi et al, 
revealed the requirement of pneumolysin in establishing colonisation, but not for prolonging 
it (Ogunniyi et al. 2007). This was evident by the low bacterial recovery of D39 Ply deficient 
strains from CBA/N mice at days 1 and 2 of the seven days sampled. On the other hand 
Richards et al successfully indicated that this protein was required for persistent colonisation 
for at least 14 days in MF1 mice (Richards et al. 2010). In two separate studies, however, 
pneumolysin knockouts in serotype 2 and 14 backgrounds behaved similarly to their 
wild-type counterparts (Kadioglu et al. 2002; Rubins et al. 1998).  
 
 
In general, Ply is required for the development of pneumococcal pneumonia and 
survival of the pneumococcus in the blood. Although there are results negating the role of Ply 
on the early stages of disease, there is convincing data indicating its importance in 
establishing and ensuring prolonged colonisation by the pneumococcus in the nasopharynx. 
Thus, Ply is important in multiple stages of pathogenesis, colonisation, pneumococcal 
pneumonia and septicaemia.  
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1.3.4.2 Serine-threonine kinase P (StkP) 
 
StkP has a key role in the regulation and in maintaining the physiology of the 
pneumococcus. The absence of the stkP gene makes the pneumococcus less competent in 
genetic transformation and more prone to extracellular stress. In addition, it leads to 
disruption of pneumococcal cell division that translates to slow growth of the pneumococcus 
in vitro (Nováková et al. 2010; Giefing et al. 2008; Fleurie et al. 2012). The role of stkP in 
virulence was demonstrated by the inability of knockout strains to infect the lungs and grow 
in the bloodstream of mice (Echenique et al. 2004).  
 
 
1.4 NASOPHARYNGEAL COLONISATION 
 
S. pneumoniae is spread from person-to-person by respiratory droplets, meaning that 
transmission to others generally occurs during coughing or sneezing. Colonisation is 
transient, dynamic, and most children experience multiple episodes of colonisation by the age 
of two. Acquisition of the pneumococcus is normally at an earlier age for children in 
developing countries compared to more developed countries (B M Gray et al. 1980; 
Kwambana et al. 2011). The risk of acquiring the pneumococcus is exacerbated by factors 
such as having siblings less than 10 years of age, overcrowding at homes and attending day 
care (Kinabo et al. 2013). Prevalence of colonisation is strongly associated with age and 
geographical location. In Gambia, over 80% of babies in the 3
rd
 month are colonised with the 
pneumococcus and remain colonised as such up until 11 months (Hill et al. 2008). This is in 
contrast to the 9% of Finnish infants who become colonised when they are 2 months old, 
increasing to 43% by 24 months of age (Syrjanen et al. 2001). Whilst the prevalence of 
nasopharyngeal colonisation declines to 10% and generally remains at that level through 
adulthood in developed countries (Goldblatt et al. 2005; Gray & Dillon 1988), a high 
prevalence of colonisation may persist in African settings among children (97%) and in 
adults (85%) in low-income settings (Hill et al. 2010). 
 
 
The initial step in the establishment of pneumococcal infection is adherence of the 
bacteria to the epithelial cells (see Figure 1.2). The host mucosal system which is greatly 
glycosylated mainly with glycan structures is the first barrier of protection against bacterial 
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infection. In order to ensure successful colonisation of the nasopharynx, the pneumococcus 
must break down the mucosal barrier and evade the host immune responses to ensure close 
contact with the host receptors. The pneumococcus expresses NanA that compromise the 
protective barrier by revealing receptors on the host cells important for adherence (King et al. 
2006). In order to evade the mucosal barrier the pneumococcus produces bacterial IgA1 
protease and pneumolysin. These virulence factors are described in detail in Section 1.3. 
 
 
Once the mucosal barrier is compromised and the receptors are exposed, adhesins, 
expressed by the pneumococcus, bind to nasopharyngeal cells through interaction with those 
human cellular receptors. For example, PsaA binds to nasopharyngeal epithelial cells through 
interaction with E-cadherin; PavB binds fibronectin and plasminogen and PspC binds 
polymeric Ig receptor (Anderton et al. 2007; Papasergi et al. 2010; Zhang 2000). In addition, 
PspC is one protein that will actually ensure a lengthy colonisation by the pneumococcus in 
the nasopharynx.  
 
 
Interestingly the pneumococcus can reside in the nasopharynx without causing any 
symptoms or disease. This can be explained by the fact that some serotypes can generate 
capsular antibodies that may effectively protect against subsequent colonisation by the 
homotypic capsular types (Weinberger et al. 2008). In a separate study, Richards et al, 
indicated that mice previously colonised with a pneumolysin negative isogenic mutant (PLN-
A) had a reduced duration of subsequent colonisation with a wild-type D39 strain and 
significantly increased survival following invasive pneumococcal challenge (Richards et al. 
2010). These studies indicate the immunising effect of prolonged colonisation as one of the 
protective factors against pneumococcal disease. The question that arises then is how does 
disease develop? Gray et al investigated carriage and disease in 82 infants for 24 months of 
life. Nasopharyngeal swabs were collected for the first six months of life and at 2-3 months 
thereafter. Pneumococcal infection which was confirmed in 31 infants with the majority of 
infection being attributed to acute otitis media (AOM), was mainly associated with a newly 
acquired serotype (Gray et al. 1980). Thus, development of disease is seldom associated with 
prolonged carriage, but rather from acquisition with a new serotype. Colonisation with 
S. pneumoniae is therefore a pre-requisite for developing pneumococcal disease when the 
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organism progresses beyond the nasopharynx into the lungs, meninges and blood. It is 
suggested that pneumococcal vaccine candidate antigens that can prevent or limit 
colonisation could prevent the development of pneumococcal disease. It is also imperative to 
develop or improve mouse models of disease that mimic the natural course of disease in 
children, to understand the dynamics of colonisation in order to combat infections due to the 
pneumococcus. 
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Figure 1.2 Schematic diagram of various virulence factors involved in S  pneumoniae 
adherence to host cells. Adapted from (Bogaert et al. 2004). 
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1.5 PNEUMOCOCCAL PATHOGENESIS 
 
S. pneumoniae can cause bacteraemia, pneumonia, paranasal sinusitis and otitis media, 
or meningitis, which is usually secondary to one of the former infections. Once in the 
bloodstream, the pneumococcus can transcend the endothelial layer covering the blood brain 
barrier (BBB) into the subarachnoid space to cause bacterial meningitis (Henriques-Normark 
& Tuomanen 2013). Acute otitis media (AOM) is defined by inflammation of the middle ear. 
The three most common otopathogens associated with AOM and carried asymptomatically in 
the nasopharynx of children are S. pneumoniae, nontypeable Haemophilus influenzae and 
Moraxella catarrhalis. Viral upper respiratory tract infections (URI) increase the risk of 
AOM by triggering proliferation of otopathogens causing inflammation of the eustachian 
tube and nasopharynx. The result of which is infection of the middle ear due to presence of 
bacteria. The presence of bacteria in the middle ear induces an influx of neutrophils (Bakaletz 
2010). The intense inflammation observed in pneumococcal otitis is directed by 
pneumococcal cell wall components such as pneumolysin and lipopolysaccharides from 
Gram- positive and –negative bacteria, respectively (Heikkinen & Chonmaitree 2000; 
Rynnel-Dagöö & Agren 2000).  
 
 
There are situations when the bacteria in the nasopharynx manage to escape the 
mucosal defensive barrier and disseminate into the alveolus, thus leading to pneumonia 
(Henriques-Normark & Tuomanen 2013). Upon encountering the lungs, pneumococci then 
adhere to pneumocytes via glycoconjugates, GalNacβ-3-Gal and GalNacβ-4-Gal. The 
subsequent process of lung epithelial invasion is mediated by the G-protein-coupled platelet 
activating factor receptor (PAF receptor). PAF receptors binds to phosphorylcholine that 
forms part of the pneumococcal cell wall and triggers a pro-inflammatory cytokines response, 
which then upregulates PAF receptor expression (Cundell et al. 1995). The pneumococcus 
thus utilises the interaction between PAF receptors and phosphorylcholine for internalisation 
through the lung epithelial cells. At this point, LytA plays a major role in the development of 
pneumonia. A study by Orihuela et al indicated a reduced ability of the lytA deficient mutant 
to replicate in the lungs of mice (Orihuela et al. 2004). LytA acts by lysing the pneumococcus 
and in the process, releasing Ply. The presence of both proteins ensures the progression of 
disease by inducing an inflammatory response that proves detrimental to the host. 
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Since the PAF receptor is also present on the surface of vascular endothelial cells, the 
pneumococcus can utilise the biological interaction between the PAF receptor and 
phosphorylcholine to reach the bloodstream. The pneumococcus can also reach the 
bloodstream by transcending the nasopharyngeal epithelial cells. PspC binds polymeric Ig 
receptor which then translocates the pneumococcus across the nasopharyngeal epithelial cells 
in order to invade the bloodstream (Zhang et al. 2000). However, the role of PspC in 
septicaemia is less defined as reviewed in section 1.3.1.1, thus giving rise to questions about 
the role of the PspC and pIgR complex in pneumococcal invasion. Another mechanism by 
which the pneumococcus can cross epithelial cells is by inter or pericellular migration. By 
binding to plasminogen, pneumococcal proteins such as enolase, CbpE and Gly3Ph enhance 
the binding of the pneumococcus to endothelial cells. The complex between pneumococcal 
proteins and plasminogen also assists in compromising the tight junctions between 
endothelial cells by degrading a cell adhesion receptor, cadherin (Attali et al. 2008; Pancholi 
et al. 2003). 
 
 
Once the pathogen is in the blood it uses its primary virulence factor, the capsule, to 
thrive. The capsule assists pneumococci to survive in the bloodstream by avoiding 
phagocytosis (Section 1.2). Key virulent factors like PspA and Ply further increase the 
survival rate of pneumococci in the blood stream by curbing the classical complement 
pathway (Sections 1.3.1.2 and 1.3.4.1). Occasionally the pneumococcus can transcend the 
endothelial layer covering the blood-brain barrier (BBB) into the subarachnoid space to cause 
bacterial meningitis. The pneumococcus can cross the blood brain barrier by utilising 
pneumolysin to disrupt the tight junctions of microvascular endothelial cells (Section 
1.3.4.1). Unlike the bloodstream that is abundant with complement components and 
phagocytes, the central nervous system is low on both. Autolysis of the pneumococcus by its 
main autolytic protein, LytA results in the release of pneumolysin, LTA and peptidoglycans 
(Koedel et al. 2002). The presence of these products activates a proinflammatory response 
and neuronal damage seen in pneumococcal meningitis.  
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1.6 VACCINES AGAINST S. PNEUMONIAE 
 
1.6.1 Polysaccharide-based vaccines 
 
The polysaccharide vaccine is a polyvalent vaccine based on the formulation of various 
capsular polysaccharide antigens. The first pneumococcal vaccine licensed was Pneumovax-
14. The formulation of Pneumovax-14 was based on the 14 pneumococcal serotypes derived 
from epidemiologic information from the United States, parts of Europe and South Africa and 
on limited immunochemical information, (Robbins et al. 1983). The 14-valent vaccine was 
reformulated to cover 23-valent serotypes after the emergence of additional data on the 
distribution of serotypes causing disease and on the biochemical and immunologic properties 
of the capsular polysaccharide (Hilleman et al. 1981; Riley et al. 1977). Pneumovax-23 is 
recommended to elderly people ≥65 years of age and to young adults who are at risk of 
contracting IPD and pneumococcal pneumonia. Since pneumovax-23 is composed entirely of 
polysaccharides, the immune response elicited by the vaccine is T-cell independent. 
Polysaccharides induce B cell activation without recruiting T-cell help. The consequence of 
this is that memory maturation in these antigens is poor since this feature is dependent on 
helper T cells (Obukhanych & Nussenzweig 2006). In addition, children below the age of 2 
years are unable to elicit a response to this vaccine since children’s T-cell independent 
immune system is immature (Douglas et al. 1983; Rijkers et al. 1998). 
 
 
In order to change the immune response from a T-cell independent to a T-cell 
dependent one, capsular polysaccharides were linked to an immunogenic carrier protein such 
as tetanus toxoid and a non-toxic knockout of diphtheria toxin (CRM197) and were shown to 
be highly immunogenic in children <2 years (Lesinski & Westerink 2001). A 7 valent 
conjugate vaccine, PCV7 (Prevnar, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.) 
was licensed in the US in 2000. It contains seven serotypes: 4, 6B, 9V, 14, 18C, 19F and 23F, 
which are the serotypes that most frequently cause invasive disease in young children in the 
USA. After introduction of PCV7 in the USA, the overall incidence of IPD among children 
aged <5 years decreased from 98.7 cases per 100,000 during 1998-1999 to 23.4 cases per 
100,000 in 2005. An additional herd effect resulted in a decrease in streptococcal infections 
in non-vaccinated children and the elderly (Smith et al. 2007). In South Africa, the overall 
incidence of IPD among children aged <2 years decreased from 54.8 cases per 100,000 
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during 2005-2008 to 17.0 cases per 100,000 in 2012. Significant reductions were also 
observed in the incidence of IPD caused by vaccine serotypes among persons 25 to 44 years 
of age (von Gottberg et al. 2014). The 9 valent pneumococcal conjugate vaccine (Wyeth 
Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.) was developed in order to address the 
increasing burden of IPD in children in developing countries, by serotypes 1 and 5. Clinical 
trials conducted in South Africa using the 9-valent pneumococcal conjugate vaccine (PCV9) 
indicated an efficacy rate of 65% in HIV-infected children and 83% in HIV-uninfected 
children against IPD, 20% in HIV-infected children against radiologically confirmed 
pneumonia and 13% in HIV-uninfected children (Klugman et al. 2003). In Gambia, the 
efficacy of PCV9 was 77% against IPD caused by vaccine serotypes, 50% against disease 
caused by all serotypes, 15% against all-cause admissions and 16% against mortality (Cutts et 
al. 2005). PCV9 was only for clinical trial purposes and was never licensed as a vaccine, but 
rather included in the 13-valent PCV formulation. 
 
 
Despite the initial success of PCV7, the limited serotype coverage has resulted in cases 
of serotype replacement, whereby the nasopharyngeal ecological niche previously occupied 
by vaccine serotypes is colonised by non-vaccine serotypes. Increases in non-vaccine 
serotypes are due to capsule switching, whereby a pneumococcus acquires a new capsule 
operon by horizontal gene transfer. The result of which is the potential for vaccine efficacy 
being diminished by an increase in non-vaccine type diseases (Singleton et al. 2007; 
Sabharwal et al. 2013). In order to meet the shortcomings of PCV7, two higher valent 
conjugate vaccines were developed. In 2009, 10-valent (PCV10; Synflorix, 
GlaxoSmithKline) which includes additional serotypes 1, 5 and 7F above the PCV7 serotypes 
was licensed for use in children less than 2 years of age. In Kilifi, 2 years after the 
introduction of PCV10 in 2011, carriage of vaccine serotypes was reduced by two-thirds in 
both children younger than 5 years and in older individuals (Hammitt et al. 2014). In 2010, 
PCV13 (Prevnar, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.) which includes 
serotypes 1, 3, 5, 6A, 7F, and 19A above the PCV7 serotypes, was introduced in some 
industrialised countries and later in 2011 in South Africa, to extend the limited serotype 
coverage of PCV7. IPD caused by the six additional serotypes included in PCV13 over and 
above those in PCV7, declined by 93% in children less > 5 years old in USA by July 2012 to 
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June 2013. The incidence of IPD among adults caused by the six additional serotypes in 
PCV13 also declined by 58-72%, depending on age by July 2012 to June 2013 (Moore et al. 
2015). 
 
 
What is clear from these studies is that despite the success of PCVs, the replacement of 
non-vaccine serotypes and the prevalence of antimicrobial resistance should be continuously 
monitored. Another challenge with PCV is that the conjugation chemistry is technically 
difficult thus making the process expensive. This translates to unaffordable polysaccharide 
conjugate vaccines to many low-income countries where the need is greatest. 
 
 
1.6.2 Protein based pneumococcal vaccines 
 
Due to the limitations and disadvantages surrounding PCVs, attention has been focused 
on other surface structures of pneumococci, such as pneumococcal proteins as vaccine 
candidates. Vaccines made from recombinant proteins are likely to be inexpensive to 
produce, offer broader serotype coverage, and are able to illicit T-cell dependent responses in 
young children. Below is a description of some of the prominent proteins that are at advanced 
stages of development. Table 1.1 summarises on-going trials on promising protein candidate 
vaccines.  
 
 
1.6.2.1 PspC 
 
The pspC gene is present in about 75% of pneumococcal strains but the lower estimate 
is at least partly due to the fact that the PspC proteins are heterogeneous in nature, and they 
are not always recognized to belong to the same group (Brooks-walter et al. 1999). 
Therefore, PspC may not seem like an ideal vaccine candidate due to its polymorphic 
heterogenous regions. Early studies, however, revealed the protective potential of choline 
binding proteins, with PspC being the dominant protein, against nasopharyngeal carriage and 
pneumococcal pneumonia (Rosenow et al. 1997). Further studies using PspC recombinant 
protein, demonstrated its protective efficacy in a mouse model of colonisation (Balachandran 
et al. 2002). Vaccination of mice with the entire length of PspC was shown to protect against 
a strain that did not produce the protein (Iannelli et al. 2002). This effect can be explained by 
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the fact that the choline binding domain of PspC is cross reactive to other choline binding 
proteins such as PspA, thus making it an ideal vaccine candidate. These results are in 
agreement with human colonisation studies conducted by McCool et al, demonstrating the 
increase in IgG titres of PspC at the onset of colonisation with the pneumococcus (McCool et 
al. 2003). Now, a PspC based vaccine that is at the preclinical stages is a pneumolysoid/ 
PspC peptide recombinant fusion protein that has been successfully demonstrated to protect 
mice in models of nasopharyngeal carriage, otitis media, pneumonia and sepsis (Mann et al. 
2014). The suggestion is to include PspC in a protein based vaccine since its production 
correlates with onset of colonisation.  
 
 
1.6.2.2 PspA 
 
Early studies on PspA revealed its indirect role in protecting mice against infection due 
to the pneumococcus, despite the lack of its purified form. McDaniel et al and Briles et al 
revealed that two monoclonal antibodies that bind to PspA were demonstrated to be 
protective against fatal pneumococcal infection by several strains (McDaniel et al. 1984; 
Briles et al. 1989). McDaniel and co-workers went further to prove that PspA
+
 pneumococci 
and not PspA
-
 pneumococci were protective against a lethal infection with pneumococci in 
Rx mice (McDaniel et al. 1987). These studies form a basis for much of research and 
advances made on this protein. Talkington et al, used PspA in its purified form and 
demonstrated its protective efficacy in a fatal pneumococcal model against 4 pneumococcal 
strains tested (Talkington et al. 1991). Ogunniyi et al, investigated the efficacy of 
recombinant PspA in a mouse model of pneumococcal invasive disease with results 
indicating the median survival time for vaccinated mice was significantly longer than those 
for unvaccinated mice (Ogunniyi et al. 2007).  
 
 
Protection against colonisation with the pneumococcus in mice vaccinated with 
recombinant PspA seems to depend on the length of PspA used. For example, mice 
vaccinated with full length recombinant PspA were protected against carriage with the 
pneumococcus and also had significantly higher PspA specific mucosal IgA antibody levels 
(Wu et al. 1997; Arulanandam et al. 2001; Palaniappan et al. 2005). However, a truncated 
PspA recombinant protein elicited less protection against pneumococcal carriage (Briles et al. 
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2003). In spite of its amino acid sequence heterogeneity, PspA can elicit antibodies that are 
cross protective and cross reactive. PspA clade4 and clade5 induce antibodies with a high 
degree of cross reactivity that protects mice against lethal challenge with the pneumococcus 
(Moreno et al. 2010). A combination of PspA clade 3 and clade 2 elicited protective and 
cross reactive antibodies against pneumococcal challenge with D39 (clade 2), WU2 (clade 2), 
TIGR4 (clade 3) and BG9739 (clade 1), EF5668 (clade 4) and ATCC 6303 (clade 5) (Piao et 
al. 2014). These results can be translated to human studies where sera from adults vaccinated 
with a PspA clade 2 cross reacted with 37 strains with different PspA clades (1-5) (Nabors et 
al. 2000). The importance of these studies emphasises the fact that a PspA based vaccine 
should contain at least one fragment from each of the two major families to enable broad 
coverage against diverse pneumococcal strains. Despite this protein being one the forerunners 
of protein based vaccine candidates, there are concerns about its potential to cross react with 
the human protein myosin, which could lead to induction of autoimmune cardiac disorders. 
This was, however, not shown to be the case by Perciani et al, who reported that the presence 
of cross-reactive antibodies does not represent a risk to the development of an autoimmune 
response. Human trials conducted should be designed to exclude PspA regions that cross 
reacts to the human protein, myosin (Perciani et al. 2012). Table 1.1 shows PspA based 
vaccines in the pre-clinical phase, indicating that these vaccines will be highly protective 
against colonisation as well as in invasive disease. 
 
 
1.6.2.3 PpmA, SlrA and IgA bacterial protease 
 
In vitro studies have demonstrated the protective potential of PpmA protein with its 
ability to opsonise several pneumococcal strains (Overweg et al. 2000). However, PpmA 
antibodies were not protective against fatal infection with a serotype 3 strain (Gor et al. 
2005).The combination of the three proteins in a Gram-positive Enhancer Matrix (GEM) 
based trivalent vaccine was protective against pneumococcal pneumonia (Audouy et al. 
2007). The presence of PpmA, SlrA and IgA bacterial protease antibodies in children induced 
by the presence of the pneumococcus, suggest that these proteins are immunogenic (Shoma et 
al. 2011). However the presence of PpmA, SlrA and IgA bacterial protease antibodies does 
not correlate with a decrease in colonisation and were not protective against subsequent 
colonisation (Adrian et al. 2004). The presence of antibodies to PpmA, SlrA and IgA 
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bacterial protease, however, partially protected against respiratory tract infection (RTI) such 
as pneumonia and otitis media (Bogaert et al. 2006; Lebon et al. 2011).  
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Table 1.1 On-going trials of promising protein vaccines antigens 
Antigens Vaccine based  
combinations 
Current status and comments         References 
CbpA/PspC A.Active CbpA peptides fused 
with L460D pneumolysoid. 
 Pre-clinical phase. 
 Broadly immunogenic against 
pneumococcal infection (colonisation, otitis 
media, pneumonia, bacteraemia, meningitis, 
and meningococcal sepsis). 
 Induced functional antibodies. 
(Brooks-walter et 
al. 1999; Mann et 
al. 2014) 
PspA A. Attenuated Salmonella typhii 
vectors, family 1, clade 2 PspA 
vaccine. 
 Phase I complete. 
 Non-immunogenic PspA antibodies passed 
safety tests. 
(Frey et al. 2013) 
 
B. Nanogel based, family1, clade 
2 PspA vaccine. 
 
 Pre-clinical phase.  
 Induces high levels of anti-PspA serum 
IgG and nasal and bronchial IgA antibodies. 
 No functionality assay performed. 
(Kong et al. 2013) 
 
C.PspA5+diphthera and tetanus 
toxoid + adjuvant; Bordetella 
pertussis lipopolysaccharide 
vaccine 
 Pre-clinical phase. 
 Induces high levels of systemic IgG and 
protects against lethal challenge in mice.  
 No functionality assay performed. 
(Lima et al. 2013) 
 
D.Conjugate serotype 6B with 
PspA clade1 as a carrier. 
 Pre-clinical phase. 
 Induces functional anti-rPspA and anti-
PS6B antibodies. 
 No functionality assay performed. 
(Perciani et al. 
2013) 
 
E.PspA-Pd fusion proteins.  Pre-clinical phase. 
 Induces high levels of systemic IgG and 
protects against lethal challenge in mice. 
 Induced functional antibodies. 
(Goulart et al. 
2011) 
Stkp+PsaA+PcsB A.IC47 vaccine.   Early stage clinical evaluation. 
 Protects against nasopharyngeal 
colonisation, pneumonia, and septicaemia. 
 No functionality assay. 
(Schmid et al. 
2011) 
SlrA+PpmA+IgA1 
bacterial protease 
A.GEM-based trivalent vaccine.  Pre-clinical phase. 
 Confers significant protection against fatal 
pneumococcal pneumonia. 
 No functionality assay performed. 
(Audouy et al. 
2007) 
Pneumolysin(Pdb) A.Pneumolysoid PlD1. 
 
 
 
 Phase 1 complete. 
 Immunogenic PlyD1 IgG antibodies with 
toxin neutralising activity. 
 Induced functional antibodies.  
(Bologa et al. 
2012) 
 
 
B.Trivalent vaccine 
[Ply+PhtD+ non-typeable 
H. influenzae (NTH1) 
protein D (PD)]. 
 
  Phase 1 complete. 
 Increased levels of antibodies in serum. 
 Transient activation of cell-mediated 
immune response. 
 No functionality assay performed. 
(Berglund et al. 
2014) 
 
C. ΔA146Ply fused with heat 
shock protein, DNA J. 
 Pre-clinical phase. 
 Protects mice against challenge with lethal 
dose of pneumococcus. Fusion protein 
induces significantly higher levels of anti-
DnaJ IgG in serum and secretory IgA (sIgA). 
 No functionality assay performed. 
(Liu et al. 2014) 
PcpA 
 
A. Bivalent PcpA-pneumococcal 
histidine triad protein D vaccine. 
 Phase I trial. 
 Induces significant systemic IgG 
antibodies. 
 No functionality assay performed. 
 
(Khan et al. 2012) 
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Antigens Vaccine based  
combinations 
 Current status and comments         References 
 B.Monovalent PcpA vaccine. 
 
 Phase I trial. 
 Immunogenic PcpA IgG antibodies. 
 No functionality assay performed.  
 
(Bologa et al. 
2012) 
 
PhtD A. Monovalent PhtD vaccine. 
 
 Phase I/Phase II complete. 
 PhtD adjuvanted with AS02v increases 
PhtD-specific cell-mediated immune 
responses in young and older adults. 
 No functionality assay performed. 
 
(Leroux-Roels et 
al. 2013; 
Plumptre et al. 
2013) 
 
 B.Truncated derivatives of PhtD.  Pre-clinical phase. 
 Protects mice against septicaemia and 
highly immunogenic over the full-length 
derivative. 
 No functionality assay performed. 
(Josée Hamel et 
al. 2004) 
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1.6.2.4 PLY 
  
Pneumolysin has potential as a candidate vaccine because of its amino acid sequence 
conservation and antigenicity among clinical isolates. However, due to its cytolytic activity, 
PLY is not a suitable vaccine in human studies. Removing or mutating certain amino acids in 
PLY toxoid (Pdb) reduces its toxicity considerably, and this has been successfully used in 
human studies (Lock et al. 1996). In humans, pneumolysin antibodies are stimulated upon 
infection with the pneumococcus (Kamtchoua et al. 2013). Presence of pneumolysin IgG 
antibodies does not, however, correlate with a decrease in pneumococcal colonisation 
(McCool et al. 2003). This observation is in agreement with animal models of disease that 
fail to show any effect of Pdb antibodies against  colonisation (Briles et al. 2000). Pdb 
antibodies are, however, protective against fulminant pneumonia and significantly increases 
survival time of mice infected with the pneumococcus (Briles et al. 2003). More importantly 
is that Pdb antibodies protects mice against 9 serotypes of the pneumococcus, displaying its 
broad spectrum capabilities (Janet E Alexander et al. 1994). It is presumed that vaccination 
with Pdb toxoid protects mice against infection by neutralising the biological functions of the 
toxoid rather that by inducing antibodies that promote bacterial opsonophagocytosis (Paton & 
Boslego 2008). Based on that fact, it is suggested to combine pneumolysin toxoid with other 
bacterial proteins that have the capability of eliciting opsonic antibodies. A phase I trial on a 
trivalent vaccine PLY D1/PhtD/PD developed by GSK was completed and results revealed it 
induced a cell mediated immune response and was safe in adults (Berglund et al. 2014). In 
addition, there is the broadly protective pneumolysin toxoid-CbpA peptide recombinant 
fusion protein, which is in the pre-clinical stages of evaluation (Mann et al. 2014). In all these 
studies, immunogenicity of Pdb is clear but whether antibodies are protective is yet to be 
determined. 
 
 
1.6.2.5 StkP 
 
StkP was protective against serotype 1- induced bacteraemia in neonatal and adult mice 
and against strains of serotypes 3- and 19F induced pneumonia in adult mice. Interestingly, 
the protective efficacy of recombinant StkP in a pneumonia model induced with a strain of 
serotype 19F was comparable to that of PCV7 (Giefing et al. 2008; Olafsdottir et al. 2012). 
StkP formed part of the study, together with PsaA and PcsB that demonstrated the 
immunogenicity of pneumococcal proteins from adults previously exposed to the 
pneumococcus (Schmid et al. 2011). The combination of these three proteins, make up a 
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candidate protein vaccine, IC47. Safety and immunogenicity testing has been completed on 
this candidate protein vaccine (Ginsburg et al. 2012). The IC47 might be beneficial for 
protection against pneumococcal colonisation because it activates the Th17 response. The 
role of Th17 cells in mucosal protection against the pneumococcus is well documented 
(Moffitt et al. 2011; Olafsdottir et al. 2012).  
 
 
1.7 Challenges with pneumococcal protein vaccines 
 
Given the wealth of information and extensive research on pneumococcal proteins, 
there is still no licenced protein based vaccine. There are a number of factors hindering 
progress in this area of research. Firstly, it is important to note that whilst an effective 
pneumococcus vaccine is available, it will be unethical to conduct placebo-based control 
trials. In such a situation, non-inferiority trials would have to be carried out including PCV 
being given to all participants. The mechanism of protection of protein based vaccines and 
PCVs will differ, hence not being able to use current correlates of protection criteria for the 
licensure of protein-based vaccines, but rather evaluation against the residual remaining 
clinical disease (Paton & Boslego 2008). This will require a large number of subjects and 
would be expensive. One way of working around the issue of ethics and costs in an 
environment when there is already an effective vaccine, is to increase the serotype coverage 
of already existing pneumococcal vaccines by combining them with pneumococcal proteins. 
One such candidate is being developed by GSK-biologicals to broaden the spectrum of 
PCV10 coverage by combining PCV10 with PhtD (pneumococcal histidine triad protein D) 
and PLYD1. The vaccine has completed phase II trials in children aged 12-23 months old in 
The Gambia and Czech Republic, and healthy adults from Sweden aged 18-40 (Leroux-Roels 
et al. 2013; Prymula et al. 2014).  
 
 
Another challenge with the development of pneumococcal protein vaccines centres on 
the choice of an appropriate functional assay for antibodies to pneumococcal proteins. 
Currently, the common method of assessing the protective ability of antibodies is by way of 
ELISA (Enzyme-Linked ImmunoSorbent Assay). This assay however cannot determine the 
functionality of antibodies compared to an Opsonophagocytosis assay (OPA) (Nahm & 
Romero-Steiner 2008). However, to date, OPA has not been well established for antibodies 
generated against the pneumococcal surface proteins. As a consequence, there is no correlate 
of protection that has been standardised for protein antigens (Genschmer et al. 2013). The 
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difficulty in standardising the correlates of protection for protein antigens lies in the 
protective mechanism of the pneumococcus driven by the capsular polysaccharide. 
(Harfouche et al. 2012). Based on these reasons, the pathway for further development of 
protein based vaccines continues to be developed. 
 
 
1.8 ANIMAL MODELS OF COLONISATION AND PNEUMONIA 
  
The choice of animal models in this study stems from the intrinsic limitations in the use 
of human experimental models. Much of the research in protein vaccine candidates is 
conducted in mice. This enables easier studies on the pathophysiological process of disease. 
Mice are easy to manipulate, cheap to acquire and easy to breed in comparison to other 
animal models (Mizgerd & Skerrett 2008). Rats have been used in pneumococcal 
colonisation studies but one study demonstrated that density of colonisation fluctuated until it 
was stabilised by administration of ampicillin (Iizawa et al. 1996). That observation casts 
doubt on the quality of data achieved on other rat models of pneumococcal colonisation that 
did not take measures on stabilising the density of colonisation. An intrathoracic 
pneumococcal model of low inoculum has been described in rats (Saladino et al. 2004). 
However, the route of infection does not mimic the natural route of infection observed in 
humans. In an attempt to find suitable animal models that are physiologically related to 
humans, Phillip and others demonstrated the use of the rhesus macaques (Philipp et al. 2012). 
Colonisation was maintained for two weeks, giving time to assess the natural course of 
disease as observed in humans. The use of larger animals, however, proved to be expensive 
and hence the decision to continue using  mice (Philipp et al. 2012).  
 
 
 Wu and his co-workers laid the foundation for establishing carriage models in mice. In 
order to induce long term carriage without the development of disease, 10µL of different 
serotypes 4, 6B, 14, and 23F at 10
7
 CFU was intranasally administered to BALB/c, C57BL/6 
and CBA/N mice (Wu et al. 1997). The robustness of the model was demonstrated by using 
different inbred mouse strains. Many researchers in demonstrating the role of pneumococcal 
proteins in pathogenesis adapted this model of colonisation. The role of PspA on the early 
stages of colonisation was not demonstrated in BALB/c and CBA/N mice models of 
colonisation (reviewed in section 1.3.1.1). These results are inconsistent with its indirect role 
on colonisation by the pneumococcus by binding lactoferrin and preventing killing by 
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apaloctoferrin. Inbred strains like the BALB/c strain are relatively resistant to infection with 
the pneumococcus (Gingles et al. 2001). In addition, duration and density of colonisation of 
BALB/c, C57BL/6 and CBA/N inbred strains has been shown to differ, as demonstrated by 
their response to the serotype 23F strain. BALB/c mice were colonised with a mean density 
of 7.1X10
5 
CFU/mL at day 3 post inoculation and by day 65, no pneumococci were detected. 
C57BL/6 mice were colonised at a mean density of 6.6X10
4
 CFU/mL at 3 days post 
inoculation and had no pneumococci detected by day 28. CBA/J mice were colonised with a 
mean density of 2.5X10
3
 CFU/mL at day 14 post inoculation and had no detectable 
pneumococci by day 42 (McCool & Weiser 2004).  
 
 
From the results of studies in inbred mice, (Wu et al. 1997; Gingles et al. 2001), it is 
clear that there is great diversity in the way that each strain responds to different 
pneumococcal serotypes which makes it difficult to choose a representative mouse strain for 
further experiments. On the other hand, outbred strains of mice such as MF-1, CD-1 and 
NMRI have been shown to produce consistent results following inoculation with 
pneumococcal strains such as D39 and WU2 (Gingles et al. 2001; Kerr et al. 2004; Cohen et 
al. 2012; Bergeron et al. 1998; Blue et al. 2003; Hamel et al. 2004). Further, outbred mice 
have been reported to produce similar and in some cases lower SDs with respect to survival 
times and bacterial outgrowth to inbred mice (Gingles et al. 2001). In comparison to inbred 
strains, outbred strains are heterogeneous and are representative of the human population, 
making them suitable choice for this study.  
 
 
There are three methods of inducing pneumonia in animals, the intranasal, aerosol and 
intratracheal route. Of all these methods, the intranasal route is the ideal method of inducing 
pneumonia since it follows the natural course of disease in humans, in that disease stems 
from the nasopharynx. The drawback with the aerosol method is that effective inoculation 
cannot be obtained and some pathogens do not survive well in aerosolised conditions 
(Bakker-Woudenberg 2003). The intratracheal route through the tracheal wall is an invasive 
method of inducing pneumococcal pneumonia and there are chances of pathogens other than 
S. pneumoniae being introduced (Candiani et al. 1997). The intratracheal inoculation via the 
oral route requires surgical skill, a lack of which can compromise the success of the 
experiment (Bakker-Woudenberg 2003).  
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Vaccine efficacy in these models can be assessed through recovery of bacteria from the 
nasopharynx or lungs. Vaccination studies using a number of these pneumococcal surface 
proteins have been shown to protect mice from disease (Ogunniyi et al. 2001; Godfroid et al. 
2011; Mann et al. 2014; Plumptre et al. 2013). However, they have limitations in that the 
vaccine efficacy is tested by having wild-type inoculated into a limited sample size of 
vaccinated and unvaccinated mice. In addition, survival can be scored when the animals 
reach the moribund state and have to be euthanized. What is evident from the literature are 
contradictions with respect to which pneumococcal protein antigens are protective and not 
protective against challenge with the pneumococcus. Using a whole genome approach 
(Wizemann et al. 2001) identified 108 antigens, but the approach did not pick PspC and 
PpmA despite the fact that these antigens have been shown to be protective in other studies 
(Rosenow et al. 1997; Overweg et al. 2000). In addition, other evidence includes the fact that 
many of the antigens are unable to protect mice on their own, such as PpmA and PspC, but in 
combination with other antigens there is a protective effect (Audouy et al. 2007; Ogunniyi et 
al. 2007) These contradictions suggests that many of the approaches used to screen 
pneumococcal protein antigens as potential vaccine epitopes in mice are not sensitive enough.  
 
 
1.9 BACKGROUND AND STUDY RATIONALE 
  
Vaccines containing polysaccharide antigens are commercially available in the 
prevention of pneumococcal disease but are restricted in their serotype coverage, and hence 
focus has been directed towards common protein-based antigens. The pneumococcus is 
estimated to express over 100 surface proteins which could be explored as possible vaccine 
candidates. Vaccination studies using a number of these pneumococcal surface proteins have 
been shown to protect mice from disease (Ogunniyi et al. 2001; Godfroid et al. 2011; Mann 
et al. 2014; Plumptre et al. 2013). However, current animal models of disease for evaluating 
pneumococcal surface proteins as potential vaccine candidates have limitations. They lack 
sensitivity in that protective potential is often difficult to demonstrate for some of the most 
promising candidates in experiments with a limited sample size. Another limitation with 
some of the current models is that they depend on inhumane endpoints such as bacteraemia, 
sepsis and mortality. These models therefore may not be appropriate for the evaluation of 
vaccines for the prevention of non-bacteraemic or mucosal pneumococcal disease. 
Considering these limitations, it is probable that the potential of some protein antigens might 
have been overlooked in previous studies by testing their efficacy in an inappropriate model. 
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In the quest to develop a refined model that is capable of detecting subtle vaccine 
effects, a lot can be learned from the approach taken by (Kerr et al. 2004; Hermans et al. 
2006) that was effective in demonstrating subtle roles in virulence of pneumococcal surface 
proteins. This approach inoculated mice with both wild-type and knockout strains expressing 
different selectable markers and subsequently measuring output with quantitative culture-
based end-points. The ratio of the co-inoculated strains in each individual mouse is the 
measureable effect. These ratios are not susceptible to variation in the inoculation dose, or 
efficiency of sample collection, and thus increase the precision with which measurements can 
be made. The consequence of this is that the sample size required for experiments gets 
reduced. The intranasal co-infection model has been employed by other groups to assess the 
role of pneumococcal proteins on colonisation and pneumococcal pneumonia (Kerr et al. 
2004; Cron et al. 2011; Ogunniyi et al. 2012; McAllister et al. 2012). In this thesis, we 
applied this model for the evaluation of five well characterised pneumococcal candidate 
antigens: PspC, PpmA, SlrA, IgA bacterial protease and PspA. In addition, we included a 
vaccinated cohort of mice that allowed us to measure the impact of opsonising antibodies on 
the clearance of the wild-type in comparison to an isogenic knockout. These data are of value 
in that they provides a rationale for applying the model in the selection of the most 
appropriate pneumococcal protein antigens to be used in future vaccines.  
 
 
1.9.1 Aims and Objectives 
 
The overall aim of this study was to evaluate pneumococcal surface proteins for their 
potential to protect against pneumococcal infection in a mouse co-infection model:  
 
The specific aims were to: 
 
i) Establish and validate an intranasal pneumonia mouse co-infection model with vaccinated 
and unvaccinated arms using PspC and PpmA candidate antigens, 
 
ii) Examine the contribution of PspC, PpmA, SlrA, IgA bacterial protease and StkP to 
pneumococcal virulence by constructing knockout mutants and testing them in the co-
infection model, 
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ii) Use this model to determine the protective potentials of SlrA, IgA bacterial protease and 
PspA candidate antigens. 
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CHAPTER 2 MATERIALS AND METHODS 
 
2.1 Bacterial strains and growth conditions 
 
S. pneumoniae was cultured on blood agar plates at 37 °C in 5% CO2, or in Todd-
Hewitt broth (Becton, Dickinson and Company, UK) supplemented with 0.5% yeast extract 
(THY). Knockout strains were grown on blood agar plates in the presence of appropriate 
antibiotic (25 µg mL
-1 
trimethoprim or 0.25 µg mL
-1
 erythromycin). Broth culture growth was 
monitored by measuring optical density (OD) at 660 nm (OD 660). S. pneumoniae strains 
were grown to an OD of between 0.1-0.2 and aliquots were stored at -70 °C in 15% glycerol. 
Pneumococcal strains used in this study are listed in Table 2.1. Escherichia coli (E. coli) 
strains DH5α, Novablue competent cells (Novagen) were grown in Luria-Bertani (LB) 
medium at 37 °C. Liquid cultures of E. coli were grown with continuous shaking at 200 rpm, 
37 °C (Kuhner AG, Switzerland) and colonies were grown on LB agar plates. Plasmid 
pBluescript was selected using ampicillin and the TOPO plasmid was selected using 
appropriate antibiotics according to manufacturer’s instructions. For long term storage, 
strains were cultured overnight in LB broth and stored at -70 ºC in 15% glycerol. When 
required the LB medium was supplemented with 100 µg/mL ampicillin and the Todd Hewitt 
yeast (THY) medium was supplemented with 100 µg/mL streptomycin.  
 
 
2.2 Viable counting 
 
Using a round-bottomed 96 well microtitre plate, serial dilutions (10
-1
-10
-6
) of 
pneumococci from broth were performed by adding 20 µL of the bacterial suspension to 
180 µL of Phosphate Buffered Saline (PBS), in duplicate. Three 20 µL volumes of each 
dilution were dispensed onto blood agar plates and incubated as previously described. After 
24 hours, viable colonies were counted in sections where between 5 and 50 colonies could be 
observed, and bacterial numbers were expressed as colony forming units per mL.  
CFU/mL = Total number of colonies counted in sector ÷ 3 x dilution factor x 50. 
 
 
2.3 Growth curves of S. pneumoniae 
 
In order to culture the bacteria, bacterial stocks stored at -80 ºC were streaked out on 
blood agar plates and incubated for 24 hours at 37 ºC with 5% CO2. An overnight culture was 
prepared with 1 colony in 5 mL of THY broth. The tubes were incubated at 37 ºC in 5% CO2 
atmosphere for 9 hours. One thousand microliters of the overnight culture were subcultured 
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in 50 mL of THY broth and the OD600 nm was measured every hour. For each strain, the 
growth curve experiments were performed in triplicate 
 
 
2.4 BACTERIAL TRANSFORMATION 
 
2.4.1 Preparation of E. coli competent cells 
 
A 50 mL overnight culture was diluted one hundred fold in LB and left to grow to an 
OD600 of 0.6-0.7. The cells were then incubated on ice for 15 min, centrifuged at 835 x g for 
5 min at 4 °C and the supernatant discarded. The pellet was then re-suspended in 1/3 of the 
original volume with Transformation buffer-1 (30 mM potassium acetate, 100 mM rubidium 
chloride, 10 mM calcium chloride, 50 mM manganese chloride, 15% glycerol (v/v), pH 5.8) 
and incubated for 15 min on ice. The cells were then centrifuged, re-suspended in 
Transformation buffer-2 (10 mM MOPS, 75 mM calcium chloride, 10 mM rubidium 
chloride, 15% glycerol (v/v), pH 6.5) at 1/12 of the original culture volume and left on ice for 
15 min. Cells were then aliquoted into ice-cold microcentrifuge tubes, flash-frozen in dry ice-
ethanol and stored at -70 °C.  
 
 
2.4.1.1 Transformation  
 
Transformation of E. coli was performed by mixing 5 µL of ligation reaction with 100 
µL of competent E. coli DH5α cell. Competent cells were first thawed on ice and 100 μL of 
cells were added to prechilled ligation mixture in a microcentrifuge tube followed by 
incubation on ice for 30 min. The cells were heat shocked at 42 °C for 30 s followed by the 
addition of 300 μL of 2X TY rescue media to the cells before incubation for an hour at 37 °C 
to allow for the expression of genes encoding for antibiotic resistance. Cells were then plated 
on YT agar plates supplemented with the relevant antibiotic and incubated overnight at 
37 °C. Correct inserts in the plasmids from the transformants were confirmed by colony PCR, 
restriction digestion and / or sequencing. 
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2.4.2 Preparation of S. pneumoniae competent cells 
 
An overnight culture of S. pneumoniae D39 was inoculated into 50 mL of pre-warmed 
Todd Hewitt Broth (THY) containing 0.5% yeast extract, 10% serum (FBS) and 1 mM 
CaCl2. S. pneumoniae PJ351 was inoculated into 50 mL of pre-warmed Todd Hewitt Broth 
(THY) containing 0.2% glucose, 0.2% BSA and 0.02% CaCl2 (pH 7.2-7.4). Pneumococci 
were made competent by growing a culture of S. pneumoniae to a density of 0.05 (D39) and 
0.4 (PJ351) at 600 nm and adding 100 ng/mL of CSP1 (D39) and 500 ng/mL of CSP2 
(PJ351). Aliquots (1 mL) were made and stored in 15% glycerol at -70 °C until used. 
 
 
 2.4.2.1 Transformation 
 
Frozen cultures (1 mL) were thawed at 37 °C and added to 1 µg/mL of DNA at the same 
temperature. The cells were pre-incubated at 30 °C for an hour and further incubated at 37 °C 
for 2 hours in the presence of 5% CO2 to allow for phenotypic expression. Viable counting 
was performed as described in section 2.2, except plating was done on antibiotic containing 
plates. The identity of successful transformants was confirmed by PCR and / or sequencing. 
 
 
2.5 DNA EXTRACTION AND PURIFICATION OF BACTERIA 
 
2.5.1Small scale extraction of plasmid DNA from E. coli  
 
Isolation of plasmid DNA was performed with either the QIAquick plasmid extraction 
kit according to manufacturer’s instructions (Qiagen, South Africa) or by a manual alkali 
lysis method. Briefly, overnight cultures of E. coli grown in 1 mL of LB were transferred into 
1.5 mL microcentrifuge tubes, centrifuged in an Eppendorf 5415D microcentrifuge at 15682 
x g for 30 s at room temperature and the supernatant discarded. The cells were then re-
suspended in 100 μL Solution I (0.5 M Glucose, 50 mM Tris.HCl pH 8.0, 10 mM EDTA), 
and lysed with the addition of 200 μL Solution II (0.2 M NaOH, 1% (w/v) SDS) with gentle 
mixing. The lysates were incubated for 5 min at room temperature. Thereafter, 150 μL of 
Solution III (3 M potassium acetate, pH 5.5) was added to neutralise the solution and this was 
followed by centrifugation at 15682 x g for 5 min. The supernatants were then transferred to 
new microcentrifuge tubes; RNase A was added to a final concentration of 50 µg/mL and 
incubated at 42 °C for 30 min. To precipitate DNA, 350 µL of isopropanol was added 
followed by incubation at room temperature for 5 min and then centrifuged for 10 min at 
15682 x g at room temperature. The supernatants were discarded and the pellets washed once 
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with 1 mL of ice-cold 70 % ethanol and air dried. The DNA was then resuspended in 50-
150 µL sterile distilled water. 
 
 
2.5.2 Bulk plasmid DNA preparation from E. coli 
 
Overnight cultures in 100 mL LB were harvested by centrifugation for 10 min at 2320 x 
g at 4 °C. Bulk plasmid DNA preparation and purification was done using the QIAquick 
plasmid extraction kit according to manufacturer’s instructions (Qiagen, South Africa).  
 
 
2.5.3 Extraction of genomic DNA from S. pneumoniae 
 
A few bacterial cells were scraped from plates using a plastic loop and re-suspended in 
500 μL of distilled water. Lysozyme at a concentration of 10 µg/mL was added to the 
bacterial cells and subsequently incubated for an hour or overnight at 37 °C. Genomic DNA 
was then extracted with the QIAquick DNA extraction kit (Qiagen) according to the 
manufacturer’s instructions. The bacterial cells were incubated as above and then incubated 
for 10 min at 100 °C. The DNA containing aqueous phase was then directly used as a 
template for PCR. To remove excess salt or inhibitors from prepared DNA samples, the 
volume of DNA containing solution was made up to 300 µL with TE. Thereafter, 1/3 of the 
volume of TE-saturated phenol (10 g phenol, 10 mL TE) was added, followed by mixing and 
centrifugation for 5 min at 15682 x g at room temperature. The aqueous phase was then 
transferred to a fresh sterile microcentrifuge tube and a 1/3 volume of chloroform/isoamyl 
alcohol (24:1 v/v) was added followed by room temperature centrifugation for 30 s at 15682 
x g. The aqueous phase was transferred to new tubes and DNA precipitated by adding 1/10 
volume of 3 M sodium acetate (pH 5.3) and 2.5 volumes of 100 % ice-cold ethanol. After 
incubation for 30 min at -20°C precipitated DNA was harvested by centrifugation at 15682 x 
g at 4°C, washed with ice-cold 70 % ethanol, air dried and suspended in sterile distilled 
water. 
 
 
2.5.4 Purification of DNA fragments from agarose gels 
 
Purification of DNA fragments from agarose gels was performed with the QIAquick 
Gel Extraction kit according to the manufacturer’s instructions (Qiagen). Briefly, DNA 
fragments were cut from low-melting agarose gels and binding DNA buffer was added to the 
fragments in a 1:1 ratio. DNA fragments were subsequently melted at 50 °C for 10 min. Once 
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dissolved, 3X the volume of isopropanol was added to the sample to ensure precipitation of 
salts. The sample was then bound to silica membrane tubes and eluted with 50 µL of distilled 
water.  
 
 
2.5.5 Purification of PCR products by Qiagen QIA quick columns 
 
Restriction digests or PCR fragments were purified with Qiagen QIA quick columns. 
Briefly, 5X the volume of PB buffer (Qiagen) was added to the reaction product, mixed and 
transferred to QiagenQIAquick columns and centrifuged at 15682 x g for 1 min. The 
membrane bound DNA was washed 2 times with 750 µL of PE buffer (Qiagen) and 
centrifuged for 2 min to remove traces of PE buffer, then eluted in 30 µL of 10 mM Tris-Cl 
pH 8.0 (Qiagen).  
 
 
2.6 DNA MANIPULATIONS 
 
2.6.1Agarose gel electrophoresis  
 
One percent agarose gels were prepared by boiling 1 g of agarose (Molecular Biology 
Grade, Melford) in 100 mL of Tris-acetic-EDTA (TAE) buffer (pH 8.0). The gel was allowed 
to cool down to about 60 °C before adding 1 mg/mL of ethidium bromide and cast into a gel 
mould. The gel was allowed to set for at least 45 min after which the gel was submerged into 
the gel tank containing TAE buffer. Three microliters of the PCR product was mixed with 
1µL of the tracking dye and loaded into the wells of the gel. The gel was run at 100 V with an 
Elpho power supply (Life sciences, Austria) for 60 min. The PCR product was visualised by 
illuminating the gel with the ultraviolet (UV) light on a transilluminator (UVP, USA). The 
relative size of the PCR products was determined by comparing them to a positive control 
band and the 1kb DNA ladder (Gene Ruler, Fermentas, Life Sciences: # SM0311). 
 
 
 2.6.2 Restriction digests Dephosphorylation and ligation of DNA fragments 
 
Restriction enzymes used in this study were obtained from Roche Biochemicals 
(Germany) or Inqaba biotech (South Africa, Pretoria). Plasmid preparations (4 ug) were 
digested with 4 U of restriction enzymes at 37 ºC. For ligations, the digested plasmid 
products were dephosphorylated by the addition of 1 U of alkaline phosphatase obtained from 
Invitrogen (United Kingdom) (20 U/µL) and incubating for up to 60 min at 37 ºC. Once 
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digested and dephosphorylated, plasmids were cleaned with a Qiagen spin kit (see above) and 
eluted in 50 µL of distilled water. Ligations were performed in a total volume of 30 µL of 1X 
ligation buffer (660 mM TrisCl pH 7.6, 50 mM MgCl2, 50 mM DTT, 10 mM ATP, pH 7.5) 
with 1 U of T4 DNA ligase (Roche Biochemicals). Ligation reactions were performed 
overnight at 4 ºC with variable ratios of prepared plasmid DNA and insert DNA (1:1 to 1:3). 
Negative controls included plasmids ligated without insert DNA and reactions without T4 
DNA ligase. A quarter of the total reaction volume was used to transform 100 μL of E. coli 
competent cells. 
 
 
2.7 Polymerase chain reaction (PCR) 
 
Standard PCR reactions were performed with the Econo Taq master mix kit 
(Fermentas, South Africa) as per manufacturer’s instructions. Amplification of fragments for 
use in homologous recombination was with the aid of either Expand High Fidelity PCR 
System (Roche Biochemicals, Germany) or High Fidelity PCR Enzyme Mix (Fermentas, 
Lithuania). Amplifications from plasmid and genomic DNA were performed with 0.1-15 ng 
and 50-100 ng of template DNA, respectively, in 25 μL reaction volumes. Standard thermal 
cycler settings were: denaturation at 94 °C for 5 min followed by 35 cycles with each cycle 
consisting of denaturation at 94 °C for 30 s, annealing at 50-65 °C for 60 s, extension at 
72 °C for 2 min, followed by a final extension at 72 °C for 7 min. Long template thermal 
cycler settings were: denaturation at 94 °C for 2 min followed by 35 cycles with each cycle 
consisting of denaturation at 94 °C for 10 s, annealing at 50-65°C for 30 s, extension at 68 °C 
for 2 min, followed by a final extension at 72 °C for 7 min. All PCR reactions were 
performed with an Eppendorf Mastercycler gradient (Eppendorf, Germany). 
 
 
2.8 Construction of pneumococcal knockouts 
 
Construction of pneumococcal knockouts were performed as previously described with 
some modifications (Mowa et al. 2009; Hermans et al. 2006). To obtain the streptomycin-
resistant S. pneumoniae D39 and PJ351 strains, the rpsL gene encoding a streptomycin-
resistant mutant of the ribosomal protein S12 was amplified from a streptomycin resistant 
S. pneumoniae clinical strain, S303 with primer pair rpsLFWD 
(TCGTCCCAAGTCCATAGTCC) and rpsLRV (ATATGAGCTGGAACGGGATG). This 
PCR product was introduced into D39 and PJ351 by CSP-1- and CSP-2-induced 
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transformation, respectively, and selected for streptomycin resistance. PspC, ppmA, pspA, 
igA1 and slrA gene fragmentswere deleted from the parental strain D39 by in-frame insertion 
deletion mutagenesis with the resistance cassette dfr13, encoding resistance to trimethoprim. 
About a 1000 bp of upstream (5' UTR) and downstream (3' UTR) flanking sequences, 
excluding the coding sequences, were amplified from chromosomal DNA from the D39 
strain. The PCR products were cloned into pBlue- Script KS and transformed into E. coli 
DH5α. To avoid inadvertent mutations, all PCR amplicons for deletion mutagenesis were 
first cloned into pCR2.1-TOPO (Table 2.2) and sequenced before cloning into pbluescript. 
All primers used for targeted gene knockout and confirmation of final pneumococcal 
constructs are outlined in Table 2.3. For a blue-white selection of both E. coli strains, solid 
media was supplemented with 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) to 
a final concentration of 40 μg/mL. These amplicons were ligated with the PCR-amplified 
dfr13 and transformed to E. coli DH5α (Invitrogen). The primers covering the 5’-flanking 
sequence of genes were designed to include PstI restriction sites that overlap the start codons 
of these genes. Similarly, dfr13 was amplified with PstI sites at the start codon, to ensure that 
resistance cassettes were cloned in the correct orientation, and were transcribed from the host 
promoters, starting from the ATG start codon. The trimethoprim-resistant knock-out 
constructs were used to delete the genes in strains D39 and PJ351 by CSP-1 and CSP-2 
induced recombination. The fragments that were removed were of equal length (500 bp) to 
the inserted cassettes to eliminate the possibility of any polar effects. Deletion of genes in 
resulting transformants was confirmed by colony PCR.  
 
 
2.9 DNA sequencing and bioinformatics software applied 
 
Sequencing was performed by Inqaba Biotech (South Africa) with a Spectrumedix 
2410 Capillary Electrophoresis automated DNA sequencer and Big Dye Terminator V3.1 
software from ABI for sequence analysis. The genomic DNA sequences of S. pneumoniae 
strains PJ351 and D39 of serotypes- 1 and 2, respectively, were obtained using the 
S. pneumoniae Sybil software (www.sybilpneumo.com). Blast searches and alignments of the 
available complete and incomplete bacterial nucleotide and protein databases were performed 
using the NCBI website (http:// www.ncbi.nlm.nih.gov/blast).  
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Table 2.1 Strains used in this study 
 
 
  
 
 
 
 
 
 
 
 
 
Str
r
, streptomycin resistance; Trim
r
, trimethoprim resistance; pspC, pneumococcal surface 
protein; ppmA, putative proteinase maturation protein 
 
Table 2.2 Plasmids used in this study 
 
Plasmid or target Relevant characteristics Reference 
source 
Plasmids   
pKOb Donor plasmid for Tm
r 
cassette This study 
pCR2.1 Cloning vector (Amp
r
, Km
r
) Invitrogen 
pBluescript (KS+) Cloning vector (Amp
r
) Stratagene 
pBSΔpspC::dfr13 Knockout vector for creating a dfr13 marked deletion in pspC of 
S. pneumoniae. 
This study 
pBSΔppmA::dfr13 Knockout vector for creating a dfr13 marked deletion in ppmA of 
S. pneumoniae. 
This study 
pBSΔpspA::dfr13 Knockout vector for creating a dfr13 marked deletion in pspA of 
S. pneumoniae. 
This study 
pBSΔigA1::dfr13 Knockout vector for creating a dfr13 marked deletion in igA1 of 
S. pneumoniae. 
This study 
pBSΔslrA::dfr13 Knockout vector for creating a dfr13 marked deletion in slrA of 
S. pneumoniae. 
This study 
 
Strains Relevant characteristics Reference 
PJ351 Wild-type (Serotype 1) ATCC BAA- 
D39 Wild-type (Serotype 2) NCTC 7466 
ΔpspC pspC deletion in strains PJ351 and D39 This study 
ΔppmA ppmA deletion in strains PJ351 and D39 This study 
ΔpspA pspA deletion in strains PJ351 and D39 This study 
ΔigA1 igA1 deletion in strains PJ351 and D39 This study 
ΔslrA slrA deletion in strains PJ351 and D39 This study 
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Table 2.3 Oligonucleotides used for constructing S. pneumoniae knockouts 
 
Primers              Relevant characteristics or nucleotide sequence (5'to 3') Amplicon 
size 
pspC F1  ATGTGgagctcTAAGTGACCAAGAACTAGAA 888 bp 
pspC R1 ATGCAAActgcagTATTTCCTTCTATATTTTTTCTTTAACCTTACTATAT 888 bp 
pspC F2  ACTAGTAAaagcttAAGCTAAAGAATCTCGAAACGAGG 1736 bp 
pspC R2 CTCCGTggtaccATTTCGCAAGCTAGCACCCTAG 1736 bp 
pspA F1 CCTCTTTTctgcagGTCATTTTCAGACTATACTTATATTAAGTATAG 1736 bp 
pspA R1 GGTGACATggatccATAGTAGTAAGCACACTATGTGGCTT 1736 bp 
pspA F2 CAAACAAAaagcttATGCTGAAGAAGTCGCTCCTCAAGCTA 900 bp 
pspA F2 CGGCTggtaccCATTCACCATTGGCA 900 bp 
stkP F1  TTTGGATctgcagGCATCCTCCTCGTTCATAGAAACAA  927 bp 
stkP R1 TGTAAGgagctcATGAAAGACGGCTGTATC 927 bp 
stkP F2  CAGTTCAaagcttGTCACCAGAGCAGGCGCGT 996 bp 
stkP R2 AATATTggtaccTTCAATAGAGAAAAAGATAGC 996 bp 
igA1 F1 GGCAATaagcttGCGCCTGAGAGAGACTACCAGCTTTT 1000 bp 
igA1 R1 TCACCAAAATACggtaccATTATTCCTCCTTGAAATAAAATTTATATATGT
TACAAAGAC 
1000 bp 
igA1 F1 TGTTTCTTgagctcAGCCGACAGAAGTTCAAGTAGTTGAAAAAC 970 bp 
igA1 F2 TATATTctgcagATGGGGCTACCTGCTCTGGTTCA 970 bp 
ppmA F1 TTTTCTTctgcagTACTCCTTTGAGATAAGTGTTACTCTATCTA   1000 bp 
ppmA F2 AAGACCGTgagctcTATATCGACTACCTCAAGGC 1000 bp 
ppmA F1 TCAAAAaagcttCTTTCGCTTTAGATGTGGATGGTGTTT 940 bp 
ppmA F2 CTACGAGggtaccATTCTCCATAGTGACCAA 940 bp 
slrA F1 TTCATTctgcagCTCTCAAAAATTCATT 1000 bp 
slrA F2 CCTTCAgagctcCTGAACGAGAGTTGGATA 1000 bp 
slrA F1 GCCTACGgtaccCAGCAGAAAGAGATT                 1000 bp 
slrA F2 AAAGATAaagcttCTAAACTCCCTACAAGCAAGTATC 1000 bp 
 
*Restriction sites within the primer sequences utilised for subsequent cloning of PCR 
fragments are italiced, F1/F2 represents a forward primer, R1/R2 represents a reverse 
primer. 
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Table 2.4 Oligonucleotides used for confirming the presence of knockouts constructs 
 
Primers              Relevant characteristics or nucleotide sequence (5'to 3') Amplicon 
size 
pspC F1 ATGTGgagctcTAAGTGACCAGGAACTAGAA 3600 bp 
pspC R2 CTCCGTggtaccATTTCGCAAGCTAGCACCCTAG 3600 bp 
pspA F1 CCTCCTTTTctgcagGTCATTTTCAGACTATACTTATATTAAGTATAG 2815 bp 
pspA R2 CGGCTggtaccCATTCACCATTGGCA 2815 bp 
stkP F1 TGTAAGgagctcATGAAAGACGGCTGTATC 2984 bp 
stkP R2 AATATTggtaccTTCAATAGAGAAAAAGATAGC 2984 bp 
igA1 F1 GGCAATaagcttGCGCCTGAGAGAGACTACCAGCTTTT 2713 bp 
igA1 R2 TATATTctgcagATGGGGCTACCTGCTCTGGTTCA 2713 bp 
ppmA F1 TTCATTctgcagCTCTCAAAAATTCATT 2928 bp 
ppmA R2 AAAGATaagcttCTAAACTCCCTACAAGCAAGTATC 2928 bp 
slrA F1 TTCATTctgcagCTCAAAAATTCATT 2800 bp 
slrA R2 AAAGATAaagcttCTAAACTCCCTACAAGCAAGTATC 2800 bp 
 
*Restriction sites within the primer sequences utilised for subsequent cloning of PCR 
fragments are italiced, F1/F2 represents a forward primer, R1/R2 represents a reverse 
primer. 
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2.10 IN VIVO METHODS 
 
2.10.1 Ethics statement 
 
All animal experiments were performed with the approval of the University of the 
Witwatersrand Animal Ethics Committee (Ethics number 2012/05/2B). 
 
 
2.10.2 Mouse strain  
 
Five-week-old female NMRI outbred mice were purchased from NICD 
(National Institute of Communicable disease in South Africa) and housed under standard 
conditions at the Central Animal Service (CAS) situated at the University of the 
Witwatersrand. Mice weighed between 20 and 25 grams at the commencement of 
experiments. Mice were acclimatised for a week prior to the experiments.  
 
 
2.10.3 Pneumococcal passaging 
 
Pneumcoccal passaging were performed as previously reported (Alexander et al. 1994). 
Five-week-old female NMRI mice were injected intraperitoneally with different 
concentrations (10
5
-10
7 
CFU) of serotype 1 (PJ351/1), serotype 2 (D39), serotype 3 (WU2), 
serotype 4 (TIGR4), serotype 5 (ATCC 6305) and serotype 6B (ATCC 6326) of 
S. pneumoniae at a dose of 100 µL. Mice were monitored for signs of disease such as 
conjunctivitis, lethargy, hunched back, spiked fur and a moribund state until the animals were 
deemed moribund. Blood samples were collected under anaesthesia by cardiac puncture and 
plated out on blood agar plates. The plates were incubated at 37 °C, for 18 hours. Three 
single colonies were then picked from blood agar plates, grown in Todd-Hewitt broth until 
OD = 0.1-0.2 and properly stored at -70 °C.  
 
 
2.10.4 Preparation of inoculum 
 
The number of viable organisms in the frozen THY stocks of wild-type and knockout 
strains was determined from a thawed aliquot from each batch, and the number of CFU/mL 
was used to calculate the dilution factor for each frozen stock. The frozen stocks were 
thawed, diluted and then centrifuged to remove traces of THY and glycerol. The cell pellet 
was resuspended in sterile PBS. Colony counts of the diluted working stock were performed 
on plain blood agar and media containing the appropriate antibiotic to confirm the wild-type 
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and knockout bacterial CFU. All mice in the same experiment were infected using the same 
aliquot to ensure consistency.  
 
 
2.10.5 Immunization of mice with pneumococcal antigens 
 
Six-week-old mice were immunised subcutaneously with pneumococcal antigens PspC, 
PspA, SlrA, IgA1 bacterial protease or PpmA. Recombinant proteins were purified and 
expressed by Dr Peter V. Adrian from our laboratory. Each mouse received three doses of 50 
µg of each antigen diluted with PBS and adjuvanted with 100 µg of saponin, at a 14 day 
interval. The unvaccinated control mice were given a placebo consisting of PBS plus the 
saponin adjuvant. Mice were subsequently challenged intranasally (I.N) with the wild-type 
PJ351 (serotype 1) or D39 (serotype 2) and their isogenic knockouts (10
6 
CFU total) 2 weeks 
after the last immunisation and sampled at 0, 6, 12 and 24 hours post-infection as described 
below. The time point of 0 hours was chosen as it was the true time zero, taking into account 
any inoculation inaccuracies.  
 
 
2.10.6 Mouse model: co-infection 
 
Co-infection of mice was performed as previously described with slight modifications 
(Hermans et al. 2006). Mice were lightly anaesthetized with 2.5 % (v/v) isofluorane over 
oxygen (1.5 litre min-
1
), administered with a calibrated vapouriser and the effect of 
anaesthesia was confirmed by observing no pinch reflex action. Once anaesthetized, the 
animals were scruffed with the nose held upright and 50 µL of a bacterial suspension 
containing 1:1 ratio (approximately 10
6
 CFU) of streptomycin-resistant S. pneumoniae wild-
type and pneumococcal knockout was administered intranasally by adding a series of small 
droplets of the inoculum into the nostrils of the mice. After inoculation, mice were held 
upright for 20 s and then laid on their backs until recovery. At 0, 6, 12, and 24 hours post 
inoculation, groups of five mice were euthanised by intraperitoneal injection (I.P) of 0.2 mL 
of sodium pentobarbital (Euthapent, Kyron Laboratories (Pty) Ltd. South Africa) and 0.5-1 
mL of blood was drawn from each mouse by cardiac puncture. Serum was separated and 
stored at -80 °C until used for immunoassays. The nasopharynx was washed using a method 
of Wu et al. (1997). Briefly, the trachea was exposed and clamped and 2 mL of sterile PBS 
was passed through the nasopharynx via a 16-gauge non-pyrogenic angiocath. BAL and lung 
were performed as previously described (Kerr et al. 2002). BAL was performed by slowly 
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delivering 1.5 mL of PBS (pH 7.3), through the tracheal tube via a 16 gauge non-pyrogenic 
angiocath. The tracheal tube was exposed and the fluid was slowly withdrawn by gentle 
suction and plated onto blood agar plates. Both lungs were removed and homogenised in 2 
mL sterile PBS. Viable counts were determined by serial 10-fold dilutions plated on BA 
plates. Bacterial loads were determined by plating out 10-fold dilutions onto blood agar plates 
containing 100 µg/mL of streptomycin or 25 µg/mL of trimethoprim. Competitive indices 
(CI) were calculated as the ratio of knockout to wild-type bacteria recovered from each 
animal and the ratio of knockout to wild-type bacteria that were inoculated into each animal. 
In this setup, a value equal to 1 indicates an equal proliferation of both strains. A value below 
one is indicative of severe attenuation of the knockout relative to the wild-type strain.  
 
 
2.11 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)  
 
ELISA assays for all proteins were performed as previously reported (Quataert et al. 
2001) with some modifications. IgG titres were determined by enzyme-linked 
immunosorbent assay (ELISA). Microtitre plates (NUNC maxi sorb) were coated overnight 
at 4 °C with 0.625 µg/mL of PspC and SlrA. PspA, IgA1 bacterial protease and PpmA were 
coated overnight with coating concentrations of 2.5 µg/mL dissolved in PBS. Antigen coating 
concentrations were determined as explained in section 2.11.1. Plates were washed with 
100 L of PBS containing 0.05% Tween (PBS-T) buffer and blocked with PBS buffer 
containing 10% foetal bovine serum (PBS-F) pH 7.3, for an hour, at 37 °C. Pre-dilutions of 
the reference, controls, and unknown sera were made in PBS-F. Samples were then serially 
diluted and 100 µL/well was added to the pre-coated microtiter plates. Following 2 hours 
incubation at 37 °C, plates were washed three times with PBS-T and alkaline phosphatase 
conjugated anti-mouse IgG (Sigma-Aldrich, Cat # A3188, Munich, Germany) was added to 
all wells and incubated for 2 hours at 37 °C. After incubation, the plate was washed three 
times with PBS-T and the colour was developed for an hour in the dark using p-nitrophenyl 
phosphate substrate (Sigma-Aldrich, Cat # 71768, Munich, Germany). Plates were read at 
405 nm with the RS 232C Labsystem Multiskan RC plate reader (Labsystems, Helsinki, 
Finland). Two internal controls were included on each plate: a medium and low control, 
consisting of a pool of in-house medium-titred and low-titred mouse sera, respectively. To 
avoid bias, serum samples from the different groups were always assayed on the same plate.  
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2.11.1 Determination of optimal antigen concentration  
  
The optimum antigen concentration for coating ELISA plates was determined as 
follows: PspC, PspA, PpmA, SlrA and IgA1 bacterial protease were diluted in increasing 
concentrations (0.01-10 µg/mL). One hundred microliters of each concentration were 
pipetted into 4 wells each of a microtiter plate and incubated overnight at 4 °C. After coating, 
the plates were washed and a standard ELISA protocol was followed with sera of high and 
low concentrations. The antigen concentration that produced the highest dynamic range, i.e. 
the strongest signal with low background was selected for further analysis (World Health 
Organization Pneumococcal Serology Reference Laboratories 2004). The optimum coating 
concentration for PspA, PpmA, and IgA1 bacterial protease was 2.5 µg/mL, and for PspC and 
SlrA, it was 0.625 µg/mL (Figure 1.1 A in appendix 1).  
 
 
2.11.2 Determination of alkaline phosphatase conjugated anti-mouse IgG 
 
Plates were coated with antigen, and washed with 100 µL of PBS containing 0.05% 
Tween (PBS-T) buffer and blocked with PBS buffer containing 10% foetal bovine serum 
(PBS-F) pH 7.3, for an hour, at 37 °C. A reference serum was serially diluted (100 µL/well) 
across the pre-coated microtiter plates to produce a maximum and minimum signal. 
Following 2 hours incubation at 37°C, plates were washed three times with PBS-T and 
alkaline phosphatase conjugated anti-mouse IgG was added (100 µL/well). The conjugate 
concentrations were tested in the range diluted from 1:1000-1:8000, and incubated at 37 °C 
for 2 hours. Following incubation at 37°C, ELISA was completed using the normal steps for 
ELISA. For each ELISA, the optimum conjugate concentration was selected as the dilution 
which produced the highest dynamic range with the lowest background (World Health 
Organization Pneumococcal Serology Reference Laboratories 2004). A maximum signal 
(>3.0) was produced at conjugate dilutions of 1:2000 and above. However, since a 
concentration of 1:1000 produced unacceptable background, a concentration of 1:2000 was 
selected for further experiments (Figure 1.1 B in appendix 1).  
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2.11.3 Competitive inhibition studies  
 
To determine the specificity of ELISA assay, inhibition studies were performed as 
previously described with slight modifications (Pickering et al. 2002). A serum with known 
high concentrations of IgG antibodies directed against PspA, PspC, SlrA, PpmA and IgA1 
bacterial protease was diluted 1:500 times. Each aliquot was incubated with an equal volume 
of one of the four purified antigens in a concentration of 6 µg/mL for 1 hour at room 
temperature. A 1:1000 dilution of the serum was used as a control. The absorbed and 
unabsorbed sera were then assayed by ELISA, as described in section 2.11. The results were 
reported as percent change in concentration in response to the addition of individual antigens 
to the serum. The addition of the homologous protein to the serum at saturated concentrations 
(6 µg/mL) resulted in a marked inhibition of the signal; 96% for PspC, 98% for PpmA, 95% 
for SlrA, 93% for PspA and 97% for IgA1 bacterial protease compared to 9.15%, 4.47%, 
9.34%, 7.50% and 8.20% in the control sample. This data suggests that the assay was highly 
specific for the antigens tested. 
 
 
2.11.4 Assay sensitivity 
 
For the determination of the sensitivity of the assay, the reference serum was diluted in 
eight steps of 3-fold dilutions. The standard deviation of the blank was calculated for each 
protein. The lower limit of quantification (LLOQ) was interpolated from the standard curve 
of the reference serum and was calculated by adding 3 SD to twenty blanks and reported in 
arbitrary units per millilitre (U/mL). Estimation of the upper limit of quantification (ULOQ) 
was based on the cut-off value of 3.5 optical densities for the ELISA method. The ULOQ was 
reported in U/mL for the ELISA. The calculated LLOQ was 0.1 U/mL for all antigens. All 
samples with an OD of 3.5 were re-diluted to fall within the measurable range of the standard 
curve of the reference serum (Pickering et al. 2002). 
 
 
2.11.5 Assay reproducibility 
 
Reproducibility of the assay was assessed by determining the variation between intra- 
and interassays of replicate ELISA results. Intra-assay variation was determined from testing 
sera assayed on different wells within one plate. Inter-assay variation was assessed by testing 
samples in different assays and time points, and then calculating the percentage of variation 
(CV%) between results from each assay (World Health Organization Pneumococcal Serology 
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Reference Laboratories 2004). The method was reproducible; the percentage for the CV of 
the high and low control samples was less than 20% in both intra- and inter-assay 
comparisons. The CVs were 6% and 4% for the high QC and low QC, respectively. ELISA 
was optimised to meet several other performance requirements mentioned in Table 1.1 found 
in appendix 1.  
 
 
2.11.6 Statistical analysis 
 
All data were analysed using GraphPad Prism version 5.0. For analysis of bacterial load 
in unvaccinated animals, a paired two-sample t-test was used to calculate statistical 
significance between the wild-type and knockout strain co-inoculated in each animal. The 
Mann-Whitney test was used for comparison of the mean bacterial load in NP, BAL fluid and 
lung homogenate between the placebo and vaccinated group. Differences in antibody titres 
between vaccinated and unvaccinated mice were analysed by the Mann- Whitney U-test and 
a P value of <0.05 was considered significantly significant. Data was mathematically 
corrected to account for the differences in bacterial count of the initial inoculum. 
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CHAPTER 3 RESULTS 
 
3.1 DEVELOPMENT OF AN INTRANASAL PNEUMONIA CO-INOCULATION 
MODEL 
 
3.1.1 Infection kinetics of PJ351 (serotype 1), D39 (serotype 2) and TIGR4 (serotype 4) 
in the nasopharynx and lungs of NMRI mice  
 
In order to identify pneumococcal strains with suitable virulence characteristics, strains 
were passaged through mice to augment their virulence. Mice were intraperitoneally injected 
with 100 µL of different concentrations (1X10
5
 to 5X10
7
) of pneumococci (PJ351, D39, 
WU2, ATCC 6305 and ATCC 6326) to determine the concentrations that were able to elicit 
invasive pneumococcal disease within 24 hours. Mice were closely monitored for signs of 
disease until the mice were deemed moribund. 
 
 
Strains were considered virulent if they caused disease in mice within a period of 24 
hours. Any strain that fell outside of this classification was excluded from further 
experiments. ATCC 6305 (serotype 5) and ATCC 6326 (serotype 6B) did not cause disease 
in mice within 24 hours of inoculation and were excluded from further analysis. WU2 caused 
conjunctivitis 18 hours after intraperitoneal injection. Even though WU2 (serotype 3) caused 
disease in mice within 18 hours of infection, it was excluded from further analysis because its 
mucoid phenotype made the counting of distinct colonies challenging. D39 was the most 
virulent, and induced a moribund state within 12 hours of inoculation with a concentration of 
10
5
 CFU. Initial infection of mice with 6X10
6
 CFU of PJ351 resulted in the presence of 
bacteria in the bloodstream following 30 hours of infection without an observation of the 
classical signs of disease already mentioned in materials and methods. A single colony was 
isolated from the collected blood and passaged at a higher concentration. Following 12 hours 
from challenge with PJ351 at a concentration of 2X10
7
 CFU, the mice showed typical signs 
of disease. Infection with 10
7
 CFU of the TIGR4 strain successfully caused septicaemia in 
mice within 21 hours of infection.  
 
 
Since PJ351, D39 and TIGR4 met the criteria of causing disease in mice within 24 
hours after I.P challenge, their virulence after intranasal challenge was studied. Five mice per 
group were challenged intranasally with 50 µL of 10
6
 CFU of PJ351, D39 or TIGR4 strains. 
At 0, 6, 12 and 24 hour time points, mice were euthanised and lung homogenates, 
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nasopharyngeal wash, BAL fluid, and blood were subsequently harvested and cultured as 
described in the materials and methods section.  
 
 
There was successful colonisation of the nasopharynx by all strains, yielding counts of 
between 10
3 
CFU and 10
5 
CFU at all-time points. For all strains, there were no statistically 
significant differences in the concentration of bacteria recovered from the nasopharynx at the 
various time points, or between pneumococcal strains. This suggests that nasal colonisation is 
stable within the 24 hour monitoring period following inoculation in this model. The specific 
data points for each mouse are illustrated in (Figure 3.1 A).  
 
 
The recovery of strains in the bronchoalveolar tract indicated variability in their growth 
over time. All three strains grew out consistently by 1 log in the first 6 hours, but thereafter, 
responses differed between strains at the 12 and 24 hour time points. A concentration of 
6.29X10
4
 CFU of the PJ351 strain was recovered in the bronchoalveolar tract of mice at 0 
hours. That count significantly increased to 2.07X10
5 
CFU (p = 0.0079) at 6 hours and 
reached 7.30X10
4
 CFU at 12 hours to (p = 1.000). Pneumococci persisted in the 
bronchoalveolar tract up to 24 hours (1.32X10
5
 CFU, p = 0.5476). The initial bacterial load 
of the D39 strain at 0 hours was 7.03X10
4
 CFU and it steadily increased to 2.94X10
5
 CFU (p 
= 0.0079) at 6 hours and reached 3.08X10
5
 CFU at 12 hours (p = 0.0556). D39 declined to a 
bacterial count of 2.23X10
5
 CFU at 24 hours (p = 0.6905). Initial bacterial load in the 
bronchoalveolar tract of mice at 0 hours was found to be 3.99X10
4 
CFU of TIGR4. There 
were no significant differences in the bacterial load recovered at 6 hours (2.01X10
5 
CFU, 
p = 0.2222). Significantly lower bacterial counts of 3.60X10
3
 CFU were found at 12 hours (p 
= 0.0079) and continued to significantly decline to 5.10X10
3
 CFU (p = 0.0079) at 24 hours 
(Figure 3.1 B).  
 
 
The different bacterial strains demonstrated different kinetics in terms of their 
outgrowth in the lungs. The bacterial counts of PJ351 rose steadily from 5.39X10
4
 CFU at 
0 hours to 8.41X10
4
 CFU (p = 0.4206 ) at 6 hours, 1.53X10
5
 CFU (p = 0.3095) at 12 hours 
and 4.53X10
5
 CFU (p = 0.0079) at 24 hours. D39 showed similar kinetics with 6.37X10
4 
CFU at 0 hours to 1.28X10
5 
CFU (p = 0.0952) at 6 hours, 2.76 X10
5
 CFU (p = 0.0079) at 12 
hours and 3.62X10
5
 CFU (p = 0.3095) at 24 hours. In contrast, the TIGR4 strain showed 
different kinetics to the other strains. The initial increase from 4.96X10
4
 CFU at 0 hours to 
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7X10
4
 CFU (p = 0.5476) at 6 hours, was not sustainable over 12 and 24 hours, with the mean 
CFU dropping by a log to 1.29X10
3
 CFU (p = 0.0937) at 12 hours and maintaining the 
growth at 1.42X10
3 
CFU (p = 0.1425) at 24 hours. Further, some mice in the group were able 
to reduce the bacterial counts of TIGR4 to below that of the detection limit (Figure 3.1 C). 
The recovery of 10
4
 CFU/mL of lung tissue immediately after inoculation suggests that the 
intranasal mode of inoculation is an effective route of introducing bacteria into the lungs in 
order to cause pneumonia. Results for PJ351 and D39 indicated little variation at all-time 
points. On the other hand, highly variable data that corresponded with the larger spread in 
bacterial numbers was obtained for the TIGR4 strain at all time points. These results suggest 
that the TIGR4 strain was highly variable in its ability to infect the lungs, compared to both 
strains. 
 
 
Further, the coefficient of variation (CV%) between PJ351, D39 and TIGR4 at different 
time points was calculated in order to determine the ability of all strains to colonise the 
nasopharynx and infect the bronchoalveolar tract and lungs. In this thesis, the confidence 
interval was abbreviated as Ci to differentiate it from the abbreviation for competitive index 
(CI), mentioned later on in the text. Coefficient of variation for the PJ351 strain from the 
nasopharynx of mice at 0, 6, 12 and 24 hour time points suggest a relatively high variability 
for the PJ351 strain as indicated by high CVs at earlier time points compared to D39 and 
TIGR4 strains. Overall, CVs for D39 and TIGR4 indicate that these two strains were more 
able to colonise the nasopharynx of mice than the PJ351 strain (Table 3.1). Results for PJ351 
from the BAL fluid suggests that there was low variation in the bacterial dispersion at all time 
points except at the 12 hours that was marked by a relatively high CV of 99%. D39 indicated 
low variation at all time points compared to both strains. TIGR4 strain, however, indicated 
relatively high variability at all time points sampled. Overall, CVs suggest that PJ351 and 
D39 strains were probably more able to infect the bronchoalveolar tract compared to the 
TIGR4 strain (Table 3.2). Results for PJ351 and D39 from the lung tissue indicated little 
variation at all-time points. On the other hand, highly variable data that corresponded with the 
larger spread in bacterial numbers was obtained for the TIGR4 strain at all time points. These 
results suggest that the TIGR4 strain was highly variable in its ability to infect the lungs, 
compared to both strains (Table 3.3). 
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Markers of invasive disease as determined by the recovery of viable pneumococci from 
the blood stream, could not be used in this model. No pneumococci of any serotype were 
recovered from the blood of any of the mice at any of the time points. Further, no clinical 
symptoms were used, as by 24 hours, none of the observable clinical symptoms of severe 
invasive disease, such as conjunctivitis, hunched back, lethargy and spiked fur were 
observed.  
 
 
In conclusion, two pneumococcal strains, PJ351 and D39 were shown to be suitable to 
use in this mouse model, in that they could be easily passaged to enhance their virulence, and 
that they were able to effectively colonise the upper and lower respiratory tract and lung 
tissue consistently over the observed 24 hour period. 
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Figure 3.1 Infection kinetics within NMRI mice after intranasal infection with PJ351, D39 and TIGR4 strains. Groups of 5-week old female mice (n = 
5/group) were infected with PJ351, D39 or TIGR4 strains. Pneumococci were recovered at 0, 6, 12 and 24 hours post infection from (A) Nasopharynx, (B) 
Bronchoalveolar tract and (C) Lungs. Each symbol represents a single mouse. Mean values are represented by horizontal bars. The dotted line shows the limit 
of detection. Data represent average CFUs from a single experiment. The calculated P-values are presented, with values below 0.05 considered significant. 
*p ≤ 0.05, **p ≤ 0.001.  
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Table 3.1 Standard deviations and coefficients of variations based on the mean bacterial counts of PJ351,  
D39 and TIGR4 strains in the nasopharynx. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2 Standard deviations and coefficients of variations based on the mean bacterial counts of PJ351,  
D39 and TIGR4 strains in the BAL fluid. 
A. NASOPHARYNX 
 PJ351 D39 TIGR4 
 0 h 6 h 12 h 24 h 0 h 6 h 12 h 24 h 0 h 6 h 12 h 24 h 
Mean 24697 11908 25431 12723 18164 6976 20322 43287 4713 5567 18013 25033 
Std. Deviation 37451 12187 11463 6400 10980 4175 10262 36295 3172 4901 20465 16142 
Lower 95% Ci of mean -21805 -3225 11197 4776 4531  1792 7580 -1780 775 -519 -7397 4991 
Upper 95% Ci of mean 71199 27041 39665 20670 31797 12160 33064 88354 8652 11652 43424 450 
Coefficient of variation (CV) 152% 102% 45% 50% 60% 60% 50% 84% 67% 88% 114% 64% 
A. BAL FLUID 
 PJ351 D39 TIGR4 
 0 h 6 h 12 h 24 h 0 h 6 h 12 h 24 h 0 h 6 h 12 h 24 h 
Mean 62868 207242 72953 132097 294200 294200 308250 77870 39870 200896 3596 5101 
Std. Deviation 35201 59631 72429 103572 133915 133915 253464 86580 30203 158145 3477 8133 
Lower 95% Ci of mean 19160 133200 -16980 3495 127921 127921 -6468 -29633 2368 4532 -720.5 -4997 
Upper 95% Ci of mean 106576 281284 162886 260699 460479 460479 622968 185373 77372 397261 7913 15200 
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Table 3.3 Standard deviations and coefficients of variations based on the mean bacterial counts and of PJ351,  
D39 and TIGR4 strains in the lungs. 
 
 
 
 
 
 
 
 
 
 
 
B. BAL FLUID 
 PJ351 D39 TIGR4 
 0 h 6 h 12 h 24 h 0 h 6 h 12 h 24 h 0 h 6 h 12 h 24 h 
Coefficient of variation (CV) 56% 29% 99% 78% 49% 46% 82% 111% 76% 79% 97% 159% 
A. LUNGS 
 PJ351 D39 TIGR4 
 0 h 6 h 12 h 24 h 0 h 6 h 12 h 24 h 0 h 6 h 12 h 24 h 
Mean 53970 84170 152789 453630 362393 275700 275700 362393 49615 70072 12830 14210 
Std. Deviation 36263 71723 138232 46579 318907 100713 100713 318907 72998 55498 28233 26756 
Lower 95% Ci of mean 8943  -4886 -18850  395794 -33585 150648 150648 -33585  -41024 1162  -22226 -19013  
Upper 95% Ci of mean 98997 173226 324428 511466 758371 400753 400753 758371 140255 138982 47886 47433 
Coefficient of variation (CV) 67% 85% 90% 10% 70% 41% 37% 88% 147% 79% 220% 188% 
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3.1.2 Construction of pneumococcal gene deletion knockouts in PJ351 and D39 strains  
 
To demonstrate the usefulness of the model to study pneumococcal virulence, pspC, 
pspA, slrA, igA1, stkP and ppmA knockout strains were constructed by in-frame insertion 
deletion mutagenesis (IDM). The genes encoding the above-mentioned genes were partially 
deleted from the parental strains PJ351 and D39 using the resistance cassette dfr13, encoding 
resistance to trimethoprim (Figure 3.2A-Figure 3.7D). These proteins were chosen due to 
their known involvement in virulence.  
 
 
The left and right flanks were successfully amplified using the primer pairs P1Fwd + 
P2Rev and P3Fwd + P4Rev. In order to partially delete the gene of interest, the left and right flanks 
were ligated to the dfr13 resistance marker cassette. The fragments of genes that were deleted 
were of equal length (500 bp) to the trimethoprim inserted cassette to eliminate the possibility 
of any polar effects. The dfr13 was introduced in such a way that it would be under the 
control of the promoter from the deleted gene. The ligated product was subsequently inserted 
into the pbluescript vector. To ensure that the orientation of the ligated product was 
maintained and to prevent self-ligation of the plasmid, two different enzymes digested the 
pbluescript vector. To demonstrate that the correct flanks were ligated to the dfr13 resistance 
marker cassette, PCR was performed using the primer pairs P1Fwd + P2Rev for the left flank + 
dfr13 and primer pairs P3Fwd + P4Rev for the right flank + dfr13 (Figure 3.2A-Figure 3.7D). 
Further, the plasmid constructs were sequenced, and it was found that the knockout 
constructs were as intended and that the DNA sequence was intact. The deletion constructs 
were then transformed into the PJ351 and D39 strains of S. pneumoniae. Deletion knockout 
strains were successfully obtained, and the deletion constructs were confirmed using the 
genomic DNA of the knockout strains as a template to amplify the junctions of the left and 
right flanks surrounding the deleted target genes (Figure 3.2E-Figure 3.7E). PCR across all 
genes using P1Fwd and P2Rev primers generated similar sized bands in the wild-type and 
knockout strains because the dfr13 gene and the deleted genes of interest were of similar size 
(Figure 3.2F-Figure 3.7F). 
 
 
To obtain the streptomycin-resistant S. pneumoniae PJ351 and D39 strains, the rpsL 
gene encoding a streptomycin-resistant knockout of the ribosomal protein S12 was amplified 
from a streptomycin resistant S. pneumoniae with primer pair rpsLFWD and rpsLRV (refer to 
materials and methods). This PCR product was introduced into PJ351and D39 by CSP-1- and 
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CSP-2-induced transformation, respectively, and selected for streptomycin resistance. 
Confirmation of the point mutation was confirmed by DNA sequencing.  
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Figure 3.2 Schematic diagram of the deletion of pspC in PJ351 and D39 by in-frame insertion 
deletion mutagenesis. (A, B) The SPD _2017/INV104_18920 gene, shaded in black, was chosen for 
deletion. (SPD_2017 and INV104_18920 are different annotations for the same gene in different 
strains). Small black arrows indicate the forward and reverse primers used for IDM to obtain the 
SPD_2017/INV104_18920 deletion constructs by replacing part of the SPD_2017/INV104_18920 
genes with the trimethoprim gene (dfr13). (C) IDM to obtain the SPD_2017/INV104_18920 deletion 
constructs by replacing part of SPD_2017/INV104_18920 with the trimethoprim genes (dfr13). (D) 
Successful ligation of the PCR product into pbluescript was confirmed by PCR with primers P1+P2 and 
P3+P4.(E) Representation of the product of transformation of the ΔSPD_2017/INV104_18920 
constructs into the D39 and PJ351 S. pneumoniae strain. (F) Gel electrophoresis images. Analysis of 
amplicons used to construct SPD_2017/INV104_18920 deficient strains. (I) 5'UTR+dfr13 (upstream 
flank+dfr13) (II) 3'UTR+dfr13 (downstream flank+dfr13) (III) Final construct (upstream 
+downstream flank+dfr13). Expected sizes for the amplicons were (I) 1382 bp (II) 2230 bp and (III) 
3600 bp. 
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Figure 3.3 Schematic diagram of the deletion of pspA in PJ351 and D39 by in-frame insertion 
deletion mutagenesis. (A, B) The SPD_0127/INV104_00920 gene, shaded in black, was chosen for 
deletion. (SPD_0127 and INV104_00920 are different annotations for the same gene in different 
strains).Small black arrows indicate the forward and reverse primers used for IDM to obtain the 
SPD_0127/INV104_00920 deletion constructs by replacing part of the SPD_0127/INV104_00920 
genes with the trimethoprim gene (dfr13). (C) IDM to obtain the SPD_0127/INV104_00920 deletion 
constructs by replacing part of SPD_0127/INV104_00920 with the trimethoprim gene (dfr13). (D) 
Successful ligation of the PCR product into pbluescript was confirmed by PCR with primers P1+P2 
and P3+P4. (E) Representation of the product of transformation of the ΔSPD_0127/INV104_00920 
constructs into the D39 and PJ351 S. pneumoniae strains. (F) Gel electrophoresis images. Analysis 
of amplicons used to construct SPD_0127/INV104_00920 deficient strains. (I) 5' UTR+dfr13 
(upstream flank +dfr13), (II) 3'UTR+dfr13 (downstream flank+dfr13) (III) Final construct 
(upstream+downstream flank+dfr13). Expected sizes for the amplicons were (I) 1382 bp (II) 2230 bp 
and (III) 3600bp. 
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Figure 3.4 Schematic diagram of the deletion of stkP in PJ351 and D39 by in-frame insertion 
deletion mutagenesis. (A, B) The SPD_1542/INV104_14760 gene, shaded in black, was chosen for 
deletion. (SPD_1542 and INV104_14760 are different annotations for the same gene in different 
strains). Small black arrows indicate the forward and reverse primers used for IDM to obtain the 
SPD_1542/INV104_14760 deletion constructs by replacing part of the SPD_1542/INV104_14760 
genes with the trimethoprim gene (dfr13). (C) IDM to obtain the SPD_1542/INV104_14760 deletion 
constructs by replacing part of SPD_1542/INV104_14760 with the trimethoprim gene (dfr13.). (D, E) 
Successful ligation of the PCR product into pbluescript was confirmed by PCR with primers P1+P2 
and P3+P4 (E) Representation of the products of transformation of the ΔSPD_1542/INV104_14760 
constructs into the D39 and PJ351 S. pneumoniae strains. (F) Gel electrophoresis images. Analysis 
of amplicons used to construct SPD_1542/INV104_14760 deficient strains. (I) 5'UTR+dfr13 
(upstream flank+dfr13) (II) 3'UTR+dfr13 (downstream flank+dfr13) (III) Final construct 
(upstream+downstream flanks+dfr13). Expected sizes for the amplicons were (I) 1394 bp, (II) 1421 
bp and (III) 2815 bp.  
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Figure 3.5 Schematic diagram of the deletion of igA1 in PJ351 and D39 by in-frame insertion 
deletion mutagenesis. (A, B) The SPD_1018/INV104_09960 gene, shaded in black, was chosen for 
deletion. (SPD_1018 and INV104_00960 are different annotations for the same gene in different 
strains). Small black arrows indicate the forward and reverse primers used for IDM to obtain the 
SPD_1018/INV104_09960 deletion constructs by replacing part of the SPD_1018/INV104_09960 
genes with the trimethoprim gene (dfr13). (C) IDM to obtain the SPD_1018/INV104_09960 deletion 
construct by replacing part of SPD_1018/INV104_09960 with the trimethoprim gene (dfr13). (D) 
Successful ligation of the PCR product into pbluescript was confirmed by PCR with primers P1+P2 
and P3+P4. (E) Representation of the product of transformation of the ΔSPD_1018/INV104_09960 
construct into the D39 and PJ351 S. pneumoniae strain. (F) Gel electrophoresis images. Analysis of 
amplicons used to construct SPD_1018/INV104_09960 deficient strains. (I) 5' UTR +dfr13(upstream 
flank+dfr13), (II)3'UTR+dfr13(downstream flank+dfr13),(III) Final construct (upstream+downstream 
flanks+dfr13) Expected sizes for the amplicons were (I)1490 bp,(II) 1494 bp and (III)2984 bp. 
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Figure 3.6 Schematic diagram of the deletion of ppmA in PJ351 and D39 by in-frame insertion 
deletion mutagenesis. (A, B) The SPD_0868/INV104_08420 gene, shaded in black, was chosen for 
deletion. (SPD_0868 and INV104_08420 are different annotations for the same gene in different 
strains). Small black arrows indicate the forward and reverse primers used for IDM to obtain the 
SPD_0868/INV104_08420 deletion constructs by replacing part of the SPD_0868/INV104_08420 
genes with the trimethoprim gene (dfr13). (C) IDM to obtain the SPD_0868/INV104_08420 deletion 
constructs by replacing part of SPD_0868/INV104_08420 with the trimethoprim gene (dfr13). (D) 
Successful ligation of the PCR product with pbluescript was confirmed by PCR with primers P1+P2 
and P3+P4 (E) Representation of the product of transformation of the ΔSPD _0868/INV104_08420 
construct into the D39 and PJ351 S. pneumoniae strain. (F) Gel electrophoresis images. Analysis of 
amplicons used to construct SPD _0868/INV104_08420 deficient strains. (I) 5' UTR+dfr13 (upstream 
flank+dfr13) (II) 3’ UTR+dfr13 (downstream flank+dfr13) (III) Final construct (upstream 
+downstream+dfr13). Expected sizes for the amplicons were (I) 1464 bp (II) 1249 bp and (III) 2713 
bp. 
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Figure 3.7 Schematic diagram of the deletion of slrA in PJ351 and D39 by in-frame insertion 
deletion mutagenesis. (A, B) The SPD_0679/INV104_06420 gene, shaded in black, was chosen for 
deletion. (SPD_0679 and INV104_06420 are different annotations for the same gene in different 
strains). Small black arrows indicate the forward and reverse primers used for IDM to obtain the 
SPD_0679/INV104_06420 and deletion constructs by replacing part of the gene with the 
trimethoprim gene (dfr13). (C) IDM to obtain SPD_0679 /INV104_06420 deletion constructs by 
replacing part of the gene with the trimethoprim gene (dfr13). (D) Successful ligation of the PCR 
product with pbluescript was confirmed by PCR with primers P1+P2 and P3+P4 (E) Representation of 
the product of transformation of the ΔSPD_0679/INV104_06420 constructs into the D39 and PJ351 
S. pneumoniae strain. (F) Gel electrophoresis images. Analysis of amplicons used to construct 
SPD_0679/INV104_06420 deficient strains. (I) 5’ UTR + dfr13 (upstream flank+dfr13), (II) 3 UTR+ 
dfr13 (downstream flank+dfr13), (III) Final construct (upstream +downstream+dfr13). Expected sizes 
for the amplicons were (I) 1434 bp, (II) 1494 bp and (III) 2928 bp. 
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All the knockout strains, with the exception of the stkP knockout, exhibited growth in 
THY broth that was similar to the wild-type strain (Figure 3.8-Figure 3.9). Since this study 
involves the co-inoculation of strains into a single mouse and the output was based on the 
ratio of the two strains, the stkP gene was excluded from further analysis because it was 
attenuated in growth rate compared to the wild-type strain in vitro. Furthermore, this 
attenuation was very severe in vivo, and by 24 hours, this strain was not detectable at all sites 
that were tested within the mouse. All the isogenic knockouts mentioned above were checked 
for the stability of the mutation by culturing the knockout strains in THY broth in the absence 
of antibiotic (and therefore with no selective pressure for the mutation) for two 8 hour growth 
cycles followed by plating onto antibiotic-free and antibiotic-supplemented plates. 
S. pneumoniae knockout strains had a similar number of colonies on the antibiotic-free and 
antibiotic-supplemented plates confirming the mutation was stable over these time periods. 
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Figure 3.8 Growth curves of PJ351 pneumococcal knockout strains in comparison with their 
PJ351 isogenic wild-type strain under standard in vitro growth conditions. An overnight culture 
was prepared with 1 colony in 5 mL of THY broth. The tubes were incubated at 37 ºC in 5% CO2 
atmosphere for 10 hours. A 1 mL aliquot of the overnight culture was subcultured in 50 mL of THY 
broth and the OD600 nm was measured every hour. Results presented are the mean ODs of triplicate 
samples for each strain and error bars indicate standard deviations between the samples. 
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Figure 3.9 Growth curves of D39 pneumococcal knockout strains in comparison with their D39 
isogenic wild-type strain under standard in vitro growth conditions. An overnight culture was 
prepared with 1 colony in 5 mL of THY broth. The tubes were incubated at 37 ºC in 5% CO2 
atmosphere for 10 hours. A 1 mL aliquot of the overnight culture was subcultured in 50 mL of THY 
broth and the OD600 nm was measured every hour. Results presented are the mean ODs of triplicate 
samples for each strain and error bars indicate standard deviations between the samples. 
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3.1.3 Validation of an intranasal pneumonia co-inoculation model in the presence of 
circulating antibodies 
 
In order to demonstrate the proof of concept of using the co-inoculation model to 
evaluate pneumococcal proteins as potential vaccine antigens, we investigated the dynamics 
of S. pneumoniae presence or survival within a host The underpinning theory being, that a 
knockout strain in an unvaccinated mouse should have identical growth characteristics to a 
knockout strain growing in a vaccinated mouse, where the antibodies present will have no 
impact in the absence of the antibody target. Should the growth characteristics of the 
knockout be identical in the vaccinated and unvaccinated host backgrounds, the knockout 
will serve as an internal calibrator with which to monitor the impact of opsonising antibodies 
on a co-inoculated wild-type strain which has the homotypic antigen present. In this setup, a 
ratio of 1 or closer to 1 indicated an equal recovery of knockout bacterial load in placebo and 
vaccinated mice. Wild-type strains in unvaccinated and vaccinated mice were also monitored 
for growth; wherein the former group could outcompete or grow at a similar rate to the latter 
group, depending on the impact that the presence of the antibodies will have on the antigen. 
A ratio of higher than 1 indicated an unequal recovery of bacterial load in both groups. 
 
 
NMRI mice (n = 5 per time point) were subcutaneously vaccinated with pneumococcal 
proteins PpmA, PspC or adjuvant (control), once every two weeks for a period of four weeks. 
Mice were subsequently challenged intranasally (10
6 
CFU total), with the wild-type PJ351 
(serotype 1) or D39 (serotype 2) and their isogenic PpmA or PspC knockouts 2 weeks after 
the last immunisation. Mice were sacrificed at 0, 6, 12 and 24 hours post-inoculation. Colony 
counts of wild-type and isogenic knockouts were performed from the nasopharyngeal wash, 
BAL fluid and lung tissue samples as described in materials and methods, on selective media. 
A ratio was calculated as the total bacterial load of knockout strains in the placebo group 
divided with that of the vaccinated group.  
 
 
The number of PJ351 and D39 pneumococcal cells per sample from the nasopharynx 
following inoculation with 10
6
 CFU of pneumococci was around 10
4
 CFU. PJ351 and D39 
bacterial counts were maintained at 10
5
 CFU in BAL fluid and lungs for the duration of the 
experiment. There were no statistically significant differences in bacterial numbers of PJ351 
knockout bacteria from the nasopharynx, BAL fluid and lungs of placebo and recombinant 
PspC or PpmA vaccinated mice at all time points observed. The ratio between the two groups 
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was closely maintained at 1 or close to 1 at all-time points shown. On the other hand, there 
were statistically significant differences in bacterial numbers of PJ351 wild-type bacteria at 
all sites sampled from the placebo and recombinant PspC and PpmA vaccinated mice, at most 
time points. The ratio between the two groups was higher than 1 at most time points, with 
ratios ranging from 2.3:2.3 – 97:97 (Figures 3.10 and 3.11).  
 
 
Results for the D39 knockout bacteria in placebo and recombinant PspC or PpmA 
vaccinated mice showed no significant differences between the two groups. Ratios between 
the two groups was closely maintained at 1 or close to 1 at all-time points observed. Bacterial 
counts for D39 wild-type bacteria recovered from the nasopharyngeal lavage, BAL fluid and 
lungs of placebo and recombinant PspC vaccinated mice indicated a non-significant 
difference at 24 hours. The difference in D39 bacterial counts for placebo and recombinant 
PpmA vaccinated mice was observed in the nasopharynx. Ratios higher than 1 were observed 
for wild-type strains between placebo and PspC or PpmA vaccinated mice (Figure 3.12 and 
Figure 3.13). 
 
 
We have successfully validated the use of this mouse model in the analysis of 
vaccinated mice data, by demonstrating that the quantitative count of the knockout strain 
remained the same in both the placebo and vaccinated mice. This was indicated by the ratio 
of 1 or closer to 1 in all sites sampled, between knockout strains in the placebo and 
vaccinated mice. Ratios between wild-type strains in the placebo and vaccinated mice were 
higher than 1 indicating that the wild-type strain was outcompeted in vaccinated mice 
compared to the wild-type strain in unvaccinated mice. This indicates that results observed in 
vaccinated mice are due to changes to the wild-type in the presence of circulating antibodies 
and this shift is unlikely to be influenced by the presence of the knockout strain.  
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Figure 3.10. Ratio analysis of the PJ351ΔpspC knockout and wild-type strains in placebo and 
vaccinated groups. Female NMRI mice were infected intranasally with an equal amount (10
6
 CFU) 
of PJ351 streptomycin-resistant wild-type and PJ351ΔpspC strains per 50 µL dose. Five animals per 
group were terminated at 6 hour time intervals for 24 hours. Samples from the (A) Nasopharynx (B) 
BAL fluid and (C) Lungs were plated on appropriate selective blood agar plates. Data are presented as 
mean CFU with standard deviation from five animals. The ratios given are the mean bacterial load of 
knockout strains in the placebo group divided with that in the vaccinated group. Data represent 
average CFUs from a single experiment and error bars indicate standard deviations from five animals. 
*p ≤ 0.05**, p ≤ 0.001. 
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Figure 3.11. Ratio analysis of the PJ351ΔppmA knockout and wild-type strains in placebo and 
vaccinated groups. Female NMRI mice were infected intranasally with an equal amount (10
6
 CFU) 
of PJ351 streptomycin-resistant wild-type and PJ351ΔppmA strains per 50 µL dose. Five animals per 
group were terminated at 6 hour time intervals for 24 hours. Samples from the (A) Nasopharynx (B) 
BAL fluid and (C) Lungs were plated on appropriate selective blood agar plates. Data are presented as 
mean CFU with standard deviation from five animals. The ratios given are the mean bacterial load of 
knockout strains in the placebo group divided with that in the vaccinated group. Data represent 
average CFUs from a single experiment and error bars indicate standard deviations from five animals. 
*p ≤ 0.05, **p ≤ 0.001.  
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Figure 3.12. Ratio analysis of the D39ΔpspC knockout and wild-type strains in placebo and 
vaccinated groups. Female NMRI mice were infected intranasally with an equal amount (10
6
 CFU) 
of D39 streptomycin-resistant wild-type and D39ΔpspC strains per 50 µL dose. Five animals per 
group were terminated at 6 hour time intervals for 24 hours. Samples from the (A) Nasopharynx (B) 
BAL fluid and (C) Lungs were plated on appropriate selective blood agar plates. Data are presented as 
mean CFU with standard deviation from five animals. The ratios given are the mean bacterial load of 
knockout strains in the placebo group divided with that in the vaccinated group. Data represent 
average CFUs from a single experiment and error bars indicate standard deviations from five animals. 
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Figure 3.13. Ratio analysis of the D39ΔppmA knockout and wild-type strains in placebo and 
vaccinated groups. Female NMRI mice were infected intranasally with an equal amount (10
6
 CFU) 
of D39 streptomycin-resistant wild-type and D39ΔppmA strains per 50 µL dose. Five animals per 
group were terminated at 6 hour time intervals for 24 hours. Samples from the (A) Nasopharynx (B) 
BAL fluid and (C) Lungs were plated on appropriate selective blood agar plates. Data are presented as 
mean CFU with standard deviation from five animals. The ratios given are the mean bacterial load of 
knockout strains in the placebo group divided with that in the vaccinated group. Data represent 
average CFUs from a single experiment and error bars indicate standard deviations from five animals.  
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3.2 GROWTH CHARACTERISTICS OF PNEUMOCOCCAL KNOCKOUTS 
RELATIVE TO WILD-TYPE STRAINS IN A CO-INOCULATION MODEL IN 
UNVACCINATED MICE AT MULTIPLE TIME POINTS 
 
Unvaccinated mice were co-inoculated with equal proportions of a PJ351 or D39 wild-
type and an isogenic knockout of either PspC or PpmA. The results were expressed as 
bacterial counts of the knockout and wild-type bacteria recovered from the nasopharynx, 
BAL fluid and lungs at multiple time points in each individual mouse.  
 
 
3.2.1 PspC and ppmA knockouts in relation to the wild-type PJ351 strain  
 
Throughout the course of the experiment, the PJ351ΔpspC knockout was less able to 
colonise the nasopharynx of mice compared to the parent strain at 6 hours (4-fold reduction, 
p = 0.0002), 12 hours (5-fold reduction, p < 0.0001), and 24 hours (9-fold reduction, 0.0001) 
(Figure 3.14 A). A significant difference between the wild-type and the pspC knockout from 
the BAL fluid was seen at 6 hours (5-fold reduction, p = 0.0001), 12 hours (4-fold reduction, 
p < 0.0001) and 24 hours (17-fold reduction, p < 0.0001) (Figure 3.14 B). Similarly, 
PJ351ΔpspC was significantly attenuated in its ability to infect the lungs compared to its 
isogenic wild-type strain starting at 6 hours (3-fold reduction, p = 0.0002), 12 hours (2-fold 
reduction, p = 0.0010) and 24 hours (18-fold reduction, p < 0.0001) (Figure 3.14 C).  
 
 
The PJ351ΔppmA knockout was less able to colonise the nasopharynx of mice 
compared to the parent strain starting at 6 hours (4-fold reduction, p < 0.0001), 12 hours (6-
fold reduction, p = 0.0042) and 24 hours (4-fold reduction, p = 0.0035) (Figure 3.15 A). 
Deletion of ppmA resulted in a significant difference in the ability of the knockout to grow 
out in the bronchoalveolar tract compared to the wild-type at 6 hours (8-fold reduction, 
p = 0.0295), 12 hours (3-fold reduction, p = 0.0079) and 24 hours (91-fold reduction, 
p = 0.0017) (Figure 3.15 B). Similarly in the lungs, the ΔppmA knockout was attenuated 
compared to the wild-type strain over time at 6 hours (7-fold reduction, p = 0.0003), 12 hours 
(80-fold reduction, p = 0.0005) and 24 hours (31-fold reduction, p < 0.0001) (Figure 3.15 C). 
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Figure 3.14. Intranasal challenge of unvaccinated mice with streptomycin-resistant 
pneumococcal strain (PJ351:: rpsL) and knockout type strain (PJ351ΔpspsC). Female NMRI 
mice were infected intranasally with an equal amount of 10
6
 CFU of PJ351 streptomycin-resistant 
wild-type and PJ351ΔpspC strains per 50 µL dose. Five animals per group were terminated at a 6 
hour time interval for 24 hours. Samples from the (A) Nasopharynx (B) BAL fluid and (C) Lungs 
were plated on appropriate selective blood agar plates. Statistical significance of changes in CFU 
between the wild-type and knockout strain were analysed with a paired-t- test. Data represent average 
CFUs from a single experiment and error bars indicate standard deviations from five animals. ***p ≤ 
0.0001.  
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Figure 3.15. Intranasal challenge of unvaccinated mice with streptomycin-resistant 
pneumococcal strain (PJ351:: rpsL) and knockout type strain (PJ351ΔppmA). Female NMRI 
mice were infected intranasally with an equal amount of 10
6
 CFU of PJ351 streptomycin-resistant 
wild-type and PJ351ΔppmA strains per 50 µL dose. Five animals per group were terminated at a 6 
hour time interval for 24 hours. Samples from the (A) Nasopharynx (B) BAL fluid and (C) Lungs 
were plated on appropriate selective blood agar plates. Statistical significance of changes in CFU 
between the wild-type and knockout strain were analysed with a paired-t- test. Data represent average 
CFUs from a single experiment and error bars indicate standard deviations from five animals *p ≤ 
0.05, **p ≤ 0.001, ***p ≤ 0.0001. 
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3.2.2 pspC and ppmA knockouts in relation to the wild-type D39 strain 
 
In our model, there was a significant decrease in nasopharyngeal colonisation at 
24 hours following intranasal inoculation, with D39ΔpspC (2-fold reduction; p < 0.0001) 
compared to the isogenic wild-type strain (Figure 3.16 A). In the BAL fluid, the pspC 
knockout was attenuated relative to the isogenic wild-type strain at 12 hours (2 fold 
reduction, p < 0.0001) and 24 hours (2-fold reduction, p = 0.0001) (Figure 3.16 B). Similarly, 
in lungs there was a significant reduction in the bacterial load between the wild-type and 
knockout; at 12 hours (2-fold reduction, p < 0.0001) and 24 hours (7-fold reduction, 
p < 0.0001) (Figure 3.16 C). 
 
 
In the nasopharynx of mice, the ppmA knockout strain showed significant attenuation in 
virulence compared to its isogenic parent strain at 12 hours (3-fold reduction, p = 0.0277) and 
24 hours (5-fold reduction; p = 0.0001) (Figure 3.17 A). In the BAL fluid, the attenuation of 
the ppmA knockout relative to the isogenic wild-type strain was observed as early as six 
hours and continued through to 24 hours (6 hours, 3-fold reduction, p = 0.0346; 12 hours, 3-
fold reduction, p = 0.0031 and 24 hours, 2-fold reduction, p = 0.0048) (Figure 3.17 B). In the 
lungs, bacterial loads of D39ΔppmA were significantly lower compared to the D39 wild-type 
strain at 6 hours (3 fold reduction, p = 0.0009), 12 hours (2 fold, p = 0.0016) and 24 hours 
(4-fold reduction, p = 0.0003) (Figure 3.17 C).  
 
 
Despite there being evidence that the pspC and ppmA knockout strains in the D39 
background are attenuated at the later time points, it is clear that the knockouts are still 
virulent and are still able to persist in the nasopharynx, bronchoalveolar tract and lungs. For 
all-time points in the D39 background, the difference was less than 1 log. Similarly, in the 
JP351 genetic background, the difference in colony counts at most time points was less than 1 
log, with a few points differing by up to 2 logs. At all-time points, the colony counts were 
always greater than 10
3
 providing statistically robust counts with a sufficient dynamic range 
to support the application of the knockout strain as a useful calibrator against possible 
changes that may occur in the wild-type strains due to pressure applied to the target antigen 
by the host immune system. 
 78 
 
 
 
Figure 3.16. Intranasal challenge of unvaccinated mice with streptomycin-resistant 
pneumococcal strain (D39:: rpsL) and knockout strain (D39ΔpspC). Female NMRI mice were 
infected intranasally with an equal amount of 10
6
 CFU of D39 streptomycin-resistant wild-type and 
D39ΔpspC strains per 50 µL dose. Five animals per group were terminated at a 6 hour time interval 
for 24 hours. Samples from the (A) Nasopharynx (B) BAL fluid and (C) Lungs were plated on 
appropriate selective blood agar plates. Statistical significance of changes in CFU between the wild-
type and knockout strain were analysed with a paired-t- test. Data represent average CFUs from a 
single experiment and error bars indicate standard deviations from five animals  ***p ≤ 0.0001.  
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Figure 3.17. Intranasal challenge of unvaccinated mice with streptomycin-resistant 
pneumococcal strain (D39:: rpsL) and knockout type strain (D39ΔppmA). Female NMRI mice 
were infected intranasally with an equal amount of 10
6
 CFU of D39 streptomycin-resistant wild-type 
and D39ΔppmA strains per 50 µL dose. Five animals per group were terminated at a 6 hour time 
interval for 24 hours. Samples from the (A) Nasopharynx (B) BAL fluid and (C) Lungs were plated 
on appropriate selective blood agar plates. Statistical significance of changes in CFU between the 
wild-type and knockout strain were analysed with a paired-t- test. Data represent average CFUs from 
a single experiment and error bars indicate standard deviations from five animals*p ≤ 0.05, **p ≤ 
0.001, ***p ≤ 0.0001.  
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3 .3 IMPACT OF VACCINATION ON THE OUTCOMPETITION OF WILD-TYPE 
PNEUMOCOCCI IN RELATION TO KNOCKOUTS IN CO-INOCULATED 
VACCINATED MICE 
 
To demonstrate the value of the co-inoculation model to evaluate the immune 
protective potential of pneumococcal antigens against colonisation and pneumonia, mice 
were subcutaneously injected with or recombinant PspC and PpmA proteins and challenged 
with either the pspC or ppmA deletion knockout in a 1:1 ratio with their isogenic wild-type 
strain. The in vivo competitive index (CI) was calculated by dividing the ratio of knockout to 
wild-type bacteria recovered from the nasopharynx, BAL fluid and lungs at each time point. 
Any impact of vaccination will be indicated by an increase in the CI value in the vaccinated 
mice in relation to the CI value in the unvaccinated mice. In vaccinated mice, a value equal to 
1 indicated that impact of the host immune response to the vaccine target present in the wild-
type strain is equivalent to the attenuation caused by the knockout. CI values above 1 in the 
vaccinated mice indicated that the target antigen in the wild-type is recognised by the 
immune system and is capable of neutralising the wild-type pneumococci to a greater effect 
than neutralisation of the target virulence factor. 
 
 
 3.3.1 PspC and ppmA knockouts in relation to the wild-type PJ351 strain 
 
At 0 hours, there was an equal ability of both strains to colonise the  the nasopharynx of 
both placebo and vaccinated mice. A significant reduction in the CI of placebo mice 
compared to an increase in CI of PspC vaccinated mice was observed from 6 hours and 
onwards in the nasopharynx (6 hours, p = 0.0117; 12 hours, p = 0.0117 and 24 hours, p = 
0.0119) (Figure 3.18 A). Likewise in the BAL fluid, a significant reduction in the CI of 
placebo mice compared to an increase in CI of vaccinated mice was observed from 6 hours 
until 24 hours (6 hours, p = 0.0119, 12 hours, p = 0.0079 and 24 hours, p= 0.0112) (Figure 
3.18 B). In the lungs, a significant difference between competitive indices of placebo and 
vaccinated mice was observed at 12 and 24 hours (12 hours, p = 0.0079 and 24 hours, p = 
0.0079) (Figure 3.18 C). 
 
 
There were no changes observed in the CIs of knockout to wild-type strains in the 
nasopharynx of placebo and PpmA vaccinated mice at 0 hours. There were no significant 
differences (p = 0.2873) at 6 hours in CI scores of placebo and vaccinated mice. At 12 hours 
and 24 hours there were significant reductions in the CI score of placebo mice compared to 
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an increase in the CI score of vaccinated mice (12 hours, p = 0.0019 and 24 hours p = 0.0079) 
(Figure 3.19 A). The CIs in both placebo and vaccinated mice from the BAL fluid was equal 
at 0 hours. Statistical comparison of CIs in the placebo and vaccinated mice at 6 hours 
indicated no significant difference (p = 0.1150). A significant reduction in competitive 
indices was observed at 12 and 24 hours (12 hours, p = 0.0119 and 24 hours, p = 0.0109). 
Competitive indices of placebo and vaccinated mice in the lung tissues indicated a significant 
reduction in CIs starting at 6 hours and onwards (6 hours, p = 0.0119; 12 hours, p = 0.0119 
and 24 hours, p = 0.0119) (Figure 3.19 C). 
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Figure 3.18. Protection against intranasal challenge with S. pneumoniae PJ351. Placebo and vaccinated mice subcutaneously injected with saponin+PBS 
and rPspC+saponin+PBS, respectively, were intranasally inoculated with PJ351 wild-type and PJ351ΔpspC strains. Pneumococci were recovered from 0, 6, 
12 and 24h post infection from A) Nasopharynx B) BAL fluid and C) Lungs of mice. The in vivo competitive index (CI) was calculated as described in the 
text. Values less than 1 indicate attenuation of the knockout and those greater than 1 indicate out-competition of the wild-type strain. Each symbol represents 
the CI obtained from an individual animal. A Mann-Whitney test was used for comparison of mean CI in placebo and vaccinated mice. Data represent 
average CIs from a single experiment. *p ≤ 0.05, ** p ≤ 0.01. 
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Figure 3.19 Protection against intranasal challenge with S. pneumoniae PJ351. Placebo and vaccinated mice subcutaneously injected with saponin+PBS 
and rPpmA+saponin+PBS, respectively, were intranasally inoculated with PJ351 wild-type and PJ351ΔppmA strains. Pneumococci were recovered at 0, 6, 12 
and 24h post infection from A) Nasopharynx, B) BAL fluid and C) Lungs of mice. The in vivo competitive index (CI) was calculated as described in the text. 
Values less than 1 indicate attenuation of the knockout and those greater than 1 indicate out-competition of the wild-type strain. Each symbol represents the 
CI obtained from an individual animal. A Mann-Whitney test was used for comparison of mean CI in placebo and vaccinated mice. Data represent average 
CIs from a single experiment. *p ≤ 0.05, ** p ≤ 0.01. 
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To demonstrate the reliability of our model, we compared CV’s based on colony counts 
with CV’s based on competitive indices for PJ351ΔpspC/PJ351::rpsL or 
PJ351ΔppmA/PJ351::rpsL strains from the nasopharynx, BAL fluid and lungs of placebo and 
PspC or PpmA vaccinated mice. Table 3.4 A-C indicates that CV’s for raw bacterial counts 
in all sites sampled were within the range of 0-200%, compared to a range of 0-30% for CV’s 
of CI scores. These results suggest that bacterial dispersion based on raw bacterial counts of 
PJ351ΔpspC/PJ351::rpsL between individual mice are high in comparison to that based on 
competitive indices. Similar results were also observed when CV’s derived from colony 
counts of PJ351ΔppmA/PJ351::rpsL, were compared to those derived from CI scores (Table 
3.5 A-C). 
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Table 3.4 Standard deviations and coefficients of variations based on the pneumococcal CFUs and competitive index scores of 
PJ351ΔpspC/PJ351::rpsL strains in the nasopharynx, BAL fluid and lungs. 
 
 A.NASOPHARYNX 
 PLACEBO  
(PJ351ΔpspC/PJ351::rpsL) 
VACCINATED 
(PJ351ΔpspC/PJ351::rpsL) 
 Pneumococcal CFUs Competitive index scores Pneumococcal CFUs Competitive index scores 
 0  
hours 
6  
hours 
12  
hours 
24  
hours 
0 
hours  
6  
hours 
12  
hours 
24  
hours 
0  
hours 
6  
hours 
12  
hours 
24  
hours 
0  
hours 
6  
hours 
12  
hours 
24  
hours 
Mean  121002 12599 15387 7551 1.0 0.23 0.19 0.11 118647 4936 4640 1105 1.0 1.16 1.50 1.50 
Std. Deviation 70523 15359 15143 2205 0.0 0.07 0.05 0.02 72230 5717 3150 1160 0.0 0.13 0.24 0.43 
Lower 95% Ci of mean 33435 -6472 -3415 4813 1.0 0.15 0.14 0.09 28962 -2162 729 -335 1.0 1.00 1.20 0.97 
Upper 95% Ci of mean 208569 31670 34190 10288 1.0 0.31 0.25 0.14 208332 12034 8551 2545 1.0 1.32 1.79 2.04 
Coefficient of variation 
(CV ) 
58% 122% 98% 29% 0% 29% 24% 17% 61% 116% 68% 105% 0% 11% 16% 29% 
 
 B.BAL 
 PLACEBO  
(PJ351ΔpspC/PJ351::rpsL) 
VACCINATED 
(PJ351ΔpspC/PJ351::rpsL) 
 Pneumococcal CFUs Competitive index scores Pneumococcal CFUs Competitive index scores 
 0  
hours 
6  
hours 
12  
hours 
24  
hours 
0 
hours  
6  
hours 
12  
hours 
24  
hours 
0  
hours 
6  
hours 
12  
hours 
24  
hours 
0  
hours 
6  
hours 
12  
hours 
24  
hours 
Mean  107000 121040 42177 186625 1.0 0.21 0.27 0.06 101541 72746 14672 5332 1.0 0.47 1.85 5.49 
Std. Deviation 54405 122515 23016 282753 0.0 0.04 0.04 0.01 32638 124926 11289 4033 0.0 0.06 0.41 0.62 
Lower 95% Ci of mean 39446 -31083 13599 -164461 1.0 0.16 0.22 0.05 61015 -82371 654.6 324 1.0 0.41 1.34 4.72 
Upper 95% Ci of mean 174553 273163 70755 537711 1.0 0.26 0.32 0.07 142067 227863 28689 10340 1.0 0.54 2.36 6.27 
Coefficient of variation 
(CV ) 
51% 101% 55% 152% 0% 20% 14% 12% 32% 171% 77% 76% 0% 12% 22% 11% 
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 B.LUNGS 
 PLACEBO  
(PJ351ΔpspC/PJ351::rpsL) 
VACCINATED 
(PJ351ΔpspC/PJ351::rpsL) 
 Pneumococcal CFUs Competitive index scores Pneumococcal CFUs Competitive index scores 
 0  
hours 
6  
hours 
12  
hours 
24  
hours 
0 
 hours  
6  
hours 
12  
hours 
24  
hours 
0  
hours 
6  
hours 
12  
hours 
24  
hours 
0  
hours 
6  
hours 
12  
hours 
24  
hours 
Mean  88140 78500 82751 54260 1.0 0.43 0.52 0.05 86020 79316 44083 4608 1.0 0.51 1.26 2.10 
Std. Deviation 44531 116061 125235 32498 0.0 0.07 0.10 0.02 64944 59000 19466 4091 0.0 0.11 0.39 0.58 
Lower 95% Ci of mean 32847 -65609 -72749 13908 1.0 0.35 0.39 0.04 5381 6058 19912 -472 1.0 0.37 0.77 1.38 
Upper 95% Ci of mean 143433 222610 238252 94612 1.0 0.51 0.65 0.07 166659 152575 68254 9688 1.0 0.64 1.74 2.82 
Coefficient of variation 
(CV ) 
51% 148% 151% 60% 0% 16% 20% 28% 76% 74% 44% 89% 0% 22% 31% 28% 
 
Table 3.5 Standard deviations and coefficients of variations based on the pneumococcal CFUs and competitive index scores of 
PJ351ΔppmA/PJ351::rpsL strains in the nasopharynx, BAL fluid and lungs. 
 
 A.NASOPHARYNX 
 PLACEBO  
(PJ351ΔppmA/PJ351::rpsL) 
VACCINATED 
(PJ351ΔppmA/PJ351::rpsL) 
 Pneumococcal CFUs Competitive index scores Pneumococcal CFUs Competitive index scores 
 0  
hours 
6  
hours 
    12  
  hours 
24  
hours 
0 
hours  
6  
hours 
12  
hours 
24  
hours 
0  
hours 
6  
hours 
12  
hours 
24  
hours 
0  
hours 
6  
hours 
12  
hours 
24  
hours 
Mean  185380 7909  15087 7384 1.0 0.22 0.17 0.38 179840 8580 6181 3272 1.0 0.19 0.60 0.82 
Std. Deviation 234631 3813   11385 9818 0.0 0.02 0.04 0.11 127064 5200 5219 2578 0.0 0.05 0.08 0.12 
Lower 95% Ci of mean -105955 3175       950 -4807 1.0 0.20 0.12 0.24 22068 2123 -299 70 1.0 0.13 0.50 0.67 
Upper 95% Ci of mean 476715 12643   29223 19575 1.0 0.25 0.22 0.52 337612 15036 12661 6473 1.0 0.26 0.71 0.97 
Coefficient of variation 
(CV ) 
127% 48%     75% 133% 0% 9% 25% 29% 71% 61% 84% 79% 0% 26% 14% 15% 
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 B.BAL 
 PLACEBO  
(PJ351ΔppmA/PJ351::rpsL) 
VACCINATED 
(PJ351ΔppmA/PJ351::rpsL) 
 Pneumococcal CFUs Competitive index scores Pneumococcal CFUs Competitive index scores 
 0  
hours 
6  
hours 
12  
hours 
24  
hours 
0 
hours  
6  
hours 
12  
hours 
24  
hours 
0  
hours 
6  
hours 
12  
hours 
24  
hours 
0  
hours 
6  
hours 
12  
hours 
24  
hours 
Mean  71708 67581 12178 68560 1.0 0.33 0.49 0.02 71483 45396 4693 2224 1.0 0.25 0.92 0.79 
Std. Deviation 49251 78083 9171 83131 0.0 0.06 0.13 0.01 39643 44409 3659 1757 0.0 0.07 0.15 0.21 
Lower 95% Ci of 
mean 
10554 -29372 791 -34661 1.0 0.25 0.33 0.01 22260 -9745 150 41 1.0 0.16 0.07 0.53 
Upper 95% Ci of 
mean 
132862 164534 23565 171781 1.0 0.41 0.64 0.03 120707 10053
8 
9237 4406 1.0 0.34 0.74 1.05 
Coefficient of 
variation (CV %) 
69% 116% 75% 121% 0% 20% 26% 23% 55% 98% 78% 79% 0% 29% 16% 27% 
 
 C.LUNGS 
 PLACEBO  
(PJ351ΔppmA/PJ351::rpsL) 
VACCINATED 
(PJ351ΔppmA/PJ351::rpsL) 
 Pneumococcal CFUs Competitive index scores Pneumococcal CFUs Competitive index scores 
 0  
hours 
6  
hours 
12  
hours 
24  
hours 
0 
hours  
6  
hours 
12  
hours 
24  
hours 
0  
hours 
6  
hours 
12  
hours 
24  
hours 
0  
hours 
6  
hours 
12  
hours 
24  
hours 
Mean  71483 45396 4693 2224 1.0 0.17 0.01 0.033 97300 14083 2855 19304 1.0 0.48 1.21 2.22 
Std. Deviation 39643 44409 3659 1757 0.0 0.05 0.004 0.007 40814 9383 2404 18333 0.0 0.11 0.32 0.59 
Lower 95% Ci of 
mean 
22260 -9745 150 41 1.0 0.12 0.002 0.02 46622 2432 -129.7 -3460 1.0 0.35 0.82 1.49 
Upper 95% Ci of 
mean 
120707 100538 9237 4406 1.0 0.22 0.008 0.04 147978 25734 5840 42068 1.0 0.67 1.61 2.96 
Coefficient of 
variation (CV %) 
55% 98% 78% 79% 0% 22%  27% 20% 42% 67% 84% 95% 0% 22% 26% 26% 
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3.3.2 Antibody responses against pneumococcal proteins 
 
In order to analyse antibody responses after subcutaneous immunisations, serum was 
collected from mice 2 weeks after the final immunisation by way of cardiac puncture and 
analysed by ELISA. Analysis showed the presence of high antibody specific IgG titres in 
immunised mice as compared to the saponin placebo group: PspC, 0.02 ± 0.02 U/mL vs 
832 ± 375 U/mL, p < 0.0001 and PpmA, 0.02 ± 0.02 U/mL vs 1162 ± 190 U/mL, p < 0.0001. 
There was, however, no detectable relationship between antibody concentration in the 
individual vaccinated animals and the competitive index ratios between the wild-type strains 
and isogenic knockouts.  
 
 
3.3.3 PspC and ppmA knockouts in relation to the wild-type D39 strain 
 
During the first 12 hours, placebo and rPspC vaccinated mice carried an equal ratio of 
knockout and wild-type bacteria in the nasopharynx. After 24 hours, the CI in the placebo 
mice dropped significantly compared to the vaccinated mice (p = 0.0012) (Figure 3.20 A). No 
changes in competitive indices were observed in the bronchoalveolar tract of placebo and 
vaccinated mice at 0 and 6 hours as there was an equal ratio of the knockout to wild-type 
pneumococci. A significant reduction in the CI of placebo mice was observed at 12 and 24 
hours (12 hours, p = 0.0079 and 24 hours, p = 0.0114) (Figure 3.20 B). No difference in CIs 
was observed at 0 and 6 hours in the lungs of placebo and vaccinated mice as there was an 
equal ratio of the knockout to wild-type pneumococci. Comparison of CI scores from the 
lungs of mice at 12 hours and 24 hours revealed a significant reduction in placebo mice 
compared to an increase in vaccinated mice (12 hours, p = 0.0079 and 24 hours, p = 0.0079 
(Figure 3.20 C). 
 
 
In the nasopharynx of mice vaccinated with rPpmA, we observed a reduction in the CI 
at all-time points in placebo mice compared to the vaccinated mice. We observed a reduction 
in CI scores at all time points in the nasopharynx of placebo mice compared to the vaccinated 
mice (6 hours, p = 0.0117; 12 hours, p = 0.0079 and 24 hours, p = 0.0119) (Figure 3.21 A). 
There were no significant differences in CIs between the placebo and vaccinated mice in the 
BAL fluid and lungs at all-time points observed (Figures 3.21 B and C).  
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Figure 3.20. Protection against intranasal challenge with S. pneumoniae D39 Placebo and vaccinated mice subcutaneously injected with saponin+PBS and 
rPspC+saponin+PBS, respectively were intranasally inoculated with an equal amount of 10
6
 CFU of D39 streptomycin-resistant wild-type and D39ΔpspC strains per 50µL 
dose. Pneumococci were recovered at 0, 6, 12 and 24h post infection from A) Nasopharynx, B) BAL fluid and C) Lungs of mice. The in vivo competitive index (CI) was 
calculated as described in the text. Each symbol represents the CI obtained from an individual animal. Values less than 1 indicate attenuation of the knockout and those 
greater than 1 indicate out-competition of the wild-type strain. Each symbol represents the CI obtained from an individual animal. A Mann-Whitney test was used for 
comparison of mean CI in placebo and vaccinated mice.Data represent average CIs from a single experiment. *p ≤ 0.05, ** p ≤ 0.01.. 
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Figure 3.21. Protection against intranasal challenge with S. pneumoniae D39. Placebo and vaccinated mice subcutaneously injected with saponin+PBS and 
rPpmA+saponin+PBS, respectively were intranasally inoculated with D39 wild-type and D39ΔppmA strains. Pneumococci were recovered at 0, 6, 12 and 24h post infection 
from A) Nasopharynx, B) BAL fluid and C) Lungs of mice. The in vivo competitive index (CI) was calculated as described in the text. Each symbol represents the CI obtained 
from an individual animal. Values less than 1 indicate attenuation of the knockout and those greater than 1 indicate out-competition of the wild-type strain. Each symbol 
represents the CI obtained from an individual animal. A Mann-Whitney test was used for comparison of mean CI in placebo and vaccinated mice. Data represent average CIs 
from a single experiment. *p ≤ 0.05, ** p ≤ 0.01. 
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The variability of each measurement of bacterial numbers was tested by calculating 
CV’s from the nasopharynx, BAL fluid and lungs of mice. Data analysis for raw bacterial 
counts for mice inoculated with D39ΔpspC/D39::rpsL strains indicated a large spread in 
bacterial counts as determined by CV’s of higher than 100%. In comparison, data analysis for 
competitive index scores indicated little variation in data as a result of lower CV’s (Table 3.6 
A-C). Likewise for data analysis for mice inoculated with D39ΔppmA/D39::rpsL strains 
indicated a similar pattern of results (Table 3.7 A-C). 
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Table 3.6 Standard deviations and coefficients of variations based on pneumococcal CFUs and competitive index scores of 
D39ΔpspC/D39::rpsL strains in the nasopharynx, BAL fluid and lungs. 
 
 A.NASOPHARYNX 
 PLACEBO  
(D39ΔpspC/D39::rpsL) 
VACCINATED 
(D39ΔpspC/D39::rpsL) 
 Pneumococcal CFUs Competitive index scores Pneumococcal CFUs Competitive index scores 
 0 hrs 6 hrs 12 hrs 
 
24hrs 
 
0hrs 6 hrs 
 
12 hrs 24 hrs 
 
0hrs 
 
6 hrs 
 
12hrs 24 hrs 
 
0hrs 
 
6 hrs 
 
12 hrs 
 
24 hrs 
 
Mean  134824 41880 17130 26516 1.0 1.0 0.90 0.45 129187 40746 18794 15248 1.0 1.06 1.00 0.88 
Std. Deviation 175425 57847 17211 42776 0.0 0.08 0.09 0.05 77358 73187 14530 7452 0.0 0.07 0.08 0.04 
Lower 95% Ci of mean -82997 -29947 -4240 -26597 1.0 0.91 0.79 0.39 33134 -50128 752 5995 1.0 0.97 0.90 0.83 
Upper 95% Ci of mean 352644 113707 38500 79629 1.0 1.10 1.01 0.51 225240 131620 36836 24501 1.0 1.15 1.10 0.92 
Coefficient of variation (CV) 130% 138% 100% 161% 0% 8% 10% 11% 60% 180% 77% 49% 0% 7% 8% 4% 
 
 B.BAL 
 PLACEBO  
(D39ΔpspC/D39::rpsL) 
VACCINATED 
(D39ΔpspC/D39::rpsL) 
 Pneumococcal CFUs Competitive index scores Pneumococcal CFUs Competitive index scores 
 0 hrs 
 
6 hrs 
 
12 hrs 
 
24 hrs 
 
0 hrs 
 
6 hrs 
 
12 hrs 
 
24 hrs 
 
0 hrs 
 
6 hrs 
 
12 hrs 24 hrs 
 
0 hrs 
 
6 hrs 
 
12hrs 
 
24hrs 
 
Mean  493619 288000 105543 105152 1.0 1.04 0.69 0.68 459487 320980 85500 68220 1.0 1.07 1.05 1.25 
Std. Deviation 484074 138116 118126 150055 0.0 0.02 0.03 0.05 323907 313159 56901 51934 0.0 0.10 0.13 0.13 
Lower 95% Ci of mean -107441 116506 -41131 -81167 1.0 1.01 0.65 0.62 57301 -67861 14848 3735 1.0 0.94 0.88 1.09 
Upper 95% Ci of mean 1e+006 459494 252216 291471 1.0 1.07 0.73 0.74 861672 709821 156152 13270
5 
1.0 1.19 1.21 1.41 
Coefficient of variation (CV)  98% 48% 112% 143% 0% 2% 5% 7% 70% 98% 67% 76% 0% 9% 12% 11% 
 
 C.LUNGS 
 PLACEBO  
(D39ΔpspC/D39::rpsL) 
VACCINATED 
(D39ΔpspC/D39::rpsL) 
 Pneumococcal CFUs Competitive index scores Pneumococcal CFUs Competitive index scores 
 0hrs 6 hrs 
 
12 hrs 24 hrs 0hrs 6hrs 12hrs 
 
24 hrs 
 
0 hrs 
 
6 hrs 
 
12hrs 
 
24 hrs 
 
0 hrs 
 
6 hrs 12 hrs 
 
24 hrs 
Mean  152215 113802 23195 143528 1.0 1.05 0.52 0.17 165799 118190 13237 28850 1.0 1.18 1.05 1.77 
Std. Deviation 114912 109734 20518 273549 0.0 0.11 0.05 0.04 159520 113245 3378 39392 0.0 0.10 0.17 0.31 
Lower 95% Ci of mean 9533 -22452 -2281 -196129 1.0 0.92 0.45 0.12 -32272 -22422 9042 -20062 1.0 1.06 0.83 1.39 
Upper 95% Ci of mean 294898 250056 48671 483185 1.0 1.20 0.58 0.22 363870 258802 17431 77762 1.0 1.30 1.26 2.16 
Coefficient of variation (CV) 75% 96% 88% 191% 0% 11% 10% 25% 96% 96% 26% 137% 0% 8% 17% 17% 
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Table 3.7 Standard deviations and coefficients of variations based on pneumococcal CFUs and competitive index scores of 
D39ΔppmA/D39::rpsL strains in the nasopharynx, BAL fluid and lungs. 
 
 A.NASOPHARYNX 
 PLACEBO  
(D39ΔppmA/D39::rpsL) 
VACCINATED 
(D39ΔppmA/D39::rpsL) 
 Pneumococcal CFUs Competitive index scores Pneumococcal CFUs Competitive index scores 
 0 hrs 
 
6 hrs 
 
12 hrs 
 
24 hrs 
 
0hrs 
  
6 hrs 
 
12 hrs 
 
24 hrs 
 
0 hrs 
 
6 hrs 
 
12 hrs 
 
24 hrs 
 
0hrs 6 hrs 
 
12 hrs 
 
24 hrs 
 
Mean  159460 66185 13782 30526 1.0 0.41 0.29 0.24 146240 31441 5063 11492 1.0 2.28 1.06 1.90 
Std. Deviation 139445 41221 14661 31248 0.0 0.05 0.07 0.05 98951 28226 4576 9852 0.0 0.45 0.20 0.52 
Lower 95% Ci of mean -13685 15002 -4423 -8274 1.0 0.35 0.21 0.18 23376 -3607 -619.2 -741.4 1.0 1.73 0.09 1.25 
Upper 95% Ci of mean 332605 117367 31986 69326 1.0 0.47 0.38 0.30 269104 66489 10745 23725 1.0 2.84 0.81 2.55 
Coefficient of variation 
(CV) 
87% 62% 106% 102% 0% 12% 24% 20% 68% 90% 90% 86% 0% 20% 19% 28% 
 
 B.BAL 
 PLACEBO  
(D39ΔppmA/D39::rpsL) 
VACCINATED 
(D39ΔppmA/D39::rpsL) 
 Pneumococcal CFUs Competitive index scores Pneumococcal CFUs Competitive index scores 
 0 hrs 
 
6 hrs 
 
12hrs 
 
24 hrs 
 
0hrs 
  
6 hrs 
 
12 hrs 
 
24 hrs 
 
0hrs 
 
6 hrs 
 
12 hrs 
 
24hrs 
 
0hrs 
 
6hrs 12hrs 
 
24hrs 
 
Mean  354666 247773 326622 264353 1.0 0.42 0.31 0.50 310583 216640 318728 335160 1.0 0.28 0.34 0.37 
Std. Deviation 545277 177659 260548 558930 0.0 0.09 0.08 0.13 192482 204972 426809 450831 0.0 0.05 0.10 0.08 
Lower 95% Ci of mean -322389 27179 3107 -429654 1.0 0.50 0.21 0.34 71584 -37867 -211228 -224623 1.0 0.21 0.24 0.27 
Upper 95% Ci of mean 1e+006 468367 650136 958360 1.0 0.13 0.42 0.66 549583 471147 848683 894943 1.0 0.34 0.49 0.47 
Coefficient of variation 
(CV) 
154% 72% 80% 211% 0% 21% 27% 26% 62% 95% 134% 135% 0% 19% 27% 21% 
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  C.LUNGS 
 PLACEBO  
(D39ΔppmA/D39::rpsL) 
VACCINATED 
(D39ΔppmA/D39::rpsL) 
 Pneumococcal CFUs Competitive index scores Pneumococcal CFUs Competitive index scores 
 0 hrs 
 
6 hrs 
 
12 hrs 
 
24 hrs 
 
0 hrs 
  
6 hrs 
 
12 hrs 
 
24 hrs 
 
0 hrs 
 
6 hrs 
 
12 hrs 
 
24 hrs 
 
0 hrs 
 
6 hrs 
 
12 hrs 
 
24 hrs 
 
Mean  90242 99985 346000 342401 1.0 0.30 0.13 0.23 87716 165197 368380 515061 1.0 0.24 0.11 0.32 
Std. Deviation 69639 29651 141458 449646 0.0 0.01 0.02 0.06 25064 125864 563566 693319 0.0 0.05 0.03 0.10 
Lower 95% Ci of mean 3773 63168 170355 -215911 1.0 0.28 0.10 0.16 56595 8915 -331383 -345813 1.0 0.18 0.07 0.21 
Upper 95% Ci of mean 176710 136802 521645 900713 1.0 0.31 0.16 0.31 118838 321478 1e+006 1e+006 1.0 0.31 0.14 0.44 
Coefficient of variation 
(CV) 
77% 30% 41% 131% 0% 4% 18% 25% 29% 76% 153% 134% 0% 20% 27% 30% 
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3.3.4 Antibody responses against pneumococcal proteins 
 
Antibody analysis indicated significant differences in antibody concentrations of sera 
between placebo and immunised mice: PspC, 0.020 ± 0.020 U/mL vs 1908 ± 1936 U/mL, 
p < 0.0001 and PpmA: 0.020 ± 0.020 U/mL vs 1265 ± 227 U/mL, p < 0.0001. There was, 
however, no detectable relationship between antibody concentration in the vaccinated 
animals and the CI scores between the wild-type strains and isogenic knockouts.  
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3.4 GROWTH CHARACTERISTICS OF PNEUMOCOCCAL KNOCKOUTS 
RELATIVE TO WILD-TYPE STRAINS IN A CO INOCULATION MODEL IN 
UNVACCINATED MICE AT A SINGLE TIME POINT 
 
To further elucidate the relevance and potential use of this model, a single time point 
(T = 24h) in which the vaccine effect was most pronounced was chosen for the remainder of 
the experiments. Additional proteins of the cell wall and membrane bound class (SlrA, PspA 
and IgA1 bacterial protease) were assessed for their potential to protect mice from infection 
with the pneumococcus using our mouse model. A group of 30 unvaccinated mice (10 mice 
per protein) were intranasally inoculated with a 1:1 ratio of 10
6
 CFU of S. pneumoniae wild-
type and knockout strains. Animals were sacrificed at 24 hours post inoculation, the number 
of CFU in the nasopharynx, BAL fluid and lungs were enumerated, and the differences in the 
bacterial load in the placebo group were determined. 
 
 
3.4.1 Virulence characteristics of pspA, igA1 and slrA knockouts in relation to the PJ351 
wild-type strain in unvaccinated mice 
 
The recovery of all knockout bacteria in the PJ351 strain was significantly lower 
compared to the wild-type strain in the nasopharynx. After 24 hours, the slrA knockout in the 
nasopharynx was significantly reduced by 10-fold, in relation to the wild-type strain 
(p = 0.0005). Similarly in the BAL fluid, the knockout was significantly reduced by 15-fold 
in relation to the wild-type (p = 0.0005). The effect of the slrA knockout was most noticeable 
in the lung tissue, which was reduced by 17-fold in relation to the wild-type (p = 0.0005) 
(Figure 3.22 A). The pspA knockout was less able to colonise the nasopharynx of mice 
compared to the parent strain following 24 hours of inoculation (6-fold, p = 0.0089). A more 
pronounced effect of the pspA knockout was observed in the BAL fluid (33-fold, p = 0.0146) 
and lungs (31-fold, p = 0.0118) (Figure 3.22 B). Similarly, the igA1 knockout was 
significantly attenuated in its ability to colonise the nasopharynx of mice (2-fold, p < 0.0001). 
There was an observation of a significant difference between the wild-type and the igA1 
knockout in the BAL fluid (8-fold, p < 0.0001) and lungs (11-fold, p < 0.0001) (Figure 3.22 
C). 
 
 97 
 
3.4.2 Virulence characteristics of pspA, igA1 and slrA knockouts in relation to the D39 
wild-type strain in unvaccinated mice 
 
Deletion of D39ΔslrA resulted in a reduction of the bacterial load in the nasopharynx of 
mice compared to the wild-type (4 fold, p < 0.0001). We found no marked reduction in 
bacterial load of D39ΔslrA compared to the wild-type strain in the BAL fluid and lungs 
(Figure 3.23 A). Likewise, the pspA knockout was attenuated in its ability to colonise the 
nasopharynx of mice (9-fold, p < 0.0001). There was also no marked reduction in bacterial 
load of D39ΔpspA compared to the parent strain in the BAL fluid and lungs (Figure 3.23 B). 
The igA1 knockout was reduced by half in relation to the wild-type strain in the nasopharynx 
of mice (p < 0.0001). Deletion of igA1 did not attenuate the ability of the D39 strain to grow 
in the BAL fluid and lungs of mice (Figure 3.23 C). 
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Figure 3.22. Intranasal challenge of unvaccinated mice with streptomycin-resistant 
pneumococcal strain PJ351 (PJ351::rpsL) and knockout type strains PJ351ΔslrA, PJ351ΔpspA 
and PJ351ΔigA1. Female NMRI mice were infected intranasally with an equal amount of 106 CFU of 
PJ351 streptomycin-resistant wild-type and knockout strains per 50µL dose. Groups of 10 mice were 
co-infected with a 1:1 mixture of wild-type and knockout strain. Pneumococci were recovered at 24h 
post infection from the (A) Nasopharynx, (B) BAL fluid and (C) Lung tissue. Statistical significance 
of changes in CFU between the wild-type and knockout strain were assessed using the Mann-Whitney 
test. ***p ≤ 0.0001. 
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Figure 3.23. Intranasal challenge of unvaccinated mice with streptomycin-resistant 
pneumococcal strain D39 (D39::rpsL) and knockout type strains D39ΔslrA, D39ΔpspA and 
D39ΔigA1. Female NMRI mice were infected intranasally with an equal amount of 106 CFU of D39 
streptomycin-resistant wild-type and knockout strains per 50µL dose. Groups of 10 mice were co-
infected with a 1:1 mixture of wild-type and knockout strain. Pneumococci were recovered at 24h 
post infection from the (A) Nasopharynx, (B) BAL fluid and (C) Lung tissue. Statistical significance 
of changes in CFU between the wild-type and knockout strain were assessed using the Mann-Whitney 
test. *p ≤0.05, ***p ≤ 0.0001.  
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3.5 IMPACT OF VACCINATION ON THE OUTGROWTH OF WILD-TYPE 
PNEUMOCOCCI IN RELATION TO KNOCKOUTS IN CO-INOCULATED 
VACCINATED MICE 
 
In order to determine whether the recombinant proteins would elicit a protective 
immune response, a competitive index analysis of the knockout strains and their isogenic 
PJ351 and D39 wild-type strains was performed. NMRI mice were immunised separately 
with 50 µg of each protein (PspA, IgA1 bacterial protease or SlrA) and four weeks later, 
challenged with 1:1 ratio of knockout strains and wild-type strains at 10
6
 of total bacteria 
(knockout and wild-type strains combined at a 1:1 ratio). Animals were sacrificed at 24 hours 
post inoculation, CI scores were performed as described in chapter 2.  
 
 
3.5.1 Impact of vaccination on slrA, pspA or igA1 knockouts in relation to the wild-type 
PJ351 strain in vaccinated and unvaccinated mice 
 
No significant changes in competitive indices were observed in the nasopharynx of 
placebo and SlrA vaccinated mice (p = 0.5966). The CI score from the BAL fluid of placebo 
mice and SlrA vaccinated mice revealed that there was no significant difference between the 
groups (p = 1.000). In the lung tissues of placebo and SlrA vaccinated mice, we observed no 
significant differences in the CI scores (p = 0.1198) (Figure 3.24 A). 
 
 
There were also no observed changes in competitive indices in the nasopharynx of 
placebo and PspA vaccinated mice (p = 0.1523). Likewise, there was no significant 
difference in the comparison of CI scores in the BAL fluid of placebo mice and PspA 
vaccinated mice (p = 0.7618). There were also no significant differences in the CI scores 
from the lung tissues between the placebo and vaccinated mice (p = 0.1301) (Figure 3.24.B). 
 
 
Similarly, in the nasopharynx of placebo mice and IgA vaccinated mice, there were no 
observed changes in the CI scores in both placebo and vaccinated mice (p = 0.3840). No 
significant differences were observed between the CI scores of placebo and vaccinated mice 
(p = 0.3254). Statistical comparison of the CI scores from the lung tissues of placebo and 
vaccinated mice showed a non-significant difference between the groups (p = 0.3285) (Figure 
3.24.C).  
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Further, CV’s calculated on mean bacterial counts for ΔslrA, ΔpspA, ΔigA and their 
parent strain from the nasopharynx, BAL fluid and lungs of placebo and vaccinated mice 
indicated high variation in data. On the other hand, CV’s calculated on CI scores indicated 
low variation in data for all strains in the placebo and vaccinated mice as evidenced by CV’s 
less than 30% (Table 3.8 A-I).  
 
 
3.5.2 SlrA, pspA or igA1 knockouts in relation to the wild-type D39 strain 
 
There was no significant difference in CI scores in the nasopharynx of mice between 
placebo and SlrA vaccinated mice (p = 0.5463). Comparison of the CI scores from the BAL 
fluid of placebo and SlrA vaccinated mice indicated no significant changes between the two 
groups (p = 0.2558). In the lung tissue of placebo and SlrA vaccinated mice we observed no 
significant differences in the CI scores (p = 0.1110) (Figure 3.25.A). 
 
 
No significant changes in competitive indices were also observed in the nasopharynx of 
placebo and PspA vaccinated mice (p = 0.2676). Similarly, no significant differences were 
observed in the BAL fluid of placebo and vaccinated mice (p = 0.0887). The same trend was 
also observed in the lung tissue of placebo and vaccinated mice in which there were no 
significant differences in the CI scores between the groups (p = 0.7748) (Figure 3.25.B). 
 
 
In contrast, a significant reduction in the CI of placebo mice was observed compared to 
an increase in CI of IgA vaccinated mice (p = 0.0002). Statistical comparison of the CI scores 
from the BAL fluid of placebo and vaccinated mice showed that there were no significant 
differences between the two groups (p = 0.7618). Same results were seen in the lung tissues 
of placebo and IgA vaccinated mice. Statistical comparison of vaccinated and placebo mice 
showed a non-significant difference in CI scores (p = 0.2404) (Figure 3.25.C). 
 
 
CV’s calculated for mean bacterial counts of all strains from the nasopharynx, BAL 
fluid and lungs of placebo and vaccinated mice revealed high dispersion in data, compared to 
CV’s calculated for CI scores (Table 3.9 A-I). 
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Figure 3.24. Protection against intranasal challenge with S. pneumoniae PJ351. Groups of 20 mice equally distributed into the vaccinated and placebo groups were 
subcutaneously injected with saponin+PBS+ (A) rSlrA,(B) rPspA or (C) rIgA1 bacterial protease and saponin+PBS, respectively. Intranasal co-inoculation was with a 1:1 
mixture of PJ351 wild-type and PJ351 knockout strains. Pneumococci were recovered at 24h post infection from the nasopharynx, BAL fluid and lung tissue. A value of 1 
indicates that both strains are proliferating equally. Values less than 1 indicate attenuation of the knockout and those greater than 1 indicate out-competition of the wild-type 
strain. A Mann-Whitney test was used for comparison of mean CI in placebo and vaccinated mice. Data represent average CIs from a single experiment. 
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Figure 3.25. Protection against intranasal challenge with S. pneumoniae D39. Groups of 20 mice equally distributed into the vaccinated and placebo groups were 
subcutaneously injected with saponin+PBS+ (A) rSlrA,(B) rPspA or (C) rIgA1 bacterial protease and saponin+PBS, respectively. Mice were subsequently inoculated with a 
1:1 mixture of D39 wild-type and D39 knockout strains. Pneumococci were recovered at 24h post infection from the nasopharynx, BAL fluid and lung tissue. A value of 1 
indicates that both strains are proliferating equally. Values less than 1 indicate attenuation of the knockout and those greater than 1 indicate out-competition of the wild-type 
strain. A Mann-Whitney test was used for comparison of mean CI in placebo and vaccinated mice. Data represent average CIs from a single experiment. ***p ≤ 0.0001.  
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Table 3.8 Standard deviations and coefficients of variations based on pneumococcal CFUs and competitive index scores of PJ351ΔslrA/PJ351::rpsL, 
PJ351ΔpspA/PJ351::rpsL and PJ351ΔigA1/PJ351::rpsL strains in the nasopharynx, BAL fluid and lungs. 
 
 
 D.NASOPHARYNX E.BAL F.LUNGS 
 PLACEBO  
(PJ351ΔpspA/ 
PJ351::rpsL) 
 
VACCINATED 
(PJ351ΔpspA/ 
PJ351::rpsL) 
PLACEBO  
(PJ351pspA/ 
PJ351::rpsL) 
VACCINATED 
(PJ351ΔpspA/ 
PJ351::rpsL)  
PLACEBO  
(PJ351ΔpspA/ 
PJ351::rpsL) 
VACCINATED 
(PJ351ΔpspA/ 
PJ351::rpsL) 
 Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score 
Mean  6262 0.19 1132 0.15 434900 0.02 12938 0.02 158650 0.02 4520 0.02 
Std. 
Deviation 
5487 0.05 1147 0.03 459556 0.01 17681 0.01 159962 0.01 5472 0.01 
Lower 95% 
Ci of mean 
2044 0.15 249.6 0.13 106150 0.02 290.2 0.02 44219 0.02 604.9 0.02 
Upper 95% 
Ci of mean 
10480 0.23 2013 0.18 763650 0.03 25586 0.03 273080 0.03 8434 0.02 
Coefficient 
of variation 
(CV) 
88% 28% 101% 20% 106% 30% 137% 22% 101% 26% 121% 28% 
 
 A.NASOPHARYNX B.BAL C.LUNGS 
 PLACEBO  
(PJ351ΔslrA/ 
PJ351::rpsL) 
 
VACCINATED 
(PJ351ΔslrA/ 
PJ351::rpsL) 
PLACEBO  
(PJ351ΔslrA/ 
PJ351::rpsL) 
VACCINATED 
(PJ351ΔslrA/ 
PJ351::rpsL)  
PLACEBO  
(PJ351ΔslrA/ 
PJ351::rpsL) 
VACCINATED 
(PJ351ΔslrA/ 
PJ351::rpsL) 
 Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score 
Mean  38111 0.01 3909 0.09 726330 0.07 49443 0.07 820810 0.05 43707 0.04 
Std. Deviation 45546 0.02 5298 0.03 831319 0.02 61579 0.02 1.52e+006 0.01 70248 0.01 
Lower 95%  
Ci of mean 
5529 0.08 118.8 0.07 131635 0.06 5392 0.06 -262628 0.04 -6546 0.03 
Upper 95%  
Ci of mean 
70693 0.11 7699 0.11 1.32e+006 0.08 93494 0.09 1.90e+006 0.05 93960 0.04 
Coefficient  
of variation 
(CV) 
120% 21% 136% 30% 114% 21% 125% 24% 185% 24% 161% 19% 
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 G.NASOPHARYNX H.BAL I.LUNGS 
 PLACEBO  
(PJ351ΔigA1/ 
PJ351::rpsL) 
 
VACCINATED 
(PJ351ΔigA1/ 
PJ351::rpsL) 
PLACEBO  
(PJ351ΔigA1/ 
PJ351::rpsL) 
VACCINATED 
(PJ351ΔigA1/ 
PJ351::rpsL)  
PLACEBO  
(PJ351ΔigA1/ 
PJ351::rpsL) 
VACCINATED 
(PJ351ΔigA1/ 
PJ351::rpsL) 
 Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score 
Mean  36908 0.27 15289 0.24 1.086e+006 0.09 127200 0.08 909063 0.08 88118 0.07 
Std. 
Deviation 
86495 0.06 36714 0.06 582835 0.02 103651 0.02 1.07e+006 0.02 131820 0.02 
Lower 95% 
Ci of mean 
-29578 0.22 -12932 0.20 598482 0.07 40544 0.07 12728 0.06 -22088 0.06 
Upper 95% 
Ci of mean 
103394 0.31 43510 0.28 1.57e+006 0.11 213856 0.09 1.81e+006 0.10 198323 0.08 
Coefficient 
of variation 
(CV) 
234% 23% 240% 26% 54% 26% 81% 22% 118% 29% 149% 26% 
 
Table 3.9 Standard deviations and coefficients of variations based on pneumococcal CFUs and competitive index scores of D39ΔslrA/D39::rpsL, 
D39ΔpspA/D39::rpsL and D39ΔigA1/D39::rpsL strains in the nasopharynx, BAL fluid and lungs. 
 
 A.NASOPHARYNX B.BAL C.LUNGS 
 PLACEBO  
(D39ΔslrA/D39::rpsL) 
 
VACCINATED 
(D39ΔslrA/ 
D39::rpsL) 
PLACEBO  
(D39ΔslrA/ 
D39::rpsL) 
VACCINATED 
(D39ΔslrA/ 
D39::rpsL)  
PLACEBO  
(D39ΔslrA/ 
D39::rpsL) 
VACCINATED 
(D39ΔslrA/ 
D39::rpsL) 
 pneumococcal 
CFUs 
CI score pneumococcal 
CFUs 
CI score pneumococcal 
CFUs 
CI score pneumococcal 
CFUs 
CI score pneumococcal 
CFUs 
CI score pneumococca
l CFUs 
CI score 
Mean  22650 0.27 6124 0.25 36104 0.94 48247 1.09 853205 0.77 730492 0.89 
Std. 
Deviation 
13701 0.08 4304 0.07 66206 0.24 55536 0.29 1.166e+006 0.12 1.038e+006 0.19 
Lower 95% 
Ci of mean 
12849 0.21 3045 0.20 -11258 0.77 8519 0.88 18888 0.68 -11912 0.75 
Upper 95% 
Ci of mean 
32451 0.33 9203 0.30 83466 1.12 87975 1.30 1.688e+006 0.86 1.473e+006 1.03 
Coefficient 
of variation 
(CV) 
60% 30% 70% 28% 183% 26% 115% 27% 137% 16% 142% 21% 
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 D.NASOPHARYNX E.BAL F.LUNGS 
 PLACEBO  
(D39ΔpspA/ 
D39::rpsL) 
 
VACCINATED 
(D39ΔpspA/ 
D39::rpsL) 
PLACEBO  
(D39ΔpspA/ 
D39::rpsL) 
VACCINATED 
(D39ΔpspA/ 
D39::rpsL)  
PLACEBO  
(D39ΔpspA/ 
D39::rpsL) 
VACCINATED 
(D39ΔpspA/ 
D39::rpsL) 
 Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score 
Mean  127620 0.09 15867 0.09 777350 0.88 663130 1.10 770278 1.02 718089 1.01 
Std. 
Deviation 
71882 0.02 15380 0.02 703577 0.20 616596 0.30 922811 0.23 833373 0.16 
Lower 95% 
Ci of mean 
76198 0.08 4865 0.07 274037 0.74 222040 0.88 60944 0.85 77503 0.89 
Upper 95% 
Ci of mean 
179042 0.10 26869 0.10 1.281e+006 1.02 1.104e+006 1.32 1.480e+006 1.20 1.359e+006 1.12 
Coefficient 
of variation 
(CV) 
56% 18% 97% 21% 91% 22% 93% 28% 120% 22% 116% 16% 
 
 G.NASOPHARYNX H.BAL I.LUNGS 
 PLACEBO  
(D39ΔigA1/ 
D39::rpsL) 
 
VACCINATED 
(D39ΔigA1/ 
D39::rpsL) 
PLACEBO  
(D39ΔigA1/ 
D39::rpsL) 
VACCINATED 
(D39ΔigA1/ 
D39::rpsL)  
PLACEBO  
(D39ΔigA1/ 
D39::rpsL) 
VACCINATED 
(D39ΔigA1/ 
D39::rpsL) 
 Pneumococcal  
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score Pneumococcal 
CFUs 
CI score 
Mean  193860 0.44 81140 1.18 70987 0.97 74929 1.01 740628 0.83 652867 0.95 
Std. 
Deviation 
109436 0.12 49300 0.22 77949 0.23 92344 0.24 1.625e+006 0.16 1.427e+006 0.22 
Lower 95%  
Ci of mean 
115574 0.36 45873 1.03 15225 0.80 8869 0.84 -422152 0.72 -367670 0.79 
Upper 95%  
Ci of mean 
272146 0.53 116407 1.34 126749 1.13 140989 1.18 1.903e+006 0.95 1.673e+006 1.11 
Coefficient  
of variation  
(CV) 
56% 27% 61% 19% 110% 24% 123% 24% 219% 20% 219% 24% 
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3.5.3 Antibody responses against pneumococcal proteins 
 
In order to analyse antibody responses after subcutaneous immunisations, serum was 
collected from mice by way of cardiac puncture and analysed by ELISA. We observed a 
significant difference in antibody concentrations between sera from the placebo mice and 
immunised mice 24 hours after challenge with PJ351 (IgA1 bacterial protease: 0.020 ± 0.020 
U/mL vs 595 ±  315 U/mL; p < 0.0001; PspA: 0.020 ± 0.020 U/mL vs 1457 ± 581 U/mL; p < 
0.0001 and SlrA: 0.020 ± 0.020 U/mL vs 882 ± 165 U/mL) and D39 (IgA1 bacterial protease: 
0.020 ± 0.020 U/mL vs 706 ±  329 U/mL; p < 0.0001; PspA: 0.020 ± 0.020 U/mL vs 1539 ± 
822 and SlrA: 0.020 ± 0.020 U/mL vs 794 ± U/mL). However, there was no detectable 
relationship between antibody concentration in the vaccinated animals and the CI ratios 
between the wild-type strains and isogenic knockouts. 
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CHAPTER 4 DISCUSSION 
 
4.1 Development of an intranasal pneumonia co-inoculation model 
 
The first part of this work was to establish an intranasal pneumonia co-inoculation 
model in NMRI mice for at least two S. pneumoniae strains, PJ351 (serotype 1) and D39 
(serotype2). We aimed to 1) Use clinically relevant strains that were relatively virulent in 
mice 2) Mimic the natural course of disease in humans 3) Reduce effects of variability 
between mice and 4) Reduce the number of mice required for an experiment. 
 
 
Mouse and pneumococcal strain selection were imperative to the success of our study. 
The outbred mouse strain was chosen in this study based on a number of reasons. Firstly, 
outbred mouse strains are representative of a human population which is heterogeneous in 
nature, making them the desirable strain to work with. Secondly, inbred strains are known to 
produce very variable results in response to pneumococcal infection whereas the survival 
times of different strains of outbred mice were more consistent (Gingles et al. 2001). Finally, 
we used NMRI mice due to the availability of a strong colony of NMRI mice in our 
institution. 
 
 
An ideal pneumococcal strain for our study was one that was clinically responsible for 
pneumococcal infection in children less than five years old and relatively virulent in mice. 
Data in this thesis indicated that PJ351 (serotype 1) and D39 (serotype 2) were more virulent 
than TIGR4 (serotype 4) as indicated by higher density values of 4.44X10
5
 CFU in the lungs 
compared to 1.42X10
4
 CFU at the end of 24 hours, for the TIGR4 strain. These observations 
indicated pneumococcal strain-specific behaviour in vivo as described previously by Stol et 
al. In their development of a non-invasive mouse model of otitis media, they found that 
TIGR4 (serotype 4) was more virulent to BALB/c mice, followed by SME215 (serotype 
19F), PJ1324 (serotype 6B) and D39 (serotype 2) (Stol et al. 2009).  
 
 
Serotype 4 is one of the serotypes responsible for 5% of pneumococcal infections in 
children <5 years old and in the elderly (Silberbauer et al. 2011) and it is one of the 13 
serotypes included in the pneumococcal conjugate vaccine. The challenge of BALB/c mice 
with serotype 4 resulted in low-level bacteraemia that slowly lead to meningitis; making this 
strain important in studies involving the pathology of meningitis (Orihuela et al. 2003). In our 
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studies, pathogenesis of TIGR4 from the nasopharynx to lungs following intranasal 
inoculation was variable. There was successful colonisation of the nasopharynx, but the 
growth of TIGR4 in the bronchoalveolar tract and lungs was defined by a reduction in 
recovery of bacterial numbers at different time points. This was not surprising because 
TIGR4 is considered a low capsule-producing strain, which can be easily cleared from lungs 
and subsequently in the bronchoalveolar tract with the aid of phagocytes (Orihuela et al. 
2003). When choosing a pneumococcal strain to work with, a virulent strain is an appropriate 
choice because it leads to successful colonisation and a higher dose of inoculum is not 
required to initiate infection. The coefficient of variation indicated high variability in the 
ability of TIGR4 to infect the bronchoalveolar tract and lung tissue, compared to PJ351 and 
D39. 
 
 
Serotype 1 is responsible for about 21% of pneumococcal infections causing invasive 
disease in children > 5 years of age in Sub-Saharan Africa (Ba et al. 2014). It is perhaps more 
clinically relevant than D39, as it includes many more strains found to cause invasive 
pneumococcal disease in humans (Brueggemann & Spratt 2003). Serotype 1 is exceptionally 
virulent in NMRI mice and is not readily cleared by host’s immune responses. Serotype 2 is 
also a highly virulent serotype and is an important cause of invasive disease in Sub-Saharan 
Africa, accounting for about 6% of pneumococcal infections in children less than five years 
of age (Donkor et al. 2013). The challenge of MF1 and CD1 mice with serotype 2 results in 
septicaemia with the end-point often being death. Our data indicated that PJ351 and D39 
were more able to invade the lung mucosae following I.N inoculation, with densities of 10
5
 
CFU being recovered at the end of 24 hours. PJ351 and D39 offer the opportunity to study 
protection by antibodies at the nasopharynx and lung mucosae, as a model of non-
bacteraemic pneumonia. 
 
 
The intranasal route was the ideal method of inducing infection in NMRI mice since it 
follows the natural course of disease in the human species, in that disease stems from the 
nasopharynx. In this thesis, the success of the intranasal route was evident as nasopharyngeal 
colonisation was maintained throughout the course of the experiment, following intranasal 
inoculation with 10
6 
CFU of pneumococci. Thus, in the placebo group, initial counts for 
PJ351 and D39 were 10
5
 CFU and dropped by only a log to 10
4
 CFU at each time point. 
Numbers of bacteria (between 10
5
 and 10
6
 CFU) in the BAL fluid and lungs were recovered 
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for the duration of the experiment, thus demonstrating efficient infection following intranasal 
inoculation.  
 
 
The cornerstone of animal testing is a three pronged strategy of replacement, reduction 
and refinement. Whilst it is extremely difficult to replace animal models in vaccine testing, 
since the complete functioning of an intact immune system cannot be emulated ex vivo, there 
is still considerable room for the improvements through reduction of the sample size required 
and refinement of the read out systems to measure the vaccine efficacy. In this thesis, we 
refined the intranasal pneumonia mouse model by bringing forward the time point for 
terminating the experiment and by extending the co-inoculation setup to include vaccinated 
mice. In contrast to previously described mouse models of disease, the 24 hour time point 
was selected since our main endpoint was bacterial outgrowth and survival. Previous data 
indicated that mice challenged I.N. with 50µL of 4.3X10
6
 CFU of serotype 1 resulted in 
heavy lung infection and bacteraemia, with 100% deaths occurring between 24 and 30 hours 
after challenge (Jakobsen et al. 1999). In another study, outbred MF1 mice intranasally 
infected with 50 µL of 10
6
 CFU of D39 displayed initial signs of clinical disease at 24 hours 
and mice survived up until 34 hours (Kerr et al. 2004). In a separate study, outbred CD1 mice 
intranasally challenged with 50 µL of 10
7
 CFU of D39 had a median survival time of 48 
hours (Cohen et al. 2012). Beyond the 24 hour time point was inhumane as mice had the 
potential of becoming septic or moribund. In this study, the 24 hour time point was used 
based on data from other studies indicating that beyond the 24 hour time point, most outbred 
strains infected with an inoculum of 10
6
 CFU had the potential to develop septicaemia which 
results in death. Refinement in this model replaced survival time in the following way: 1) 
Numbers of colonising bacteria are derived entirely from bacterial counts rather than survival 
of the host animals and it can therefore distinguish between knockout strains whose 
attenuation is too subtle to be detected by survival time. Furthermore, survival time relies on 
the number of animals surviving the infection whereas the competitive index is obtained from 
the numbers of bacteria before and after the infection, providing a figure that is based on a 
much larger sample size, 2) The quantitative counts are performed on multiple sample types 
(nasopharyngeal lavage, bronchoalveolar tract lavage fluid and lung tissue), which yields 
more data per mouse to scrutinise and 3) By co-inoculating and using the ratio of the two 
strains in a particular mouse, one eliminates the sources of variability in the procedures, such 
as inoculum uptake and sample collection. Considering the reduced number of mice used in 
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this model (5 animals per time point), the variability and precision in this model is 
acceptable, in that the CV’s of the CI values in a co-inoculation situation ranged from 0-30% 
depending on the strain and protein used. Whereas the CV’s of colony counts within a group 
for a particular bacterial strain ranged from 0-200%. These refinements contribute to the 
reduction in sample size. Thus for experiments reported in Figures 3.14-3.21, 5 mice per time 
totalling point 20 mice per experimental group were used compared to the approximately 89 
mice per time point (356 mice per experimental group) that would have been required if the 
wild-type and knockout strains were inoculated into different mice as determined by a post-
hoc sample size calculation (mu1=52764; mu2=72165; SD=92095, power= 0.80, α=0.05).  
 
 
One of the concerns with this model is the possibility of competition between the wild-
type and knockout strains. However, several factors support its use: 1) Both strains were 
inoculated at a low (non-competitive) dose and given ample space to grow at a same rate, 
further, the two strains are essentially the same strain with respect to most factors e.g. capsule 
type, bacteriocin production (Son et al. 2011) and hence the immune system does not see 
them as different, and the strains are unlikely to react to each other in a different way, 2) In 
the co-inoculation setup, the knockout remains constant to indicate that the calibrator (which 
is the knockout) is not influenced by a decrease in the wild-type strain and 3) The knockout 
strain is invisible to the vaccine induced host immune response, thus it is not targeted by 
antibodies.  
 
 
4.1.2 Construction of pneumococcal deletion knockouts in PJ351 and D39 strains 
 
PpmA, slrA, pspA, pspC, stkP and igA1 are found in all pneumococcal strains and their 
flanking sequences are highly similar in strains chosen for this study (PJ351 and D39). As 
such, it was possible to use the same primer design for constructing PJ351 and D39 
knockouts strains. The successful creation of knockouts, in general, is due to a deletion 
strategy used by (Hermans et al. 2006) that allows for in-frame deletion. The success of this 
cloning strategy is hinged on the ability to remove fragments of equal length to the inserted 
cassettes to eliminate the possibility of any polar effects. Although it would have been 
beneficial to this study to conduct genotypic verification and genetic complementation, there 
were some budget and time constraints that prohibited that possibility. The recovery of all 
knockout strains was significantly lower compared to the wild-type strains in the 
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nasopharynx 24 h after co-inoculation of unvaccinated mice with equal proportions of a 
PJ351 or D39 wild-type and the isogenic knockout strains. Thus, no genetic rearrangements 
were expected in resulting knockouts: The observed behaviour of the knockout strains were 
supported by publications related to similar knockouts as discussed in more detail in section 
4.2. 
 
 
The limitation of our model is that we can only target non-essential genes which show 
no attenuation of growth in vitro when knocked out using the model. It is also important to 
note that most essential genes are housekeeping genes (involved in protein synthesis, 
glycolysis etc.) (Riddle et al. 1997)which are unlikely to make good vaccine components. 
Since they are not surface exposed (cytoplasmic), they are not specific and likely to cross-
react with similar antigens on the surface of other organisms, including those that make up 
the host commensal flora (Peng & Gao 2014; Klein & Jones 1994). However, there are a few 
exceptions such as StkP and PcsB that are surface exposed proteins (Giefing et al. 2008) and 
have been demonstrated to contribute to pneumococcal virulence and identified as potential 
vaccine candidates. Despite the limitation of our model, it is important to note that 66% of all 
genes in the pneumococcal genome are non-essential (Bijlsma et al. 2007) and therefore 
despite the limitation of only testing non-essential genes with similar in vitro growth 
characteristic, the model can still be applied to a significant portion of the genome. In support 
of this statement is work that was done by others such as Hermans et al. (2006), Kerr et al. 
(2004) and Cron et al. (2011). In their studies, using the co-inoculation model, they 
uncovered novel non-essential genes (slrA, ppmA, ami-aliA/aliB Permease and two DHH 
Subfamily 1 Proteins) that were demonstrated to contribute to pneumococcal virulence.  
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4.2 Usefulness of the intranasal pneumococcal pneumonia co-inoculation model to study 
pneumococcal virulence 
 
An added benefit of this model, is that we were able to analyse differences in the 
behaviour of the wild-type and knockout strains in the unvaccinated mice which enables us to 
gain insight into the function of these proteins with respect to their roles in virulence, such as 
the ability of the knockouts to establish colonisation of the NP, infection of the BAL fluid 
and lungs. 
 
 
Pneumococcal surface protein C (PspC) is one of the well-studied proteins which is 
preferentially expressed in the transparent phase favoured in the nasopharynx (Rosenow et al. 
1997). In our mouse model, PJ351- and D39 pspC knockout strains were attenuated in their 
ability to colonise the nasopharynx. Our data are comparable to previously published data 
that demonstrated the role of PspC in nasopharyngeal colonisation in a rat and mouse models 
(Rosenow et al. 1997; Balachandran et al. 2002).  
 
 
The bronchoalveolar tract is a transitional pathway of bacteria from the nasopharynx to 
the lungs. It holds valuable information about the status of the lungs in infected animals. In 
our co-inoculation pneumococcal pneumonia mouse model, PJ351 pspC and D39 pspC 
knockouts displayed an inability to colonise the bronchoalveolar tract and grow out in the 
lungs of mice. The contribution of PspC on the growth of the pneumococcus in the 
bronchoalveolar tract has been previously studied. In a study concentrating on the role that 
proteins have in the progression of disease, pspC was instrumental in the transition of the 
bacteria from the nasopharynx to the lungs (Orihuela et al. 2004). On the other hand, there 
are conflicting results regarding the role of PspC on lung infection. Using an MF-1 fatal 
pneumonia mouse model, strain specificity in virulence of pspC was demonstrated. Serotypes 
2, 3 and 19 deficient in pspC behaved similarly to their isogenic wild-type strains; whereas 
pspC serotype 4 deficient strain was easily cleared from the system (Kerr et al. 2006). A 
pspC knockout in a D39 background was not attenuated in a CBA/N fatal pneumonia mouse 
model (Ogunniyi et al. 2007). The discrepancy in our results with another data is probably 
due to the use of challenge models that rely on survival as an endpoint. In this regard, our 
intranasal pneumonia co-inoculation model is more relevant to determine the role of PspC on 
pneumonia because our main endpoint was bacterial growth. 
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Putative proteinase maturation protein (PpmA) is a surface associated lipoprotein that is 
conserved in most pneumococcus strains. In this study, we confirmed the contribution of 
PpmA on colonisation in both the PJ351 and D39 strains. We also indicated that 
pneumococcal knockouts of PJ351 and D39 lacking the gene encoding PpmA were easily 
cleared from the upper airways and lungs. This is in agreement with Cron et al who 
demonstrated the contribution of PpmA on colonisation in the genetic background strains of 
D39 and TIGR4 (Cron et al. 2009). In another study, mice infected with pneumococcal 
knockouts deficient in PpmA survived longer than mice infected with the wild-type strain 
(Overweg et al. 2000), thus indicating their contribution in virulence of mice.  
 
 
PspA is an extensively studied protein in the family of choline binding proteins. Our 
results clearly demonstrated that deletion of pspA in the PJ351 and D39 strains resulted in the 
inability of the strain to colonise the nasopharynx of mice, thus indicating its contribution in 
the early stages of infection, colonisation. Our results concur with a previous study that 
showed that PspA-deficient pneumococci had a reduced ability to infect the nasopharynx of 
mice (Ogunniyi et al. 2007). We further went on to demonstrate the involvement of PspA in 
PJ351 on growth in the bronchoalveolar tract and lungs of mice. This was evidenced by the 
reduced ability of the PJ351 strain lacking PspA to grow in the bronchoalveolar tract and 
lungs of mice. In support of our data, is a study by Hava and Camilli that showed the inability 
of the TIGR4 strain lacking the pspA gene to grow in the lungs of mice; thus indicating its 
role in the establishment of pneumonia (Hava & Camilli 2002). Another study that is in 
support of our data is by Ren et al, who showed that a WU2 strain (serotype 3) deficient in 
PspA had significant reductions in virulence compared to its isogenic wild-type strain (Ren et 
al. 2003). We, however, failed to demonstrate the contribution of PspA in the D39 
background on growth in the bronchoalveolar tract and lungs of mice. A study by Orihuela et 
al supports our findings (Orihuela et al. 2004). They showed that a D39 PspA deficient strain 
infected the lungs of mice in a similar manner as the wild-type strain. Berry and Paton further 
revealed no significant differences in growth following infection with 10
5
 CFU of a D39 
strain deficient in PspA and its isogenic wild-type strain (Berry & Paton 2000), thus 
indicating that PspA did not attenuate the D39 strain. This contrasting information suggests 
that the virulence of PspA is dependent on the strain-specific background. An explanation for 
strain-specific behaviour is due to the presence or absence of other virulence genes directly or 
indirectly contributing to observed phenotypes (Cron et al. 2011). 
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Streptococcal lipoprotein rotamase A (SlrA) is a surface-exposed lipoprotein that 
promotes colonisation by the pneumococcus. Using our intranasal pneumococcal pneumonia 
co-inoculation model, we showed that SlrA contributed on colonisation of the PJ351 and D39 
pneumococci. This was indicated by the reduced ability of the PJ351 and D39 strains 
deficient in slrA to colonise the nasopharynx of mice. This finding is corroborated by results 
of a previous study showing that SlrA is required for colonisation by the pneumococcus 
(Hermans et al. 2006). We further demonstrated the involvement of slrA on the growth of the 
pneumococcus in the bronchoalveolar tract and lungs of mice. We showed that the PJ351 
strain lacking slrA was attenuated in its ability to grow in the bronchoalveolar tract and lungs 
of mice. On the other hand, we failed to demonstrate the contribution of slrA on the growth of 
D39 in the bronchoalveolar tract and lungs of mice. This was evidenced by the equal 
recovery of the ΔslrA and wild-type strains from the bronchoalveolar lavage fluid and lungs 
of mice. Our data are comparable to a study by Hermans et al; by using an invasive mouse 
pneumonia model, they revealed non-significant differences in the survival times between 
mice challenged with D39 and the slrA knockout (Hermans et al. 2006). We thus conclude 
that SlrA is involved in the establishment of colonisation, assists in the transition of the PJ351 
pneumococcus from the nasopharynx to the lungs and in the establishment of pneumococcal 
pneumonia. 
 
 
Bacterial IgA1 protease is a surfaced exposed protein that is present in all 
pneumococcal strains. Using our intranasal pneumonia co-inoculation model, we were able to 
demonstrate that bacterial IgA1 protease plays a role in bacterial colonisation since the 
PJ351- and D39 igA1 deficient strains were attenuated in their ability to colonise the 
nasopharynx of mice. Our data is in accordance with other studies that have demonstrated the 
role of IgA1 protease in colonisation by the pneumococcus (Weiser et al. 2003). In their 
study, by using human anti-capsular polysaccharide IgA1, they showed that IgA1 protease 
modified IgA1 antibody so that it promoted rather than inhibited pneumococcal adherence to 
epithelial cells. In our model, the ability of IgA1 protease in the PJ351 strain to infect the 
bronchoalveolar tract and lungs was demonstrated by a reduced inability of the PJ351ΔigA 
strain to grow in the bronchoalveolar tract and lungs of mice. A study by Chiavolini et al, 
also demonstrated the prolonged survival of mice infected with a null igA1 strain compared to 
a TIGR4 wild-type strain thus indicating its role towards certain stages of virulence 
(Chiavolini et al. 2003). On the other hand, the role of IgA1 protease in the growth of the 
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D39 strain in the BAL fluid and lungs were not successfully demonstrated. D39 strains 
deficient in igA1 were equal in their ability to replicate in the bronchoalveolar tract and lungs 
of mice. Our data is in accordance with the signature tagged mutagenesis data of Lau et al, 
who did not find that zinc metalloproteinases genes contributed to the virulence of serotype 3 
WU2 strain (Lau et al. 2001). This difference in data suggests that the virulence of IgA1 
might be dependent on the strain-specific background, as already discussed in text. 
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4.3 Usefulness of the intranasal pneumococcal pneumonia co-inoculation model to study 
protection of pneumococcal proteins 
 
In order to demonstrate the sensitivity of our model in evaluating the efficacy of 
vaccine candidate molecules, we co-inoculated vaccinated mice with either wild-type PJ351 
or D39 and their isogenic knockouts. We suggest that a lot of assays might not be sensitive 
enough to show protection of vaccine candidate pneumococcal proteins in a lethal challenge 
model with survival as an endpoint. As a result, the potential of some protein antigens might 
have been overlooked in previous studies by testing their efficacy in mouse models that rely 
on survival as an endpoint. 
 
 
PspC is a promising candidate for the composition of a protein vaccine against S. 
pneumoniae (Lima et al. 2013). In our model, PspC has been shown to elicit a significant 
level of protection against infection by the pneumococcus. Using a setup that allows the 
infection of the knockout and wild-type strains into one mouse, we demonstrated protection 
of PspC against pneumococcal infection. Other studies, however, were not sensitive enough 
to show protection of a single recombinant PspC in a lethal challenge model with survival as 
an endpoint. In a study done by Ferreira et al, no significant changes in pneumococcal CFU 
in the lungs and no significant survival were observed among all mice vaccinated with any 
PspC formulation, using an invasive intranasal mouse model (Ferreira et al. 2009), despite 
this protein being implicated in the process of pneumonia. In another study in which mice 
were vaccinated with recombinant PspC and challenged intraperitoneally with a lethal dose of 
10
7
 CFU of D39, recombinant PspC did not elicit significant protection against the 
pneumococcus over that of the placebo (Ogunniyi et al. 2001). In a separate study, in lieu of 
demonstrating the protective efficacy of PspC, mice were intraperitoneally vaccinated with 
the protein and subsequently challenged with different doses of 10
2
, 10
5
 and 10
6
 CFU of D39 
and 6A. Mice were, however, not significantly protected against pneumococcal infection 
(Ogunniyi et al. 2007). This data clearly demonstrates limitations of invasive mouse models 
in demonstrating the efficacy of single recombinant PspC against pneumococcal infections 
compared to our intranasal pneumonia co-inoculation mouse model.  
 
 
PpmA is a promising vaccine candidate, which has been included in studies evaluating 
natural responses in children towards pneumococcal proteins (Lebon et al. 2011). PpmA is a 
lipoprotein that is embedded in the cell membrane and therefore not detectable on the surface 
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of the pneumococcus. Further, surface accessibility to exogenous antibody has been 
demonstrated to be hindered by the presence of the cell wall and capsule (Gor et al. 2005), 
thus making it a poor vaccine candidate. However, our intranasal pneumonia co-inoculation 
model shows that the PpmA protein has the potential of protecting mice against colonisation 
and pneumonia. The PJ351 bacterial counts recovered from the nasopharynx, BAL fluid and 
lungs of mice were significantly reduced, whereas the D39 counts were only significantly 
lowered in the nasopharynx of mice. In support of our results is an in vitro study that showed 
that PpmA antibodies facilitated phagocytosis of serotypes 4, 6A, 9V, 14, 18C, 19F, and 23F 
(Overweg et al. 2000), thus indicating the potential of PpmA in protecting mice against 
pneumococcal infection. On the other hand, current mouse models of disease have failed to 
demonstrate the protective potential of PpmA. PpmA did not afford any protection in mice 
against lethal systemic infection with 500 CFU of a serotype 3 strain (Gor et al. 2005). 
Another group failed to demonstrate its protective efficacy in a co-inoculation pneumonia 
mouse model (Audouy et al. 2007). In their study, there were no significant reductions in the 
D39 bacterial numbers in mice vaccinated with PpmA compared to placebo mice. Comparing 
our data to these studies, it seems the difference in results was dependent on the type of 
mouse model used. PpmA did not afford any protection in a mouse model of lethal infection 
as revealed in the Gor et al study whereas in our mouse model, which relied on relative 
bacterial outgrowth as an endpoint, protection was successfully demonstrated. Audoy et al 
used counts which have a high CV between mice from each group. We used CI’s which have 
low CV’s between mice in each group. Therefore, our model was statistically more sensitive. 
 
 
SlrA is an immunogenic protein that elicits antibody responses early in life (Lebon et 
al. 2011). SlrA was, however, not protective against colonisation and pneumonia with the 
PJ351 and D39 strains in our mouse model. Given the results obtained for PpmA, it was 
expected that SlrA could elicit some protective potential against pneumococcal infection. 
However, a dissimilarity in results might indicate a difference in relative expression levels of 
SlrA and PpmA and capsular structure (Jomaa et al. 2005). 
 
 
Bacterial IgA1 has a high affinity to secretory IgA which is predominant in the 
nasopharynx of human, thus it follows that bacterial IgA should contribute to the stages of 
colonisation rather than invasive disease. In our intranasal pneumonia co-inoculation model, 
we clearly showed the protective efficacy of bacterial IgA against pneumococcal 
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colonisation. This was indicated by a reduction in the D39 bacterial counts in the 
nasopharynx of mice following immunisation with bacterial IgA1. Our data does not match 
the results obtained by Audouy et al, who demonstrated that bacterial counts in the 
nasopharynx were not lowered in the presence of monovalent bacterial IgA1, in a pneumonia 
mouse model (Audouy et al. 2007). Audouy et al used single inoculation of bacteria which 
has a lower statistical power due to variability in the inoculation preparation and sampling as 
opposed to our model which used co-inoculation of bacteria and thus increasing the precision 
with which measurements are made. 
 
 
PspA is an important candidate for an alternative vaccine against pneumococcal 
infections, as demonstrated in pre-clinical and phase I studies (Vadesilho et al. 2014). 
Surprisingly, in our model the protective efficacy of PspA was not demonstrated. Our data 
are in accordance to work done by McDaniels et al, explaining that PspA was not protective 
against the virulent strain D39-serotype 2 (Mcdaniel et al. 1991). In her paper, Shilpa 
Basavanna also explained that recombinant PspA did not elicit protective antibodies against 
the D39 strain (Basavanna et al. 2009). Further work by the Intercell team also showed the 
inability of PspA to protect mice against serotype 1 and 4 (Intercell AG fact sheet 2005). 
Different from our data is work by Wu et al, who showed that intranasal immunisation of 
mice with PspA protected them against lethal infection with an A66 strain-serotype 3 (Wu et 
al. 1996). Recent work by Kong et al also revealed the protective capabilities of a nanogel 
based PspA vaccine against infection with an A66 strain (Kong et al. 2013). The likely 
explanation for our data, based on this information, is that PspA is not protective against 
virulent pneumococcal strains such as serotype 1 and 2. For instance, pathogenesis of 
pneumococcal strains in NMRI mice revealed that serotype 3 was detected late in the blood 
compared to serotype 1 and 2 (Saeland et al. 2000), thus indicating that it was less virulent. In 
BALB/c mice, serotype 3 caused pneumonia, whereas serotype 2 resulted in high-grade 
septicaemia (Orihuela et al. 2003). These studies explain serotype 3 as being less virulent 
than serotype 1 and 2, thus supporting our claims. In this thesis, we successfully 
demonstrated the efficacy of most of our proteins in protecting mice against colonisation and 
pneumococcal pneumonia.  
 
 
In this thesis, antibody concentrations at the time of challenge in vaccinated mice 
were within the range of 595-1908 U/mL compared to a range of 0.020-0.020 U/L in placebo 
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mice. This demonstrated the efficacy of most of our proteins in protecting mice against 
colonisation and pneumococcal pneumonia. However, there was no detectable relationship 
between antibody concentration in vaccinated mice and the competitive index ratios between 
the wild-type and knockout strains. The observation was that at certain time point’s bacterial 
CFU numbers recovered from the nasopharynx, BAL fluid and lungs were lower in 
vaccinated mice compared to placebo mice. The importance of antibodies in protecting 
against IPD and colonisation can be demonstrated by the success of pneumococcal conjugate 
vaccines (Feldman & Anderson 2014). However, there is overwhelming evidence that 
indicates that aside from antibodies, there is another mechanism that dependents on CD4
+
 T 
cell (Malley 2010; Trzcinski et al. 2005) and TH17 responses (Moffitt et al. 2011). Case in 
point is a study that revealed that most unimmunised children at 36 months in the USA have 
antibody concentrations that are not at the protective level, yet disease from serotypes 10 and 
14 is almost 10 fold lower at that age compared to immunised children at 12 months (Lipsitch 
et al. 2005). In mice, the ability to clear colonisation between a mouse strain deficient in 
antibody production and the wild-type mouse strain was similar. There was also no 
correlation between the density of colonisation and amounts of serum or of mucosal 
antibodies. This finding precluded the involvement of antibodies in clearance of 
pneumococcal colonisation, thus attributing it to other effectors of protection (McCool & 
Weiser 2004).  
 
 
One feature of this model is that by using the knockout strain as a calibrator, one can 
achieve an idea as to the level of protection by the vaccine, and gain some hint at the 
mechanism behind the protection. For example, in the presence of a host immune response, 
the colony counts of wild-type strain can be reduced relative to the knockout by two related 
mechanism. The target antigen can be neutralised with respect to its normal functioning by 
bound antibody, or antigen target recognition can elicit clearance of the wild-type strain. 
Whilst both can occur concurrently and are interrelated, it is noteworthy, that the maximum 
effect on the CI by target neutralisation alone is a CI of 1, where the wild-type has been 
reduced to the same levels as the knockout strain. In cases where the CI is >1 in the 
vaccinated mice, any reduction of the wild-type over and above the levels of the knockout 
strain must be achieved by opsonophagocytic killing. Thus, in this model, CIs >1 denote the 
most promising antigen candidates.  
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What is clear from the ELISA and mouse model results is that protection against 
colonisation and pneumonia might be antibody mediated and there could also be a strong cell 
mediated immune component. In support of our findings are studies by (Lu et al. 2011; Lu et 
al. 2009) that indicate that the subcutaneous route of immunisation can protect mice from 
mucosal colonisation by triggering both the antibody and cell mediated immune response. 
Thus subcutaneous tissues can effectively serve as effective antigen presenting sites for 
mucosal immune responses to antigens. Another study, conducted in humans, that aimed to 
determine whether PcsB, StkP, PsaA were able to induce adaptive immune responses in the 
elderly group, indicated that the elderly have a naturally acquired humoral and cellular 
immune response to pneumococcal proteins (Schmid et al. 2011). This study indicates that 
both mechanims of protection observed in humans could also be observed in mice models, as 
might be the case in our study.  
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4.4 CONCLUSION 
 
We have successfully established a mouse model to evaluate pneumococcal candidate 
vaccines that offer several benefits over existing models. These includes refined endpoints 
that are able to detect vaccine efficacy with greater sensitivity than conventional endpoint 
models and the use of internal controls/calibrators that are able to reduce the variance in 
sampling that can reduce the numbers of mice required per time point by a factor of 18. The 
model offers the benefit of being able to establish information on the contribution of the 
target antigens towards virulence. A concern with the model is the variability in the response 
of the studied antigens in different pneumococcal host backgrounds. This coupled with the 
labour involved in the construction of the knockouts and the intensive sampling and colony 
counting, makes this a difficult model to implement in an industrial high throughput 
screening scenario. 
 
 
4.4.1 Potential future directions 
 
 The difference in attenuation levels observed between the PJ351 and D39 strains led to the 
speculation of whether differential expression of other pneumococcal genes, in the absence of 
pspC, ppmA, slrA, igA and pspA, could attribute to the observed results. It might be beneficial 
in future to analyse the expression of other pneumococcal genes in the PJ351 and D39 strains 
during establishment of colonisation, transition from the nasopharynx to lungs and 
establishment of pneumococcal pneumonia. 
 
 
Based on the suggested mechanism of action for PspC, PpmA and bacterial IgA1 protease 
reported in this study, we speculated that protection afforded by immunisation of mice with 
the various protein antigens is antibody mediated. We suggest that passive immunisation 
challenge experiments should be conducted in future to support the speculations. 
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APPENDIX 1. Validation of Enzyme Linked Immunosorbent assay (ELISA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Selection of the optimal concentrations of antigens and anti-mouse alkaline phosphatase conjugate. (A). PspC, PspA, PpmA, SlrA and IgA 
were adsorbed onto the surface of a microtiter plate in increasing concentrations (0.01-10 µg/mL) and dropped into microtiter plates 100 µL per well (4 wells 
for each concentration) breadthways. Following overnight incubation at 4 °C, the normal steps for ELISA were followed as mentioned in section 3.10 in 
materials and methods. (B ). Microtitre plates were coated overnight at 4 °C with 0.625 µg/mL of PspC and SlrA. PspA, IgA and PpmA were coated 
overnight with coating concentrations of 5 µg/mL dissolved in PBS. Following 2 hours incubation at 37 °C, plates were washed three times with PBS-T and 
alkaline phosphatase conjugated anti-mouse IgG was diluted at 1:1000-1:8000, dropped into coated wells lengthways and incubated at 37 °C for 2 hours. 
Following incubation at 37 °C, ELISA was completed using the protocol in section 3.10 in materials and methods. 
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Table 1.1  Results of optimization of ELISA assays 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Performance 
characteristic 
Expected acceptance criteria Optimization results Comments 
Background All blanks should be <0.1 Range:  0.080 – 0.085  
Stability of assay 
(inter-assay precision) 
Quality control sera should be  
within 2 SD of established 
value or %CV <20 
High QC: CV=8-10% 
Low QC: CV=0-4% 
Samples were tested on different 
plates and time points.  
Intra-assay precision 
 
Intra-plate well-to-well CV 
must be <10% 
Sample 1: 92 wells, 
mean OD = 1.77, SD = 
0.077, CV = 4% 
Sample 2: 92 wells, 
mean OD = 1.85, SD = 
0.075, CV = 4% 
2 different samples on multiple 
wells within the plate 
Linearity Goodness of fit of the 
transformed reference curve to 
a straight line. An R
2
 value 
between 0.99 and 1 is expected  
R
2
 = 0.99 for all 
standard curves 
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APPENDIX 2: CULTURE MEDIA, BUFFERS AND REAGENTS 
 
YT agar composition (per litre) 
 
Add the following to 800 mL H2O 
 
yeast extract  5 g 
tryptone  8 g 
NaCl   5 g 
Agar,   15 g  
Adjust pH to 7.0 with NaOH 
Adjust volume to 1 L with dH2O 
Sterilise by autoclaving 
 
LB broth composition (per litre) 
 
Add the following to 800 mL H2O 
yeast extract 5 g 
tryptone 10 g 
NaCl 10 g 
Adjust pH to 7.5 with NaOH 
Adjust volume to 1 L with dH2O 
Sterilise by autoclaving 
 
Todd Hewitt broth 
 
Add the following to mL H2O 
Todd Hewitt broth  
Yeast extract  
 144 
Transformation buffer I (200 mL) 
 
30 mM    Potassium acetate  0.588 g 
100 mM Rubidium chloride  2.42 g 
10 mM    Calcium Chloride  0.294 g 
50 mM    Manganese Chloride  2.0 g 
15%       Glycerol 30m L 
pH 5.8 with dilute acetic acid and filter sterilise 
 
Transformation buffer II (100 mL) 
 
10mM    MOPS  0.21 g 
75mM    Calcium chloride  1.1 g 
10mM    Rubidium chloride    0.121 g 
15%       Glycerol  15 mL 
pH 6.5 with dilute NaOH and filter sterilise  
 
50 X TAE buffer (1 litre) 
 
Dissolve 242 g Tris in 500 mL H2O. 
Add 100 mL 0.5 M Na2EDTA (pH 8.0) and 57.1 mL glacial acetic acid. 
Adjust volume to 1 litre with H2O. 
Store at room temperature 
 
1M Tris (1 Litre) 
 
Dissolve 121.14 g Tris (hydroxymethyl) aminomethane (Tris, MW=121.14) in 800 mL H2O. 
Adjust pH to 8.0 by adding concentrated HCl. 
Adjust volume to 1 litre with H2O 
Sterilise by autoclaving. 
Store at room temperature 
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0.5 M Na2EDTA (1 Litre) 
 
Dissolve 186.12 g disodium ethylenediamimetetraacetate-2H2O in 800 mL H2O; stir vigorously 
on a magnetic stirrer. 
Adjust to pH 8.0 with NaOH (~ 20g NaOH pellets) and adjust the volume to 1 litre with H2O. 
Sterilise by autoclaving 
Store at room temperature 
 
5M NaCl (1 Litre) 
 
Dissolve 292.2 g sodium chloride in 800 mL H2O. 
Adjust volume to 1 litre with H2O 
Sterilise by autoclaving. 
Store at room temperature 
 
3M NaOAc (1 Litre) 
 
Dissolve 408.24 g sodium acetate-3H2O in 800 mL H2O. 
Adjust to pH 5.2 with glacial acetic acid. 
Adjust volume to 1 Litre with H2O 
Sterilise by autoclaving 
Store at room temperature 
 
0.1 M IPTG (50 mL) 
 
Dissolve 1.19 g isopropyl β-D-thiogalactopyranoside in 40 mL H2O. 
Adjust volume to 50mL with H2O 
Sterilise by filtration. 
Store at -20°C. 
 
X-gal (20 mg/mL) 
 
Dissolve 400 mg 5-Bromo-4-Chloro-3-Indolyl-β-D-galactoside (X-gal) in 20 mL N’, N’-
dimethylformamide. 
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Store protected from light at -20°C. 
 
10% SDS- (1 Litre) 
 
Dissolve 100g sodium dodecyl sulphate crystals (SDS) in 900 mL H2O. 
Heat to 68°C to solute the crystals 
Adjust pH to 7.2 with HCl 
Adjust volume to 1 litre with H2O 
 
Lysozyme (10 mg/mL) 
 
Dissolve 0.1 g of lysozyme in 10 mL of dH2O 
 
Proteinase K (10mg/mL) 
 
Dissolve 0.1 g of proteinase K in 10 mL of dH2O 
Store at -20°C 
 
Ampicillin (50 mg/mL) 
 
Dissolve 0.5 g of ampicillin in 10 mL of dH2O 
Store at -20°C 
 
Trimethroprim (50 mg/mL) 
 
Dissolve 0.5 g of trimethoprim in 10 mL of dH2O 
Store at -20°C 
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APPENDIX 3: FORMULAS, REAGENTS AND EQUIPMENT  
 
Formula used for calculations 
 
Needed grams= Concentration x Molecular weight x final volume  
 
Conversions 
 
mg -g= divide by 100 
mg -µg=multiply by 1000 
µg-ng= divide by 1000 
mL-l= multiply by 1000 
mM-m=multiply by 1000 
 
Reagents 
 
Absolute ethanol 
Acrodisc syringe filters (0.2µm supor membrane) 
Acetic acid 
Agarose 
Ampicillin 
Autoclavable micropipettes 
Bacto tryptone 
Bacto agar 
Bacto Todd Hewitt broth 
Bromophenol blue 
Calcium chloride 
Chloroform 
CTAB 
Disposable plastic pipettes 
Disposable inoculating loops and needles 
Eppendorf tubes –RNase and DNase free (0.2, 0.6, 1.5 mL) 
EDTA 
Expand long template PCR system 
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Glycerol 
IPTG 
Isopropanol 
Lysozyme 
Manganese (II) chloride 
MOPS 
Molecular weight markers 
Petri dishes 
Potassium acetate 
PCR nucleotide mix 
Proteinase K 
PCR nucleotide mix 
Primer pairs 
Qiaquick gel extraction kit (Qiagen) 
Rubidium chloride 
Rapid DNA ligation kit 
Restriction enzymes 
SDS 
Sodium Chloride 
StrataPrep plasmid miniprep kit (Stratagene/Agilent technologies) 
Tris base ultrapure 
Trimethoprim 
X-gal 
 
Equipment 
 
CO2 incubator 
Centrifuge machine 
Dry bath 
ELPHO power supply 
Eppendorf master cycler gradient  
Incubator 
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Orbital shaker 
pH meter 
Spectrophotometer 
UV transilluminator 
Weighing machine 
Water bath 
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APPENDIX 4 ANIMAL ETHICS CERTIFICATE 
 
 
 
